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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 10, Revision 3 
(FGE.10Rev3): 
Aliphatic primary and secondary saturated and unsaturated alcohols, 
aldehydes, acetals, carboxylic acids and esters containing an additional 
oxygenated functional group and lactones from chemical groups 9, 13 and 
301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food 
Safety Authority was requested to evaluate 63 flavouring substances in the Flavouring Group 
Evaluation 10, including additional two substances in this Revision 3, using the Procedure in 
Commission Regulation (EC) No 1565/2000. For one substance [FL-no: 10.170] a concern for 
genotoxicity could not be ruled out. The remaining 62 substances were evaluated through a stepwise 
approach (the Procedure) that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The 
Panel concluded that the 62 substances do not give rise to safety concerns at their levels of dietary 
intake, estimated on the basis of the MSDI approach. Besides the safety assessment of these flavouring 
substances, the specifications for the materials of commerce have also been considered. For four 
substances evaluated through the Procedure, the stereoisomeric composition has not been specified 
sufficiently.  
© European Food Safety Authority, 2012 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to advise the Commission on the implications for human 
health of chemically defined flavouring substances used in or on foodstuffs in the Member States. In 
particular, the Panel was requested to evaluate 63 flavouring substances in the Flavouring Group 
Evaluation 10, Revision 3 (FGE.10Rev3), using the Procedure as referred to in the Commission 
Regulation (EC) No 1565/2000. These flavouring substances belong to chemical groups 9, 13 and 30, 
Annex I of the Commission Regulation (EC) No 1565/2000. 
The present revision of FGE.10, FGE.10Rev3, includes the assessment of two additional candidate 
substances [FL-no: 09.951 and 10.170]. 
The flavouring substances are alcohols, aldehydes, acetals, carboxylic acids and esters containing 
additional oxygenated functional groups and lactones. 
Thirty-six of the candidate substances possess one or more chiral centres and eight can exist as 
geometrical isomers due to the presence and the position of a double bond. For five of these substances 
[FL-no: 10.038, 10.040, 10.059, 10.063 and 10.170] the stereoisomeric composition / composition of 
mixture has not been specified sufficiently. 
Fifty-five candidate substances belong to structural class I, six belong to structural class II, and two 
belong to structural class III according to the decision tree approach presented by Cramer et al. (1978). 
Fifty of the flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intakes” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic estimate 
of the intakes of the flavouring substances, the Panel has decided also to perform an estimate of the 
daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” (mTAMDI) 
approach based on the normal use levels reported by Industry. In those cases where the mTAMDI 
approach indicated that the intake of a flavouring substance might exceed its corresponding threshold of 
concern, the Panel decided not to carry out a formal safety assessment using the Procedure. In these 
cases the Panel requires more precise data on use and use levels. 
The candidate substances which have been assigned to structural class I have estimated European daily 
per capita intakes (MSDI) ranging from 0.0012 to 1500 microgram. The candidate substances from 
structural class II have MSDIs ranging from 0.0012 to 1.2 microgram and the two candidate substances 
assigned to structural class III have estimated European daily per capita intakes of 0.011 and 1.2 
microgram (Table 6.1). These intakes are below the thresholds of concern of 1800, 540 and 90 
microgram/person/day for structural class I , II and III, respectively. 
The combined estimated daily per capita intake as flavourings of the 55 candidate substances assigned 
to structural class I is 1600 microgram, which does not exceed the threshold of concern for a substance 
belonging to structural class I of 1800 microgram/person/day. Likewise, the combined estimated daily 
per capita intake as flavouring of the six candidate substances assigned to structural class II is 1.2 
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microgram, which does not exceed the threshold of concern for a substance belonging to structural class 
II of 540 microgram/person/day. 
For 5-pentyl-3H-furan-2-one [FL-no: 10.170], the flavour Industry informs that the commercial product 
is a mixture of two structural isomers – 2/3 is the named compound (5-pentyl-3H-furan-2-one) and 1/3 
is the structural isomer - 5-pentyl-5H-furan-2-one. This latter isomer is identical to [FL-no: 10.054], 
which is an alpha, beta-unsaturated alcohol (after hydrolysis of the lactone), allocated to subgroup 4.1 of 
FGE.19 (FGE.217). The Panel concluded that 5-pentyl-3H-furan-2-one [FL-no: 10.170] should not be 
evaluated through the Procedure until the additional gentoxicity data for [FL-no: 10.054] are available, 
as stated in FGE 217.  
The Panel reconsidered the fact that 1-hydroxypropan-2-one [FL-no: 07.169] is an endogenous 
metabolite of acetone. Acetone is endogenously formed from the degradation of body fat/fatty acids and 
occurs in the blood of healthy humans not exposed to external sources of acetone in amounts of 
approximately 4 - 12 mg/person, corresponding to 0.7 to 2 mg/l blood. Under these conditions, the 
majority of the acetone in blood would be metabolised to 1-hydroxypropan-2-one, which is rapidly 
further metabolised to endogenous compounds (methylglyoxal, pyruvate and glucose) in the 
methylglyoxal pathway. The estimated exposure of 0.22 microgram/capita/day is considerably lower 
than that resulting from the metabolism of acetone and would not significantly add to the internal 
exposure to 1-hydroxypropan-2-one in the body and would not perturb the normal catabolism of the 
compound to innocuous endogenous products. The Panel therefore decided that further genotoxicity 
data are not required and that the substance could be taken through the Procedure. 
For the remaining candidate substances, the genotoxic potential cannot be assessed adequately, 
however, from the limited data available there were no indications that genotoxicity for these substances 
should give rise to safety concern. So, 62 substances are evaluated through the Procedure in the present 
revision of FGE.10. 
It can be anticipated that, at the estimated levels of intake as flavouring substances, 59 of the alcohols, 
aldehydes, acetals, carboxylic acids and esters with an additional oxygenated functional group and 
aliphatic lactones included in the present FGE are generally hydrolysed and completely metabolised to 
innocuous products, many of which are endogenous in humans. For three of the flavouring substances 
[FL-no: 02.242, 06.097 and 09.824], it cannot be concluded that they are metabolised to innocuous 
products. Adequate margins of safety could be established for these three substances in step B4 of the 
Procedure. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present Flavouring Group Evaluation using the Procedure. 
It was considered that on the basis of the default MSDI approach that the flavouring substances, to 
which the Procedure have been applied, would not give rise to safety concerns at the estimated levels of 
intake arising from their use as flavouring substances. 
The mTAMDI for the flavouring substances, for which use levels information is available, range from 
800 to 5100 microgram/person/day. For 58 of these substances the mTAMDI is above the threshold of 
concern of their structural classes and for three substances the mTAMDI is below the threshold. The 
three flavouring substances which have mTAMDI intake estimates below the threshold of concern for 
their structural class are also expected to be metabolised to innocuous products. For two flavouring 
substances use levels have not been provided and no mTAMDI could be estimated. Thus, for 60 
flavouring substances, further information is required. This would include more reliable intake data and 
then, if required, additional toxicological data.  
Thus, in conclusion, 62 of the 63 flavouring substances were evaluated through the Procedure (based 
on the MSDI approach), as one flavouring substance, 5-pentyl-3H-furan-2-one [FL-no: 10.170] could 
not be evaluated through the Procedure until adequate genotoxicity data become available. 
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In order to determine whether the conclusion for the candidate substances evaluated using the Procedure 
can be applied to the materials of commerce, it is necessary to consider the available specifications. 
Specifications including complete purity criteria and identity for the materials of commerce have been 
provided for 58 flavouring substances. For four substances [FL-no: 10.038, 10.040, 10.059 and 10.063] 
information on composition of mixture and / or stereoisomerism has not been specified sufficiently. For 
one substance [FL-no: 10.063] an identity test is missing. 
Thus, the final evaluation of the materials of commerce cannot be performed for four substances [FL-
no: 10.038, 10.040, 10.059 and 10.063], pending further information. 
For the remaining 58 candidate substances [FL-no: 02.132, 02.198, 02.242, 05.149, 06.088, 06.090, 
06.095, 06.097, 06.102, 06.135, 07.169, 08.053, 08.082, 08.090, 08.103, 08.113, 09.333, 09.345 - 
09.354, 09.360, 09.502, 09.558, 09.565, 09.580, 09.590, 09.601, 09.626, 09.629, 09.633, 09.634, 
09.644, 09.683, 09.815, 09.824, 09.832, 09.833, 09.862, 09.874, 09.916, 09.951, 10.039, 10.045, 
10.047 - 10.049, 10.052, 10.055, 10.058, 10.068 and 10.168] the Panel concluded that they would 
present no safety concern at the estimated levels of intake based on the MSDI approach. 
KEYWORDS 
Flavourings, safety, lactones, saturated, unsaturated, primary, secondary, alcohols, aldehydes, acids, 
acetals, esters, additional oxygenated functional group, FGE.10. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION 
The first version of the Flavouring Group Evaluation 10 (FGE.10) dealt with 51 alcohols, aldehydes, 
acetals, carboxylic acids and esters containing an additional oxygenated functional group and lactones. 
The first revision of FGE.10, FGE.10Rev1, included the assessment of eight additional candidate 
substances [FL-no: 06.088, 06.095, 06.102, 06.135, 09.565, 09.916, 10.040 and 10.168] and additional 
information on 32 substances [FL-no: 02.132, 02.198, 02.242, 06.090, 06.097, 07.169, 08.090, 09.333, 
09.349, 09.360, 09.502, 09.580, 09.590, 09.601, 09.629, 09.633, 09.644, 09.683, 09.815, 09.824, 
09.832, 09.862, 09.874, 10.038, 10.039, 10.043, 10.045, 10.048, 10.049, 10.052, 10.058 and 10.068] 
which had become available since the first FGE. Furthermore, substance [FL-no: 10.043], which can 
be metabolised to an alpha, beta-unsaturated ketone, was withdrawn from FGE.10Rev1 to be 
evaluated together with other alpha, beta-unsaturated ketones in FGE.217 (EFSA, 2008b). 
The second revision of FGE.10 concerned the assessment of three additional candidate substances 
[FL-no: 08.113, 10.059 and 10.063] as well as additional information submitted by the Industry on the 
stereoisomeric composition/composition of mixture requested in FGE.10Rev1 for eight substances 
[FL-no: 06.088, 06.095, 06.135, 09.565, 09.916, 10.038, 10.040 and 10.168], and identity information 
for [FL-no: 06.088 and 06.095]. 
FGE Opinion 
adopted by 
EFSA 
Link No. Of 
candidate 
substances 
FGE.10 28 October 
2005 
http://www.efsa.eu.int/science/afc/afc_opinions/1232_en.html 51 
FGE.10Rev1 30 January 
2008 
http://www.efsa.europa.eu/en/efsajournal/pub/934.htm 58 
FGE.10Rev2 23 March http://www.efsa.europa.eu/en/efsajournal/pub/2164.htm 61 
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 2011 
FGE.10Rev3 1 February 
2012 
 63 
 
The present revision of FGE.10, FGE.10Rev3, includes the assessment of two additional candidate 
substances [FL-no: 09.951 and 10.170]. No toxicity or metabolism data were provided for these two 
substances. A search in open literature was conducted for metabolism, genotoxicity, repeated dose 
toxicity as well as reproductive/developmental toxicity for [FL-no: 09.951 and 10.170]. This search 
did not reveal any pertinent new information on the two substances.  
FGE.10Rev3 also include additional information submitted by the Industry on specifications for [FL-
no: 06.135 and 08.113] which had been requested in FGE.10Rev2. 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC)  No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
After the finalisation of the evaluation programme, in their letters of the 30th July 2010 and 20th 
September 2010, the Commission requested EFSA to carry out an evaluation of the flavouring 
substances 5-pentyl-3H-furan-2-one [FL-no: 10.170] and dioctyl adipate [FL-no: 09.951], also 
according to Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 10, Revision 3 
1.1. Description 
The present Flavouring Group Evaluation 10, Revision 3 (FGE.10Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with 63 alcohols, aldehydes, acetals, carboxylic acids 
and esters containing an additional oxygenated functional group and lactones from chemical groups 9, 
13 and 30, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a).  
The flavouring substances (candidate substances) under consideration are listed in Table 1, as well as 
their chemical Register name, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of 
Europe- (CoE-) and Flavor and Extract Manufactures Association- (FEMA-) numbers, structure and 
specifications.   
The outcome of the Safety Evaluation is summarised in Table 2a. 
Fifteen  candidate substances are aliphatic lactones [FL-no: 10.038, 10.039, 10.040, 10.045, 10.047, 
10.048, 10.049, 10.052, 10.055, 10.058, 10.059, 10.063, 10.068, 10.168 and 10.170]; thirty-two 
candidate substances are esters or diesters [FL-no: 09.333, 09.345 - 09.354, 09.360, 09.502, 09.558, 
09.565, 09.580, 09.590, 09.601, 09.626, 09.629, 09.633, 09.634, 09.644, 09.683, 09.815, 09.824, 
09.832, 09.833, 09.862, 09.874, 09.916 and 09.951]; six candidate substances are acetals [FL-no: 
06.088, 06.090, 06.095, 06.097, 06.102 and 06.135]; one candidate substance is an alpha-hydroxyacid 
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[FL-no: 08.090]; one candidate substance is a ketoalcohol [FL-no: 07.169]; one candidate substance is 
an alkoxy-alcohol [FL-no: 02.242]; two candidate substances are diols [FL-no: 02.132 and 02.198]; 
one candidate substance is a dialdehyde [FL-no: 05.149] and four candidate substances are aliphatic 
dicarboxylic acids [FL-no: 08.053, 08.082, 08.103 and 08.113].  
The hydrolysis products of candidate esters, lactones and acetals as well as their evaluation status are 
listed in Table 2b. 
The candidate substances are structurally related to 29 aliphatic lactones (supporting substances) 
evaluated at the 49th JECFA meeting (JECFA, 1998a) and to 47 aliphatic primary alcohols, aldehydes, 
carboxylic acids, acetals and esters containing additional oxygenated functional groups evaluated at 
the 53rd JECFA meeting (JECFA, 2000c). These supporting substances are listed in Table 3, together 
with their evaluation status. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variation of 
their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Thirty-six of the substances possess one or more chiral centres [FL-no: 02.132, 02.198, 06.088, 
06.090, 06.095, 06.135, 08.090, 09.333, 09.346, 09.349, 09.360, 09.502, 09.580, 09.590, 09.601, 
09.629, 09.633, 09.644, 09.683, 09.815, 09.824, 09.832, 09.862, 09.874, 09.916, 10.038, 10.039  
10.040, 10.045, 10.048, 10.049, 10.052, 10.058, 10.068, 10.168 and 10.170]. For thirty-five 
substances the stereoisomeric composition has been specified. For [FL-no: 10.170] the Industry has 
informed that the commercial substance is a mixture of two structural isomers. One of these isomers 
possesses a chiral centre for which the configuration has not been specified. 
Due to the presence and the position of a double bond, eight substances can exist as geometrical 
isomers [FL-no: 09.350, 09.351, 09.565, 10.038, 10.039, 10.040, 10.059 and 10.063]. For four of the 
substances [FL-no: 10.038, 10.040, 10.059 and 10.063] the stereoisomeric composition / composition 
of stereoisomeric mixture has not been specified sufficiently. Industry has stated that [FL-no: 10.038 
and 10.040] exist as mixtures of (Z)- and (E)-isomers (EFFA, 2010a), however, the composition of the 
isomeric mixtures have to be provided. 
1.3. Natural Occurrence in Food 
Fifty of the flavouring substances have been reported to occur in one or more of the following food 
items: fruits (apple, pineapple, melon, guava, banana, starfruit, papaya, raspberry, mango, plum, 
citrus), oats, chestnut, juice, butter, meat, cheese, milk and milk products, skimmed milk powder, 
green tea, coffee, beer, wine and whisky. 
Quantitative data on the natural occurrence in food have been reported for thirty-eight of the candidate 
substances (TNO, 2000; TNO, 2010). These reports include: 
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1.3.1 Candidate substances reported to occur in food (TNO, 2000; TNO, 2010) 
FL-no: Name: Quantitative data reported:
02.198 Octane-1,3-diol Up to 21 mg/kg in apple and up to 95.1 mg/kg in apple juice 
02.242 2-Butoxyethan-1-ol 0.02 mg/kg in mozzarella cheese 
06.088 2-Ethyl-4-methyl-1,3- Up to 2 mg/kg in port wine 
06.095 4-Methyl-2-propyl-1,3- Up to 2 mg/kg in port wine 
06.097 1,1,3-Triethoxypropane Up to 3 mg/kg in pear brandy and less than 0.8 mg/kg in whisky 
06.135 2-Isobutyl-4-methyl-1,3-dioxolane Up to 2 mg/kg in port wine 
07.169 1-Hydroxypropan-2-one Up to 4 mg/kg in coffee 
08.103 Nonanedioic acid Up to 1.5 mg/kg in beer 
09.590 Isobutyl lactate 20 mg/kg in port wine 
09.916 Ethyl 3-hydroxyoctanoate Up to 0.05 mg/kg in papaya, 0.02 mg/kg in orange juice and 0.03 
10.045 Heptano-1,5-lactone Up to 0.4 mg/kg in green tea 
10.047 Hexadecano-1,16-lactone 0,0145 mg/kg in skimmed milk powder 
10.048 Hexadecano-1,4-lactone Up to 16.7 mg/kg in heated butter 
10.049 Hexadecano-1,5-lactone Up to 10.6 mg/kg in butter and up to 1.3 mg/kg in heated lamb and mutton fat 
 
According to TNO, 13 of the substances have not been reported in any food items. These substances 
are listed in Table 1.3.1 (TNO, 2000; TNO, 2010): 
1.3.1 Candidate substances not reported to occur in food (TNO, 2000; TNO, 2010) 
FL-no: Name: 
06.102 2-Hexyl-5-hydroxy-1,3-dioxane 
08.113 Succinic acid, disodium salt 
09.502 Ethyl butyryl lactate 
09.633 Methyl 5-hydroxydecanoate 
09.644 Methyl lactate 
09.824 Ethyl 2-acetylbutyrate 
09.832 Ethyl 3-acetohexanoate 
09.833 iso-Propyl 4-oxopentanoate 
09.874 Di(2-methylbutyl) malate 
10.040 Dec-8-eno-1,5-lactone 
10.059 Hexadec-7-en-1,16-lactone 
10.063 Hexadec-9-en-1,16 lactone 
10.068 Pentadecano-1,14-lactone 
 
2. Specifications 
Purity criteria for the substances have been provided by the Flavouring Industry (EFFA, 2003c; EFFA, 
2004ag; Flavour Industry, 2011a; Flavour Industry, 2010g; Flavour Industry, 2010n; Flavour Industry, 
2011g) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), this information is adequate for 62 substances. For one substance [FL-no: 10.063] an identity 
test is missing. 
Furthermore, for five substances [FL-no: 10.038, 10.040, 10.059, 10.063 and 10.170], the 
stereoisomeric composition has not been specified sufficiently (see Section 1.2 and Table 1). 
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3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) (SCF, 1999) 
approach, which involves the acquisition of data on the amounts used in food as flavourings (SCF, 
1999a). These data are derived from surveys on annual production volumes in Europe. These surveys 
were conducted in 1995 by the International Organization of the Flavour Industry, in which flavour 
manufacturers reported the total amount of each flavouring substance incorporated into food sold in 
the EU during the previous year (IOFI, 1995). The intake approach does not consider the possible 
natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The total annual volumes of production of the candidate substances from use as flavouring substances 
in Europe has been reported to be approximately 13220kg (EFFA, 2000c; EFFA, 2003d; EFFA, 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is 
consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for 
the enlarged EU. 
Flavouring Group Evaluation 10, Revision 3
 
 
12 EFSA Journal 2012; 10(3):2563 
2008b; Flavour Industry, 2010g; Flavour Industry, 2010n). For the 60 of the 76 supporting substances 
the annual volume of production is 357000 kg (JECFA, 1999b; JECFA, 2000b). 
On the basis of the annual volumes of production reported for the candidate substances, the daily per 
capita intakes for each of these flavourings have been estimated (Table 2a).  
98 % of the total annual volume of production for the candidate substances is accounted for by three 
substances, succinic acid disodium salt [FL-no: 08.113], hexadec-9-en-1,16-lactone [FL-no: 10.063] 
and diethyl maleate [FL-no: 09.351]. The estimated daily per capita intake of succinic acid disodium 
salt from use as a flavouring substance is 1500 microgram, that of hexadec-9-en-1,16-lactone is 48 
microgram and that of diethyl maleate is 12 microgram. The daily per capita intakes for each of the 
remaining substances are less than 10 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For 61 candidate substances information on food categories and normal and maximum use levels5,6,7 
were submitted by the Flavour Industry (EFFA, 2001a; EFFA, 2003c; EFFA, 2003s; EFFA, 2004ag; 
EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2010g; Flavour Industry, 2010n). For two 
substances [FL-no: 06.135 and 08.113] no use levels have been provided for the food categories as 
listed in Commission Regulation (EC) No 1565/2000. 
The candidate substances, for which use levels have been provided, are used in flavoured food 
products divided into the food categories, outlined in Annex III of the Commission Regulation (EC) 
No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present calculation of mTAMDI, the 
reported normal use levels were used. In the case where different use levels were reported for different 
food categories the highest reported normal use level was used. 
According to the Flavour Industry the normal use levels for the candidate substances, for which use 
levels have been provided, are in the range of 1 - 101 mg/kg food, and the maximum use levels are in 
the range of 5 - 1005 mg/kg (EFFA, 2001a; EFFA, 2003c; EFFA, 2003s; EFFA, 2004ag; EFFA, 
2007a; Flavour Industry, 2006a; Flavour Industry, 2010g; Flavour Industry, 2010n).  
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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Table 3.1 Use of Candidate Substances in Various Food Categories for 61 Candidate Substances for 
which Data on Use have been provided. 
Food 
category 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 All except [FL-no: 
09.951] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 
09.951] 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 
09.951] 
04.1 Processed fruits All except [FL-no: 
09.951] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no: 10.170] 
05.0 Confectionery All except [FL-no: 
09.951] 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
All except [FL-no: 
09.951] 
07.0 Bakery wares All except [FL-no: 
09.951] 
08.0 Meat and meat products, including poultry and game All except [FL-no: 
10.170] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 
08.090, 09.551 and 
10.170 ] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 
06.095, 09.551 and 
09.644] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 
06.095, 09.551, 
09.644 and 10.170] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All except [FL-no: 
09.951] 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All except [FL-no: 
09.951] 
15.0 Ready-to-eat savouries All except [FL-no: 
09.951] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All 
* Information on use levels has not been provided for [FL-no: 06.135 and 08.113] 
 
The mTAMDI values for the 54 candidate substances from structural class I, for which use levels have 
been reported, range from 800 to 5100 microgram/person/day, for the five candidate substances from 
structural class II, for which use levels are available, the mTAMDI range from 3800 to 3900 
microgram/person/day for each. For the two candidate substances from structural class III the 
mTAMDIs are 3800 and 4100 microgram/person/day.  
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
In general, lactones are formed by acid-catalysed intramolecular cyclisation of hydroxycarboxylic 
acids. In an aqueous environment, a pH-dependent equilibrium is established between the open-chain 
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hydroxycarboxylate anion and the lactone ring. In basic and neutral media, such as blood, the open-
chain hydroxycarboxylate anion is favoured while in acidic media, such as gastric juice and urine, the 
lactone ring is favoured. Enzymes, such as lactonase, may catalyse the hydrolysis reaction, but for 
simple saturated lactones, the ring-opening reaction and reverse cyclication are in equilibrium, mainly 
controlled by pH conditions. Both the aliphatic lactones and the ring-opened hydroxycarboxylic acids 
can be absorbed from the gastrointestinal tract. However, the simple lactones, with low molecular 
weight, being uncharged may cross the cell membrane more easily than the acidic form, which 
penetrates the cells as a weak electrolyte. The hydroxycarboxylic acid obtained from lactone 
hydrolysis enters the fatty acid pathway and undergoes alpha- or beta-oxidation and cleavage to form 
acetyl CoA and a chain-shortened carboxylic acid. The carboxylic acid is then reduced by 2-carbon 
fragments until either acetyl CoA or propionyl CoA is produced. These fragments are then 
metabolised in the citric acid cycle. The Panel anticipated that the two unsaturated omega-lactones 
([FL-no: 10.059], hexadec-7-en-1,16-lactone and [FL-no: 10.063], hexadec-9-en-1,16-lactone) are 
metabolised like the structurally related saturated lactones, namely through ring opening followed by 
fatty acid degradation. 
In humans, paraoxonase (PON1), a serum enzyme belonging to the class of A-carboxyesterases 
(Aldridge, 1953), is known to rapidly hydrolyse a broad range of aliphatic lactone substrates including 
beta-, gamma-, delta- and omega-lactones and lactones fused to alicyclic rings such as 2-(2-
hydroxycyclopent-4-enyl)ethanoic acid gamma-lactone (Billecke et al., 2000). Activities of 
paraoxonase isoenzymes (Q & R) in human blood exhibit a bimodal distribution that is accounted for 
by a Q/R (glutamine or arginine) polymorphism with Q-type homozygotes showing a lower activity 
than QR heterozygotes or R homozygotes (Humbert et al., 1993). 
Mono- and di-esters included in the present FGE are expected to undergo hydrolysis in humans to 
yield their corresponding alcohol (linear or branched-chain aliphatic alcohols) and acid components 
(i.e. alpha-, beta- or gamma-keto or hydroxy acids, or simple aliphatic acids, diacids or triacids), 
which would be further metabolised and excreted. It has to be noted that the 2-acetyl butyric acid, 
formed as one of the hydrolysis products of the candidate substance ethyl 2-acetylbutyrate [FL-no: 
09.824], has some structural similarities to valproic acid, which, together with a number of its 
derivatives, has been recognised as teratogenic in rodents and in humans (Nau and Löscher, 1986; 
Samren et al., 1997; Kaneko et al., 1999). Although it can be predicted that 2-acetylbutyric acid is 
further metabolised through the usual pathways of detoxication for carboxylic acids (i.e. mainly via 
glucuronidation reaction), the structural similarity with valproic acid does not allow the prediction that 
ethyl 2-acetylbutyrate [FL-no: 09.824] is metabolised only to innocuous products. 
The presence of a second oxygenated functional group has little if any effect on hydrolysis of these 
esters. The most probable metabolic reactions of the hydrolysis products are, oxidation of alcohols to 
aldehydes and acids, conjugation of alcohols and acids to glucuronides and sulphates and beta- and 
omega-oxidation of carboxylic acids. 
Beta-keto acids and derivatives like acetoacetic acid undergo ready decarboxylation. Along with 
alpha-keto and alpha-hydroxyacids, they yield breakdown products, which are incorporated into 
normal biochemical pathways. The gamma-keto acids and related substances may undergo complete 
or partial beta-oxidation to yield metabolites that are eliminated in the urine. Omega-substituted 
derivatives are readily oxidised and/or excreted in the urine. Simple aliphatic di- and tricarboxylic 
acids participate in the tricarboxylic acid cycle. For instance, succinic acid is a normal intermediary 
metabolite and a constituent of the citric acid cycle; it occurs normally in human urine (1.9 - 8.8 
mg/L). Succinic acid is readily metabolized when administered to animals, but may be partly excreted 
unchanged in the urine if large doses are given (Patty, 1993, Vol. II, p. 3579). 
One of the candidate substances, 1-hydroxypropan-2-one [FL-no: 07.169] (acetol), is a metabolite of 
acetone, which is an endogenous substance formed from the degradation of body fat / fatty acids. The 
major metabolic pathway in mammals of acetone at low blood concentrations (i.e. in healthy humans 
not exposed to external sources, acetone occurs in amounts of approximately 4 - 12 mg per person, 
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corresponding to approximately 0.7 to 2 mg/l blood (Ashley et al., 1994; Dick el al., 1988; Wang et al, 
1994c), is via the methylglyoxal route, where acetone is first oxidised to 1-hydroxypropan-2-one, 
which is then oxidised to 2-oxopropanal (methylglyoxal [FL-no: 07.001]). 2-Oxopropanal will after 
further metabolism give rise to glucose (Morgott, 1993; WHO, 1998a; NAS/COT, 2005). 
Six candidate substances [FL-no: 06.088, 06.090, 06.095, 06.097, 06.102 and 06.135] are acetals, 
which may be expected to undergo acid catalysed hydrolysis in the gastric environment to yield their 
component aldehydes and alcohols prior to absorption. Once hydrolysed, the component alcohols and 
aldehydes are expected to be metabolised primarily through the above mentioned common routes of 
biotransformations and excreted. 
The linear and branched-chain aliphatic primary alcohol components of candidate substances that are 
simple aliphatic di- and tricarboxylic acid esters would be oxidised in the presence of alcohol 
dehydrogenase to their corresponding aldehydes which, in turn, would be oxidised to their 
corresponding carboxylic acids. The two diols [FL-no: 02.132 and 02.198] may be anticipated to 
participate in the same routes of biotransformation. It may be anticipated that glutaraldehyde [FL-no: 
05.149] is biotransformed through the common pathways of detoxication of aldehydes to innocuous 
products. 
Among the candidate substances, an alkoxy-alcohol, 2-butoxyethanol [FL-no: 02.242], is mainly 
metabolised to butoxyacetic acid, which has been identified as the metabolite responsible for the 
haemolysis of red blood cells induced by 2-butoxyethanol. 
In summary, it can be anticipated that primary and secondary aliphatic saturated or unsaturated 
alcohols, aldehydes, carboxylic acids, acetals and esters with a second oxygenated functional group 
and aliphatic lactones included in the present FGE are generally metabolised to innocuous products 
(many of which are endogenous in humans), at the estimated level of intake as flavouring substances. 
The consideration on the actual levels of intake becomes particularly relevant for one candidate 
substance, diethyl maleate [FL-no: 09.351], as when administered at high doses, it is able to induce 
severe GSH depletion, due to its prompt metabolism to GSH-conjugates. This may also be the case for 
the structurally related diethyl fumarate [FL-no: 09.350]. 
For three of the candidate substances it cannot be concluded that they are metabolised to innocuous 
products. These are 2-butoxyethan-1-ol [FL-no: 02.242], the major metabolite of which butoxyacetic 
acid has been recognised as responsible for haematotoxic effects induced by 2-butoxyethanol [FL-no: 
02.242], 1,1,3-triethoxypropane [FL-no: 06.097], which may be metabolised to 3-ethoxypropanoic 
acid, a substance with structural similarities to 2-butoxyethanol and finally, ethyl 2-acetylbutyrate 
[FL-no: 09.824], of which hydrolysis gives rise to 2-acetylbutyric acid, which shows some structural 
similarities to valproic acid, a known teratogenic compound. 
A more detailed description of the metabolism of the candidate substances in this FGE is given in 
Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For 5-pentyl-3H-furan-2-one [FL-no: 10.170] flavour industry informs that the commercial product is 
a mixture of two structural isomers – 2/3 is the named compound (5-pentyl-3H-furan-2-one) and 1/3 is 
the structural isomer - 5-pentyl-5H-furan-2-one. This latter isomer is identical to [FL-no: 10.054], – 
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which is an alpha,beta-unsaturated alcohol (after hydrolysis of the lactone) allocated FGE.19 subgroup 
4.1. This subgroup was evaluated in FGE.217 with the conclusion – additional genotoxicity data 
required. Therefore, the Panel concluded that [FL-no.10.170] should not be evaluated through the 
Procedure until these data are available. 
In its first evaluation of this group of aliphatic alcohols, aldehydes, acetals, carboxylic acids and esters 
containing an additional oxygenated functional group and lactones (EFSA, 2005b) the Panel 
considered that the candidate substance, 1-hydroxypropan-2-one [FL-no: 07.169], should not be 
evaluated through the Procedure until new data became available because it was found to be genotoxic 
in vitro in bacterial assays. However, in the first revision of FGE.10 (FGE.10Rev1) the Panel 
reconsidered this compound and concluded that it is an endogenous metabolite of acetone which is 
formed from the degradation of body fat/fatty acids and that it would be further metabolised to 
innocuous compounds, and thus not be of concern at the exposure levels resulting from its use as a 
flavouring substance (see Section 8.4, conclusion on the genotoxicity). The Panel therefore decided 
that 1-hydroxypropan-2-one [FL-no: 07.169] could be evaluated along the A side of the Procedure in 
FGE.10Rev1. 
For the safety evaluation of the 62 candidate substances in the present revision of FGE.10 the 
Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations 
of the substances are summarised in Table 2a. 
Step 1 
Fifty-five of the candidate substances are classified according to the decision tree approach by Cramer 
et al. (1978) into structural class I, six are classified into structural class II [FL-no: 02.242, 06.088, 
06.090, 06.095, 06.097 and 06.135] and one into structural class III [FL-no: 06.102]. 
Step 2 
For three of the candidate substances it cannot be concluded that they are metabolised to innocuous 
products. These are 2-butoxyethanol [FL-no: 02.242], the major metabolite of which butoxyacetic acid 
has been recognised as responsible for haematotoxic effects induced by 2-butoxyethanol [FL-no: 
02.242], 1,1,3-triethoxypropane [FL-no: 06.097], which may be metabolised to 3-ethoxypropanoic 
acid, a substance with some structural similarities to 2-butoxyethanol and finally, ethyl 2-
acetylbutyrate [FL-no: 09.824], of which hydrolysis gives rise to 2-acetylbutyric acid, which shows 
some structural similarities to valproic acid, a known teratogenic compound. Therefore, these 
substances are evaluated via the B-side of the Procedure. The evaluation of the remaining 59 candidate 
substances proceeds via the A-side of the Procedure. 
Step A3 
Step A3 applies to 54 candidate substances from structural class I [FL-no: 02.132, 02.198, 05.149, 
07.169, 08.053, 08.082, 08.090, 08.103, 08.113, 09.333, 09.345 - 09.354, 09.360, 09.502, 09.558, 
09.565, 09.580, 09.590, 09.601, 09.626, 09.629, 09.633, 09.634, 09.644, 09.683, 09.815, 09.832, 
09.833, 09.862, 09.874, 09.916, 09.951, 10.038, 10.039, 10.040, 10.045, 10.047 - 10.049, 10.052, 
10.055, 10.058, 10.059, 10.063, 10.068 and 10.168], four candidate substances from structural class II 
[FL-no: 06.088, 06.090, 06.095 and 06.135] and one candidate substance from structural class III [FL-
no: 06.102]. 
The 54 candidate substances which have been assigned to structural class I have estimated European 
daily per capita intakes (MSDI) ranging from 0.0012 to 1500 microgram. The four candidate 
substances from structural class II have MSDIs ranging from 0.0012 to 1.2 microgram and the one 
candidate substance assigned to structural class III has an estimated European daily per capita intake 
of 0.011 microgram (Table 6.1). These intakes are below the thresholds of concern of 1800, 540 and 
90 microgram/person/day for structural class I , II and III, respectively. 
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Accordingly, these 59 candidate substances do not pose a safety concern when used at estimated levels 
of intake as flavouring substances, based on the MSDI approach. 
Step B3 
The MSDIs of the candidate substances 2-butoxyethan-1-ol [FL-no: 02.242], 1,1,3-triethoxypropane 
[FL-no: 06.097] and ethyl 2-acetylbutyrate [FL-no: 09.824], were estimated to be 0.0012 
microgram/capita/day for each. Thus, the MSDI-values of all three candidate substances are below the 
threshold of concern for their structural classes of 540 microgram/person/day (class II) for [FL-no: 
02.242 and 06.097] and of 1800 microgram/person/day (class I) for [FL-no: 09.824]. Accordingly, the 
three substances proceed to step B4 of the Procedure. 
Step B4 
The candidate substance ethyl 2-acetylbutyrate [FL-no: 09.824] is expected to be hydrolysed to the 
corresponding alpha-ethylated carboxylic acid, 2-acetylbutyric acid and ethanol. No toxicity studies 
that would permit establishing a No Observed Adverse Effect Level (NOAEL) are available for ethyl 
2-acetylbutyrate or its hydrolysis product 2-acetylbutyric acid. 2-Acetylbutyric acid is structurally 
related to 2-ethylhexanol [FL-no: 02.082] for which the JECFA has established an ADI of 0.5 mg/kg 
bw/day (JECFA, 1993b). The estimated daily per capita intake, based on the MSDI approach and 
expressed in microgram/kg bw/day for the hydrolysis product of the candidate substance ethyl 2-
acetylbutyrate (and 2-acetylbutyric acid) is approximately 25 x 106 fold below the acceptable daily 
intake (ADI) value of the structurally related 2-ethylhexanol. Furthermore, the hydrolysis product, 2-
acetylbutyric acid, shows some structural similarities to valproic acid, a known teratogenic compound. 
If 2-acetylbutyric acid is considered to be as potent as valproic acid (NOAEL = 600 mg/kg bw/day) 
the margin of safety would be 3 x 109, based on the MSDI of 0.0012 microgram/capita/day. 
Accordingly, it is concluded that ethyl 2-acetylbutyrate [FL-no: 09.824] does not pose a safety 
concern at the estimated level of intake, based on the MSDI approach. 
For the candidate substances 2-butoxyethan-1-ol [FL-no: 02.242] and 1,1,3-triethoxypropane [FL no: 
06.097], the hydrolysis product of which has some structural similarities to 2-butoxyethan-1-ol, a 
NOAEL could not be established in sub-chronic/chronic toxicity studies with respect to 
haemotoxicity. Thus, strictly according to the Procedure additional toxicity data would be needed to 
finalise the evaluation of these two substances in step B4 of the Procedure. However, reconsidering 
and updating the previous version of this FGE, the Panel noted that at least for 2-butoxyethan-1-ol 
[FL-no: 02.242] a wealth of toxicity data is available, so that this substance can be evaluated on a 
broader basis than only the Procedure for the Evaluation of Flavouring substances, which in principle 
has been designed for the evaluation of data-poor substances. 
Considering the data available, especially those on kinetics and mechanism of action (see US-EPA, 
1999 and draft EU-RAR 2007, human health part) it becomes clear that there are major differences in 
sensitivity between humans and rats regarding the prime toxic effect (haemotoxicity) of this substance, 
with humans (together with dog, guinea pig, pig, cat and rabbit) being considerably less sensitive than 
rats (together with mouse, hamster and baboon). For that reason it seems inappropriate to ask for 
further toxicity data in animals, as the available data already cover the most sensitive species. In this 
case an alternative approach is needed and possible for this data-rich substance (EPA, 1999; EU-RAR, 
2007). 
In their evaluation, US-EPA, using a Bench Mark Dose approach, combined with physiologically-
based kinetic modelling arrived at an oral Reference dose (RfD) for chronic exposure of 0.5 mg/kg 
body weight (bw)/day (EPA, 1999). 
In the EU-RAR (2007) a Human equivalent Lowest Observed Adverse Effect Level (LOAEL) of 9.5 
mg/kg bw/day is used, which was derived from the LOAEL in the rat using the same kinetic models as 
applied by US-EPA. A Margin of Safety of 3 between the Human equivalent LOAEL and estimates 
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for chronic exposure of "Consumers" or "Humans, exposed via the Environment" was considered 
sufficient to reach a conclusion of no concern. 
For each of the two candidate flavouring substances 2-butoxyethan-1-ol [FL-no: 02.242] and 1,1,3-tri-
ethoxypropane [FL no: 06.097] an MSDI of 0.0012 microgram/capita/day (see Table 6.1) can be 
calculated. The RfD from US-EPA and the LOAEL from the draft EU-RAR are factors of 2.5 × 107 or 
4.75 × 108 above the MSDI, respectively. The Panel concluded that these margins are sufficiently 
large to decide that based on the MSDI exposure estimates, these substances are of no concern when 
used as flavouring substances. 
In conclusion the Panel considered that all candidate substances evaluated through the Procedure were 
of no safety concern at the estimated levels of intake based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The mTAMDI for the 54 candidate substances in structural class I and for which use levels 
information is available, range from 800 to 5100 microgram/person/day. For 51 of these substances 
the mTAMDI is above the threshold of concern of 1800 microgram/person/day.  
The mTAMDI of the five substances assigned to structural class II, and for which use levels 
information is available, range from 3800 to 3900 microgram/person/day, which is above the threshold 
of concern of 540 microgram/person/day.  
For the two substances from structural class III the mTAMDI is 3800 and 4100 microgram/person/day, 
which is above the threshold of 90 microgram/person/day. 
Thus, for the 58 candidate substances further information is required as the mTAMDIs are above the 
threshold for the structural class. This would include more reliable intake data and then, if required, 
additional toxicological data. For two substances [FL-no: 06.135 and 08.113] use levels are required 
for the food categories as listen in Commission Regulation (EC) No 1565/2000 (EFFA, 2001a; EFFA, 
2003c; EFFA, 2003s; EFFA, 2004ag; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 
2010g; Flavour Industry, 2010n). 
For comparison of the MSDI- and mTAMDI-values see Table 6.1. 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.132 Butane-1,3-diol 0.0061 3900 Class I 1800 
02.198 Octane-1,3-diol 0.0012 3900 Class I 1800 
05.149 Glutaraldehyde 0.055 1600 Class I 1800 
07.169 1-Hydroxypropan-2-one 0.22 1600 Class I 1800 
08.053 Malonic acid 0.0012 3200 Class I 1800 
08.082 Glutaric acid 0.0012 3200 Class I 1800 
08.090 2-Hydroxy-4-methylvaleric acid 0.0012 3800 Class I 1800 
08.103 Nonanedioic acid 0.0012 3200 Class I 1800 
08.113 Succinic acid, disodium salt 1500  Class I 1800 
09.333 sec-Butyl lactate 3.7 3900 Class I 1800 
09.345 Di-isopentyl succinate 0.037 3900 Class I 1800 
09.346 Dibutyl malate 0.0012 3900 Class I 1800 
09.347 Dibutyl succinate 0.12 3900 Class I 1800 
09.348 Diethyl adipate 0.027 3900 Class I 1800 
09.349 Diethyl citrate 0.12 3900 Class I 1800 
09.350 Diethyl fumarate 0.0012 3900 Class I 1800 
09.351 Diethyl maleate 12 3900 Class I 1800 
09.352 Diethyl nonanedioate 0.0012 3900 Class I 1800 
09.353 Diethyl oxalate 0.0012 3900 Class I 1800 
09.354 Diethyl pentanedioate 0.0012 3900 Class I 1800 
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Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
09.360 Ethyl 2-acetoxypropionate 4.9 3900 Class I 1800 
09.502 Ethyl butyryl lactate 0.5 3900 Class I 1800 
09.558 Dimethyl malonate 0.097 3900 Class I 1800 
09.565 Hex-3-enyl 2-oxopropionate 0.74 3900 Class I 1800 
09.580 Hexyl lactate 0.49 3900 Class I 1800 
09.590 Isobutyl lactate 3.7 3900 Class I 1800 
09.601 Isopentyl lactate 7.2 5100 Class I 1800 
09.626 Methyl 2-oxopropionate 0.024 3900 Class I 1800 
09.629 Methyl 3-acetoxyhexanoate 0.0012 3900 Class I 1800 
09.633 Methyl 5-hydroxydecanoate 0.24 3900 Class I 1800 
09.634 Methyl acetoacetate 0.012 3900 Class I 1800 
09.644 Methyl lactate 0.34 3600 Class I 1800 
09.683 Pentyl lactate 0.61 3900 Class I 1800 
09.815 Propyl lactate 0.62 3900 Class I 1800 
09.832 Ethyl 3-acetohexanoate 0.33 3900 Class I 1800 
09.833 iso-Propyl 4-oxopentanoate 0.24 3900 Class I 1800 
09.862 Ethyl 3-acetoxy octanoate 0.0012 3900 Class I 1800 
09.874 Di(2-methylbutyl) malate 0.015 3900 Class I 1800 
09.916 Ethyl 3-hydroxyoctanoate 0.011 3900 Class I 1800 
09.951 Dioctyl adipate 6.1 800 Class I 1800 
10.038 Dec-7-eno-1,4-lactone 0.37 3900 Class I 1800 
10.039 cis-Dec-7-eno-1,4-lactone 1.2 3900 Class I 1800 
10.040 Dec-8-eno-1,5-lactone 0.011 3900 Class I 1800 
10.045 Heptano-1,5-lactone 0.012 3900 Class I 1800 
10.047 Hexadecano-1,16-lactone 0.024 3900 Class I 1800 
10.048 Hexadecano-1,4-lactone 0.0061 3900 Class I 1800 
10.049 Hexadecano-1,5-lactone 0.024 3900 Class I 1800 
10.052 3-Methylnonano-1,4-lactone 0.61 3900 Class I 1800 
10.055 Pentano-1,5-lactone 0.012 3900 Class I 1800 
10.058 Tridecano-1,5-lactone 0.61 3900 Class I 1800 
10.059 Hexadec-7-en-1,16-lactone 1.9 3900 Class I 1800 
10.063 Hexadec-9-en-1,16 lactone 48 3900 Class I 1800 
10.068 Pentadecano-1,14-lactone 0.9 3900 Class I 1800 
10.168 5,6-Dimethyl-tetrahydro-pyran-2-one 1.2 3900 Class I 1800 
09.824 Ethyl 2-acetylbutyrate 0.0012 3900 Class I 1800 
06.088 2-Ethyl-4-methyl-1,3-dioxolane 0.0061 3900 Class II 540 
06.090 4-Hydroxymethyl-2-methyl-1,3-dioxolane 0.012 3900 Class II 540 
06.095 4-Methyl-2-propyl-1,3-dioxolane 0.012 3800 Class II 540 
06.135 2-Isobutyl-4-methyl-1,3-dioxolane 1.2  Class II 540 
02.242 2-Butoxyethan-1-ol 0.0012 3900 Class II 540 
06.097 1,1,3-Triethoxypropane 0.0012 3900 Class II 540 
06.102 2-Hexyl-5-hydroxy-1,3-dioxane 0.011 4100 Class III 90 
10.170 5-Pentyl-3H-furan-2-one 1.2 3800 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
As one of the candidate substances, 5-pentyl-3H-furan-2-one [FL-no: 10.170] show possible genotoxic 
potential in vitro, the substance is not taken through the Procedure. This substance is therefore not 
included in the calculation of the combined intake of the candidate substances evaluated in 
FGE.10Rev3. 
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On the basis of the reported annual production volumes in Europe (EFFA, 2000c; EFFA, 2003d; 
EFFA, 2008b; Flavour Industry, 2010n), the combined estimated daily per capita intake as flavourings 
of the 55 candidate flavouring substances assigned to structural class I is 1600 microgram, of the six 
candidate flavouring substances assigned to structural class II is 1.2 microgram and of the one 
candidate substance assigned to structural class III, 0.01 microgram. These estimates do not exceed the 
thresholds of concern for the corresponding structural classes of 1800, 540 and 90 
microgram/person/day, respectively. 
The candidate lactones are structurally related to 278 supporting lactones from structural class I, for 
which the combined intake based on the MSDI approach is approximately 20000 
microgram/capita/day. The supporting substances were evaluated by the JECFA at the 49th meeting, 
where it was noted that although the combined intake exceeds the threshold for the structural class, the 
lactones are expected to be hydrolysed and completely metabolised to innocuous products at the 
estimated level of intake as flavouring substances, and would not give rise to perturbations outside the 
physiological range. The Panel agreed with this view and concluded that the additional intake of about 
55 microgram/capita/day for the candidate lactones is negligible compared to the combined intake of 
20000 microgram/capita/day of the supporting lactones. 
Likewise 41 candidate substances are structurally related to 339 supporting aliphatic primary alcohols 
and related substances containing an additional oxygenated functional group from structural class I, 
and for which intake data are available. The combined intake of these supporting substances amounts 
to approximately 24000 microgram/capita/day based on the MSDI approach. These substances were 
evaluated at the 53rd JECFA meeting, where it was also noted that the substances are expected to be 
efficiently metabolised to innocuous products and would not give rise to perturbations outside the 
physiological range. The Panel agreed with this view and concluded that the contribution from the 
combined intake of the candidate substances of 1540 microgram/capita/day would not alter the 
JECFA conclusion based on a combined intake of 24000 microgram/capita/day. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for 16 of the candidate substances (Annex IV, Table IV.1). For the majority of 
candidate substances, oral LD50 values, in mice or rats, varied from 100 mg/kg up to more than 5000 
mg/kg body weight (bw). For butane-1,3-diol [FL-no: 02.132] and octane-1,3-diol [FL-no: 02.198] 
LD50 values between 20 g/kg bw and approximately 30 g/kg bw are reported (Annex IV, Table IV.1). 
Forty-three supporting substances were tested for acute toxicity in mice and/or rats (Annex IV, Table 
IV.1). For the majority of the supporting substances, oral LD50 values, in mice or rats, varied from 
1300 mg/kg up to 18500 mg/kg bw. For diethyl sebacate [FL-no: 09.475] and tributyl acetylcitrate 
[FL-no: 09.511] LD50 values larger than 30 g/kg bw are reported. 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
                                                     
 
8 European production volumes are only available for 27 of the 29 JECFA evaluated lactones – these substances 
have been evaluated by JECFA before 2000 and accordingly no EFSA considerations have been performed 
including requests for production volumes. 
9 European production volumes are only available for 33 of the 47 JECFA evaluated alcohols and related 
substances – these substances have been evaluated by JECFA before 2000 and accordingly no EFSA 
considerations have been performed including requests for production volumes. 
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8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Subacute/subchronic/chronic toxicity data are available for five candidate substances, 2-butoxyethan-
1-ol [FL-no: 02.242], butane-1,3-diol [FL-no: 02.132], malonic acid [FL-no: 08.053], glutaraldehyde 
[FL-no: 05.149], nonanedioic acid [FL-no: 08.103] and for 20 supporting substances of the present 
Flavouring Group Evaluation (JECFA, 1998a; JECFA, 2000c). Additionally, data are available for 
two to succinic acid, disodium salt [FL-no: 08.113] structurally related substances, succinate 
monosodium and disodium hexahydrate. 
Available data on repeated dose toxicity show that haemolysis is the primary and critical response 
elicited in the main animal test models (rats and mice) following oral exposure to 2-butoxyethan-1-ol, 
in which the haematotoxic action is produced by the metabolite butoxyacetic acid (this effect is also 
seen following other exposure routes such as inhalation or dermal exposure. These exposure routes are 
not considered relevant for this evaluation as data from oral exposure are available). Notably, the 
haematotoxic effect exhibits a pronounced species difference. In sensitive species (rat, mouse, 
hamster, baboon), 2-butoxyethan-1-ol produces a characteristic toxicity that is revealed clinically by 
the appearance of haemoglobinuria and pathologically by changes in a variety of blood parameters 
(EPA, 1999; EU-RAR, 2004a). Slight decrease in body weight gain, haematological and liver effects 
have been reported for male and female rats, respectively (NTP, 1993a). Human erythrocytes are about 
100-times less sensitive than rat erythrocytes as judged by prehaemolytic changes in vitro (increase in 
mean erythrocyte volume, erythrocyte deformability) consistently observed in both species. Studies 
have also shown that potentially sensitive human sub-populations, including children, the elderly and 
those with sickle cell anemia, do not show increased sensitivity to the haemolytic action of 2-
butoxyethan-1-ol. Furthermore, the in vivo blood concentrations producing haemolysis in the animal 
experiments are considered unlikely to occur under normal conditions of human exposure to 2-
butoxyethan-1-ol (EU-RAR, 2004a). 
Carcinogenicity:  
In a two year inhalation study, F344/N rats were exposed to 0, 0.031, 0.0625 and 0.125 mg/m3  and 
B6C3F1 mice were exposed to 0, 0.0625, 0.125 and 0.250 mg/m3 2-butoxyethan-1-ol (NTP, 2000b). 
The exposure caused a low incidence of haemangiosarcoma in male mice at the highest exposure 
concentration; haemangiosarcoma did not occur in female mice or in rats. In female mice, 2-
butoxyethan-1-ol caused an increased incidence of forestomach tumours. It was not carcinogenic in 
rats. The occurrence of haemangiosarcoma in male mice only at highest exposure concentration is 
suggestive of a threshold phenomenon, related to the induction of haemolysis in rodent species. With 
regard to human relevance, the mechanism proposed for the induction of haemangiosarcomas strongly 
supports the conclusion that 2-butoxyethan-1-ol is unlikely to be a carcinogenic hazard at the 
estimated level of intake as flavouring substance, because human erythrocytes are demonstrably more 
resistant to haemolysis than are rodent erythrocytes.  
Glutaraldehyde10 [FL-no: 05.149] (50, 250, 1000 mg/l in drinking water, resulting in doses of 2.9-6.9, 
14.5-31.8 and 54.7-104.6 mg/kg/day, respectively) was not tumorigenic in a two year carcinogenicity 
                                                     
 
10 Glutaraldehyde is also used in food contact material (FCM). It was evaluated by the former Scientific Committee on Food 
(SCF List 7, http://europa.eu.int/comm/food/fs/sc/scf/out50_en.pdf), however, this is not a final evaluation. According to 
German recommendations, glutardialdehyde (synonym: glutaraldehyde) may be used for the production of artificial sausage 
skin (maximum use level 0.1 %). The maximum residual amount of glutardialdehyde is 50 mg per kg artificial sausage skin 
(ready for use). Furthermore, glutardialdehyde may be used as anti slime agent for the production of paper as FCM 
(maximum use level 2.5 % based on dry fibre material). The maximum residual amount of glutardialdehyde is 2 mg per kg 
paper (ready for use). The Panel noted that maximum residual amounts of glutaraldehyde in food contact material (as set e.g. 
in German recommendations) could apparently conflict with reported use levels of glutaraldehyde as flavouring. However, in 
the German recommendations, the maximum residual amounts were set considering the technologically needed use levels 
(limited data submitted) rather than on toxicological data, and the Panel therefore did not find the low maximum residual 
amounts for glutaraldehyde as such in conflict with higher use levels for glutaraldehyde as flavouring, which could therefore 
go through the Procedure. 
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study on male and female rats (Van Miller et al., 2002). Furthermore, malonic acid [FL-no: 08.053] 
was negative in a liver foci tumour promotion assay.  
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Data on developmental toxicity and reproductive toxicity are available for the following five candidate 
substances: 2-butoxyethan-1-ol [FL-no: 02.242], butane-1,3-diol [FL-no: 02.132], glutaric acid [FL-
no: 08.082], glutaraldehyde [FL-no: 05.149] and nonanedioic acid [FL-no: 08.103]. Studies for 
supporting substances comprise butyro-1,4-lactone [FL-no: 10.006] and adipic acid [FL-no: 08.026] 
(JECFA, 1998a; JECFA, 2000c) and one structurally related substance, succinate disodium 
hexahydrate (Annex IV, Table IV.3). 
For 2-butoxyethan-1-ol [FL-no: 02.242] no effects on fertility were observed in female and male mice 
given 2-butoxyethan-1-ol in the drinking water in a continuous breeding study in which a NOAEL of 
720 mg/kg was derived (EU-RAR, 2004a). As to developmental toxicity, studies performed on 
animals via various administration routes did not demonstrate any teratogenic potential, and 
foetotoxicity and embryotoxicity (lethality and resorptions) were only observed in the presence of 
maternal toxicity (regenerative haemolytic anaemia). Other effects seen on foetuses were an increase 
in the incidence of skeletal variations, which are generally described as ossification delays. The effects 
seen in developmental toxicity studies with 2-butoxyethan-1-ol are considered to result from 
haemolysis and subsequent maternal anemia (EU-RAR, 2004a). Overall, 2-butoxyethan-1-ol is not 
considered to pose a safety concern with respect to reproduction and development at the estimated 
level of intake as flavouring substance. 
No information is available on ethyl 2-acetyl butyrate [FL-no: 09.824], the hydrolysis product of 
which, 2-acetyl butyric acid, has some structural similarities to valproic acid, which, together with a 
number of its derivatives, has been recognised as teratogenic in rodents and in humans (Nau and 
Löscher, 1986; Samren et al., 1997; Kaneko et al., 1999). Offspring of mothers using > 1000 mg/kg 
bw/day valproic acid per day were at a significantly increased risk of major congenital malformations 
especially neural tube defects, compared to offspring exposed < or 600 mg valproic acid/day (RR 6.8; 
95 % CI: 1.4 - 32.7). No difference in risk of major congenital malformations was found between the 
offspring exposed to 601 - 1000 mg/day and < or = 600 mg/kg bw/day. Thus, 600 mg/day is 
considered as NOAEL for the teratogenic effects of valproic acid in humans. 
Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Genotoxicity data were provided for 12 of the candidate substances. These 12 substances are pentano-
1,5-lactone [FL-no: 10.055], 5,6-dimethyl-tetrahydro-pyran-2-one [FL-no: 10.168], glutaraldehyde 
[FL-no: 05.149], 1-hydroxypropan-2-one [FL-no: 07.169], butane-1,3-diol [FL-no: 02.132], malonic 
acid [FL-no: 08.053], diethyl maleate [FL-no: 09.351], diethyl adipate [FL-no: 09.348], methyl 
acetoacetate [FL-no: 09.634], 2-butoxyethan-1-ol [FL-no: 02.242], glutaric acid [FL-no: 08.082] and 
succinic acid, disodium salt [FL-no: 08.113]. There were genotoxicity data on 22 supporting 
substances and for one structurally related substance (Annex IV, Table IV.4 and IV.5). 
For 5-pentyl-3H-furan-2-one [FL-no: 10.170] flavour industry informs that the commercial product is 
a mixture of two structural isomers – 2/3 is the named compound (5-pentyl-3H-furan-2-one) and 1/3 is 
the structural isomer - 5-pentyl-5H-furan-2-one. This latter isomer is identical to [FL-no: 10.054], 
which is an alpha,beta-unsaturated alcohol (after hydrolysis of the lactone) allocated to FGE.19 
subgroup 4.1. This subgroup was evaluated in FGE.217 with the conclusion that additional 
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genotoxicity data required. Therefore, the Panel concluded that [FL-no: 10.170] should not be 
evaluated through the Procedure until these data are available. 
In vitro 
Pentano-1,5-lactone [FL-no: 10.055], 5,6-dimethyl-tetrahydro-pyran-2-one [FL-no: 10.168] methyl 
acetoacetate [FL-no: 09.634] and succinic acid [FL-no: 08.113] were reported to be negative in 
microbial mutagenicity assays.  
1-Hydroxypropan-2-one [FL-no: 07.169] was positive in Ames tests using strains TA 100 and TA 104 
in the presence and absence of S-9 metabolic activation (Garst et al., 1983; Marnett et al., 1985a; 
Yamaguchi, 1982; Yamaguchi and Nakagawa, 1983);. These results are consistent across the four 
reported studies which, despite limitations in study design and reporting, suggest that 1-
hydroxypropan-2-one should be considered an in vitro mutagen in bacteria. There are no data provided 
on either in vitro endpoints nor on in vivo studies.  
Diethyl maleate [FL-no: 09.351] was reported to produce mutations in the TK +/- locus of L5178Y 
mouse lymphoma cells. However, the concentration required for a two-fold increase of mutations 
results in 70 % growth reduction (Wangenheim and Bolcsfoldi, 1988), rendering this effect 
questionable. Diethyl maleate was positive in an aneuploidy test using V79 Chinese hamster lung cells 
at 8.7 x10-6 M but not at 5.2 x10-6 M (Önfelt, 1987); generally aneuploidy is considered as a threshold 
phenomenon.  
In vitro and/or in vivo 
Glutaric acid [FL-no: 08.082] was reported to be negative in the Ames and Rec test as well as in an in 
vivo test for rat bone marrow aberrations.  
2-Butoxyethan-1-ol [FL no: 02.242] was negative in the Ames test and in in vitro tests in mammalian 
cells for induction of forward mutations, chromosomal aberrations and sister chromatid exchanges 
(SCE). Positive results were only reported in one study in V79 cells (for induction of forward 
mutations, SCE and micronuclei) at doses above the maximum level recommended by current OECD 
Guidelines. Equivocal positive results were reported in an unscheduled DNA synthesis (UDS) assay in 
primary rat hepatocytes. In vivo, negative results were obtained in an adequate micronucleus tests in 
rats and mice following oral or intraperitoneal administration. No evidence of DNA binding or 
alteration of DNA methylation was obtained in a study in rats and mice. The overall experimental 
evidence indicated that 2-butoxyethan-1-ol is not genotoxic (see Table IV.5). 
Glutaraldehyde [FL-no: 05.149] exhibits genotoxic effects in in vitro tests, most consistently in the 
bacterial mutagenicity assays. Forward gene mutation tests in vitro in mammalian cells have given 
variable results depending on the locus: negative with HGPRT and positive with TK. Also, SCE, 
chromosome aberration and UDS tests have shown no effect to a weakly positive effect, depending on 
the laboratory, protocol, dosages and sampling times. However, that any in vitro potential for 
genotoxic effects will not be expressed in vivo is indicated by the in vivo study results, which include 
chromosomal aberrations, mammalian erythrocyte micronucleus test, UDS and recessive lethal 
mutations. The only study suggesting an in vivo effect was an increase in micronuclei in mouse blood 
cells up to 15 mg/kg bw. However, the data are insufficiently reported. The negative results from the 
well-conducted in vivo studies may be related to the rapid metabolism and protein binding 
characteristics of glutaraldehyde, and the related observation that although 14C-labelled 
glutaraldehyde may be detected in cell cytoplasm there is no nuclear fraction radioactivity (Vergnes 
and Ballantyne, 2002). 
Butane-1,3-diol [FL-no: 02.132] was reported as not inducing chromosomal aberration in bone 
marrow and was negative in a rat dominant lethal assay. Butane-1,3-diol [FL-no: 02.132] was checked 
for cytogenetic effects over a period of three generations at doses of 5 % (5000 mg/kg/day), 10 % and 
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24 %. None of the doses produced abnormal rates of bone marrow metaphase cells as compared to 
controls (Hess et al., 1981). 
Malonic acid [FL-no: 08.053] was found negative in a rat liver foci assay, diethyl adipate [FL-no: 
09.348] was reported to be negative in a mouse dominant lethal assay. 
Genotoxicity tests are available for 22 supporting substances. Some positive test results from in vitro 
studies are reported for 4-hydroxybutyric acid lactone [FL-no: 10.006], which, however, was found 
negative in a reliable Drosophila in vivo sex-linked recessive lethal mutation assay (Table IV 4 and 5). 
Results of in vivo bone marrow micronucleus assays in mice available for 4-hydroxybutyric acid 
lactone were also negative, however, since the PCE/NCE ratio was not reported it is not clear if the 
test substance reached the bone marrow (Table IV.5). Positive in vitro data that cannot be evaluated 
are reported for hexano-1,5-lactone [FL-no: 10.010], nonano-1,4-lactone [FL-no: 10.001], undecano-
1,4-lactone [FL-no: 10.002], undecano-1,5-lactone [FL-no: 10.011] and ethyl acetoacetate [FL-no: 
09.402] (Annex IV, Table IV.4). 
Conclusions on genotoxicity 
Genotoxicity data are only available on a very limited number of the candidate substances in this 
Flavouring Group Evaluation and none has a complete package of mutagenicity endpoints. 
One of the candidate substances (1-hydroxypropan-2-one [FL-no: 07.169]) induced gene mutations in 
bacteria but has not been studied in vivo or in other in vitro assays. 
In its first evaluation of this group of aliphatic alcohols, aldehydes, acetals, carboxylic acids and esters 
containing an additional oxygenated functional group and lactones (EFSA, 2005b) the Panel 
considered that for the candidate substance, 1-hydroxypropan-2-one [FL-no: 07.169], it was necessary 
to request additional in vitro data from studies in mammalian cells. However, in the first revision of 
FGE.10 (FGE.10Rev1) the Panel reconsidered the fact that 1-hydroxypropan-2-one is an endogenous 
metabolite of acetone. Acetone is endogenously formed from the degradation of body fat/fatty acids 
and occurs in the blood of healthy humans not exposed to external sources of acetone in amounts of 
approximately 4 - 12 mg/person corresponding to 0.7 to 2 mg/l blood. Under these conditions, the 
majority of the acetone in blood would be metabolised to 1-hydroxypropan-2-one, which is rapidly 
further metabolised to endogenous compounds (methylglyoxal, pyruvate and glucose) in the 
methylglyoxal pathway. The estimated exposure of 0.22 microgram/capita/day is considerably lower 
than that resulting from the metabolism of acetone and would not significantly add to the internal 
exposure to 1-hydroxypropan-2-one in the body and would not perturb the normal catabolism of the 
compound to innocuous endogenous products. The Panel therefore concluded that 1-hydroxypropan-
2-one [FL-no: 07.169] would not be of safety concern at the exposure level resulting from its use as a 
flavouring substance. Consequently, the Panel decided that further studies on the in vitro genotoxicity 
of 1-hydroxypropan-2-one [FL-no: 07.169] would not be required. 
Glutaraldehyde was tested in vitro and in vivo, with positive findings in vitro. However, based upon 
the negative results of in vivo genotoxicity assays, along with the lack of tumorigenicity in mice and 
rats, the in vitro genotoxicity data are not considered relevant for the safety evaluation of 
glutaraldehyde. 
Disodium succinate [FL-no: 08.113] did not induce mutations in bacterial reverse mutation assays 
using S.typhimurium strains TA97, TA94, TA98, TA100, TA1535, and TA1537 at 5 mg/plate (with 
metabolic activation)  and in TA97 and TA102 at 15 mg/plate (with or without metabolic activation). 
A chromosomal test with Chinese hamster lung (CHL) cells revealed equivocal effects on polyploidy 
at 15 mg/mL (Ishidate et al., 1984; Fujita et al., 1994; OECD, 2003). These results are supported by 
studies on disodium succinate hexahydrate. 
5-pentyl-3H-furan-2-one [FL-no: 10.170] should not be evaluated through the Procedure until the 
additional gentoxicity data for FL-no: 10.054 are available, as stated in FGE 217. 
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The available experimental data indicate that 2-butoxyethan-1-ol is not genotoxic. 
For the remaining candidate substances, the genotoxic potential cannot be assessed adequately, 
however, from the limited data available there were no indications that genotoxicity for these 
substances should give rise to safety concern. 
Genotoxicity data are summaries in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The candidate substances are alcohols, aldehydes, acetals, carboxylic acids and esters containing 
additional oxygenated functional groups and lactones. 
The present revision of FGE.10, FGE.10Rev3, includes the assessment of two additional candidate 
substances [FL-no: 09.951 and 10.170]. 
Thirty-six of the candidate substances possess one or more chiral centres and eight can exist as 
geometrical isomers due to the presence and the position of a double bond. For four of these eight 
substances [FL-no: 10.038, 10.040, 10.059 and 10.063] the stereoisomeric composition has not been 
specified sufficiently. For [FL-no: 10.170] the Industry has informed that the commercial substance is 
a mixture of two structural isomers. One of these isomers posses a chiral centre for which the 
configuration has not been specified. 
Fifty-five of the candidate substances belong to structural class I, six of the candidate substances 
belong to structural class II, and two belong to structural class III according to the decision tree 
approach presented by Cramer et al. (1978). 
Fifty of the flavouring substances in the present group have been reported to occur naturally in a wide 
range of food items. 
The candidate substances which have been assigned to structural class I have estimated European daily 
per capita intakes (MSDI) ranging from 0.0012 to 1500 microgram. The candidate substances from 
structural class II have MSDIs ranging from 0.0012 to 1.2 microgram and the two candidate 
substances assigned to structural class III have estimated European daily per capita intakes of 0.011 
and 1.2 microgram (Table 6.1). These intakes are below the thresholds of concern of 1800, 540 and 90 
microgram/person/day for structural class I, II and III, respectively. 
The combined estimated daily per capita intake as flavourings of the 55 candidate substances assigned 
to structural class I is 1600 microgram, which does not exceed the threshold of concern for a substance 
belonging to structural class I of 1800 microgram/person/day. Likewise, the combined estimated daily 
per capita intake as flavouring of the six candidate substances assigned to structural class II is 1.2 
microgram, which does not exceed the threshold of concern for a substance belonging to structural 
class II of 540 microgram/person/day. 
The candidate lactones are structurally related to 27 supporting lactones from structural class I, for 
which the combined intake based on the MSDI approach is approximately 20000 
microgram/capita/day. The supporting substances were evaluated by JECFA at the 49th meeting, 
where it was noted that although the combined intake exceeds the threshold for the structural class, the 
lactones are expected to be hydrolysed and completely metabolised to innocuous products at the 
estimated level of intake as flavouring substances, and would not give rise to perturbations outside the 
physiological range. The Panel agreed with this view and concluded that the additional intake of about 
55 microgram/capita/day for the candidate lactones is negligible compared to the combined intake of 
20000 microgram/capita/day of the supporting lactones. 
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Likewise 41 candidate substances are structurally related to 33 supporting aliphatic primary alcohols 
and related substances containing an additional oxygenated functional group from structural class I, 
and for which intake data are available. The combined intake of these supporting substances amounts 
to approximately 24000 microgram/capita/day based on the MSDI approach. These substances were 
evaluated at the 53rd JECFA meeting, where it was also noted that the substances are expected to be 
efficiently metabolised to innocuous products and would not give rise to perturbations outside the 
physiological range. The Panel agreed with this view and concluded that the contribution from the 
combined intake of the candidate substances of 1540 microgram/capita/day would not alter the 
JECFA conclusion based on a combined intake of 24000 microgram/capita/day. 
For 5-pentyl-3H-furan-2-one [FL-no: 10.170], the flavour Industry informs that the commercial 
product is a mixture of two structural isomers – 2/3 is the named compound (5-pentyl-3H-furan-2-one) 
and 1/3 is the structural isomer - 5-pentyl-5H-furan-2-one. This latter isomer is identical to [FL-no: 
10.054], which is an alpha, beta-unsaturated alcohol (after hydrolysis of the lactone), allocated to 
subgroup 4.1 of FGE.19 (FGE.217).The Panel concluded that 5-pentyl-3H-furan-2-one [FL-no: 
10.170] should not be evaluated through the Procedure until the additional gentoxicity data for [FL-
no: 10.054] are available, as stated in FGE 217.  
The Panel reconsidered the fact that 1-hydroxypropan-2-one [FL-no: 07.169] is an endogenous 
metabolite of acetone. Acetone is endogenously formed from the degradation of body fat/fatty acids 
and occurs in the blood of healthy humans not exposed to external sources of acetone in amounts of 
approximately 4 - 12 mg/person corresponding to 0.7 to 2 mg/l blood. Under these conditions, the 
majority of the acetone in blood would be metabolised to 1-hydroxypropan-2-one, which is rapidly 
further metabolised to endogenous compounds (methylglyoxal, pyruvate and glucose) in the 
methylglyoxal pathway. The estimated exposure of 0.22 microgram/capita/day is considerably lower 
than that resulting from the metabolism of acetone and would not significantly add to the internal 
exposure to 1-hydroxypropan-2-one in the body and would not perturb the normal catabolism of the 
compound to innocuous endogenous products. The Panel therefore decided that further genotoxicity 
data are not required and that the substance could be taken through the Procedure. 
For the remaining candidate substances, the genotoxic potential cannot be assessed adequately, 
however, from the limited data available there were no indications that genotoxicity for these 
substances should give rise to safety concern. 
It can be anticipated that, at the estimated levels of intake as flavouring substances, the alcohols, 
aldehydes, acetals, carboxylic acids and esters with an additional oxygenated functional group and 
aliphatic lactones included in the present FGE are generally hydrolysed and completely metabolised to 
innocuous products, many of which are endogenous in humans. The consideration on the actual levels 
of intake becomes particularly relevant for one candidate substance, diethyl maleate [FL-no: 09.351], 
as when administered at high doses, it is able to induce severe GSH depletion, due to its prompt 
metabolism to GSH-conjugates. This may also be the case for the structurally related diethyl fumarate 
[FL-no: 09.350]. However, as the estimated levels of intake as flavouring substances are sufficiently 
low for these two substances, profound GSH depletion is not expected. For three of the candidate 
substances it cannot be concluded that they are metabolised to innocuous products. These are 2-
butoxyethanol [FL-no: 02.242], the major metabolite of which butoxyacetic acid has been recognised 
as responsible for haematotoxic effects induced by 2-butoxyethanol [FL-no: 02.242], 1,1,3-
triethoxypropane [FL-no: 06.097], which may be metabolised to 3-ethoxypropanoic acid, a substance 
which has structural similarities to 2-butoxyethanol and finally, ethyl 2-acetylbutyrate [FL-no: 
09.824], of which hydrolysis gives rise to 2-acetylbutyric acid, which shows some structural 
similarities to valproic acid, a known teratogenic compound. Adequate margins of safety could be 
established for these three substances in step B4 of the Procedure. 
Otherwise, it was noted that where toxicity data were available they were consistent with the 
conclusions in the present Flavouring Group Evaluation using the Procedure. 
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It was considered that on the basis of the default MSDI approach that the 62 flavouring substances, to 
which the Procedure have been applied, would not give rise to safety concerns at the estimated levels 
of intake arising from their use as flavouring substances. 
The mTAMDI for the 54 candidate substances in structural class I, for which use levels information is 
available, range from 800 to 5100 microgram/person/day. For 51 of these substances the mTAMDI is 
above the threshold of concern of 1800 microgram/person/day. The mTAMDI of the five substances 
assigned to structural class II, and for which use levels information is available, range from 3800 to 
3900 microgram/person/day, which is above the threshold of concern of 540 microgram/person/day. 
For the two substances from structural class III the mTAMDIs are 3800 and 4100, which is above the 
threshold of 90 microgram/person/day. For two substances [FL-no: 06.135 and 08.113] no use levels 
have been provided for the food categories as listed in Commission Regulation (EC) No 1565/2000. 
Thus, for 60 candidate substances further information is required. This would include more reliable 
intake data and then, if required, additional toxicological data. The three candidate substances [FL-no: 
05.149, and 07.169 and 09.951] which have mTAMDI intake estimates below the threshold of concern 
for structural class I are also expected to be metabolised to innocuous products. 
Thus, in conclusion, 62 of the 63 flavouring substances were evaluated through the Procedure (based 
on MSDI approach), as one flavouring substance, 5-pentyl-3H-furan-2-one [FL-no: 10.170] could not 
be evaluated through the Procedure until adequate genotoxicity data become available. 
In order to determine whether the conclusion for the 62 candidate substances, which have been 
evaluated using the Procedure, can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Specifications including complete purity criteria and identity for the 
materials of commerce have been provided for 58 flavouring substances. For four substances [FL-no: 
10.038, 10.040, 10.059 and 10.063] information on composition of mixture and/or stereoisomerism 
has not been specified sufficiently. For one substance [FL-no: 10.063] an identity test is missing. 
Thus, the final evaluation of the materials of commerce cannot be performed for four substances [FL-
no: 10.038, 10.040, 10.059 and 10.063], pending further information. 
For the remaining 58 candidate substances [FL-no: 02.132, 02.198, 02.242, 05.149, 06.088, 06.090, 
06.095, 06.097, 06.102, 06.135, 07.169, 08.053, 08.082, 08.090, 08.103, 08.113, 09.333, 09.345 - 
09.354, 09.360, 09.502, 09.558, 09.565, 09.580, 09.590, 09.601, 09.626, 09.629, 09.633, 09.634, 
09.644, 09.683, 09.815, 09.824, 09.832, 09.833, 09.862, 09.874, 09.916, 09.951, 10.039, 10.045, 
10.047 - 10.049, 10.052, 10.055, 10.058, 10.068 and 10.168] the Panel concluded that they would 
present no safety concern at the estimated levels of intake based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN FGE.10REV3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.132 
 
Butane-1,3-diol OH
OH  
 
 
107-88-0 
Liquid 
C4H10O2 
90.12 
Soluble 
Freely soluble 
102 (13 hPa) 
 
MS 
95 % 
1.436-1.442 
0.992-0.998 
 
Racemate. 
02.198 
 
Octane-1,3-diol 
OH
OH
 
 
 
23433-05-8 
Liquid 
C8H18O2 
146.23 
Sparingly soluble 
Freely soluble 
82 (7 hPa) 
 
MS 
95 % 
1.452-1.458 
0.980-0.986 
 
Racemate. 
02.242 
 
2-Butoxyethan-1-ol O
OH
  
10182 
111-76-2 
Liquid 
C6H14O2 
118.18 
Slightly soluble 
Freely soluble 
170 
 
MS 
95 % 
1.416-1.422 
0.899-0.905 
 
 
05.149 
 
Glutaraldehyde O O   
 
111-30-8 
Liquid 
C5H8O2 
100.12 
Soluble 
Freely soluble 
188 
 
MS 
95 % 
1.430-1.436 
1.005-1.011 
 
 
06.088 
 
2-Ethyl-4-methyl-1,3-dioxolane 
OO
 
 
 
4359-46-0 
Liquid 
C6H12O2 
116.16 
Soluble 
Freely soluble 
116 
 
MS 
95 % 
1.402-1.408 
0.916-0.922 
 
Mixture of ((R/R), (R/S), 
(S/R) & (S/S) in equal 
ratios) (EFFA, 2010a). 
06.090 
 
4-Hydroxymethyl-2-methyl-1,3-
dioxolane 
O
O
HO
 
 
 
3674-21-3 
Liquid 
C5H10O3 
118.13 
Practically insoluble 
or insoluble 
Freely soluble 
187 
 
MS 
95 % 
1.440-1.446 
1.120-1.126 
 
Racemate. CASrn in 
Register to be changed to 
3773-93-1 (EFFA, 2006ac). 
CASrn in Register refers to 
the (2R, 4S) enantiomer. 
06.095 
 
4-Methyl-2-propyl-1,3-dioxolane 
O
O
 
 
 
4352-99-2 
Liquid 
C7H14O2 
130.19 
Soluble 
Freely soluble 
143 
 
MS 
95 % 
1.409-1.415 
0.907-0.913 
 
Mixture of ((R/R), (R/S), 
(S/R) & (S/S) in equal 
ratios) (EFFA, 2010a). 
06.097 
 
1,1,3-Triethoxypropane 
O O
O
 
 
10075 
7789-92-6 
Liquid 
C9H20O3 
176.26 
Practically insoluble 
or insoluble 
Freely soluble 
185 
 
MS 
95 % 
1.403-1.409 
0.890-0.896 
 
 
06.102 
 
2-Hexyl-5-hydroxy-1,3-dioxane 
O
O
HO
 
 
2016 
1708-36-7 
Solid 
C10H20O3 
188.22 
Practically insoluble 
or insoluble 
Freely soluble 
255 
44 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
06.135 
1732 
2-Isobutyl-4-methyl-1,3-dioxolane 
O
O
 
4378 
 
18433-93-7 
Liquid 
C8H16O2 
144.21 
Insoluble 
Soluble 
150 
 
MS 
96 % 
n.a. 
0.895 
 
Mixture of ((R/R), (R/S), 
(S/R) & (S/S) in equal 
ratios) (EFFA, 2010a). 
07.169 
 
1-Hydroxypropan-2-one O
OH  
 
11101 
116-09-6 
Liquid 
C3H6O2 
74.08 
Soluble 
Freely soluble 
146 
 
MS 
95 % 
1.420-1.426 
1.084-1.090 
 
 
08.053 
 
Malonic acid 
HO OH
O O
 
 
2264 
141-82-2 
Solid 
C3H4O4 
104.16 
Soluble 
Freely soluble 
264 
135 
MS 
95 % 
n.a. 
n.a. 
 
 
08.082 
 
Glutaric acid O
HO
O
OH  
 
 
110-94-1 
Solid 
C5H8O4 
132.12 
Soluble 
Freely soluble 
303 
98 
MS 
95 % 
n.a. 
n.a. 
 
 
08.090 
 
2-Hydroxy-4-methylvaleric acid 
OH
OH
O
 
 
10118 
498-36-2 
Solid 
C6H12O3 
132.16 
Sparingly soluble 
Freely soluble 
249 
76 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
08.103 
 
Nonanedioic acid HO OH
O O  
 
10079 
123-99-9 
Solid 
C9H16O4 
188.22 
Sparingly soluble 
Freely soluble 
225 (13 hPa) 
107 
MS 
95 % 
n.a. 
n.a. 
 
 
08.113 
 
Succinic acid, disodium salt 
Na+
-O
O
O
O-
Na+
 
3277 
 
150-90-3 
Solid 
C4H4Na2O4 
162.05 
Soluble 
Insoluble 
426.03 
156.43 
IR 
60 
n.a. 
n.a. 
 
Anhydrous when heated to 
120°C. Min.assay: 
Anhydrous 60 %, hydrate 40 
% (Fenaroli, 1995). 
09.333 
 
sec-Butyl lactate 
O
OH
O  
 
 
18449-60-0 
Liquid 
C7H14O3 
146.19 
Slightly soluble 
Freely soluble 
172 
 
MS 
95 % 
1.414-1.420 
0.970-0.976 
 
Racemate. 
09.345 
 
Di-isopentyl succinate 
O
O
O
O  
 
10555 
818-04-2 
Liquid 
C14H26O4 
258.36 
Practically insoluble 
or insoluble 
Freely soluble 
298 
 
MS 
95 % 
1.431-1.437 
0.955-0.961 
 
 
09.346 
 
Dibutyl malate 
OH
O
O
O
O
 
 
 
1587-18-4 
Solid 
C12H22O5 
246.30 
Practically insoluble 
Freely soluble 
170 (16 hPa) 
82 
MS 
95 % 
n.a. 
n.a. 
 
CASrn in Register to be 
changed to 6280-99-5 
(racemate). 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.347 
 
Dibutyl succinate O
O
O
O
 
 
 
141-03-7 
Liquid 
C12H22O4 
230.30 
Practically insoluble 
or insoluble 
Freely soluble 
275 
 
MS 
95 % 
1.426-1.432 
0.973-0.979 
 
 
09.348 
 
Diethyl adipate 
O
O
O
O  
 
 
141-28-6 
Liquid 
C10H18O4 
202.25 
Practically insoluble 
or insoluble 
Freely soluble 
244 
 
MS 
95 % 
1.425-1.431 
1.004-1.010 
 
 
09.349 
 
Diethyl citrate 
O O
O
OH
OHO
O
 
 
 
32074-56-9 
Solid 
C10H16O7 
248.23 
Sparingly soluble 
Freely soluble 
354 
237 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate. 
CASrn in Register refers to 
incompletely defined 
substance. 
09.350 
 
Diethyl fumarate 
O
O
O
O  
 
 
623-91-6 
Liquid 
C8H12O4 
172.18 
Practically insoluble 
or insoluble 
Freely soluble 
218 
 
MS 
95 % 
1.438-1.444 
1.049-1.055 
 
 
09.351 
 
Diethyl maleate 
O O
O O
 
 
10551 
141-05-9 
Liquid 
C8H12O4 
172.18 
Practically insoluble 
or insoluble 
Freely soluble 
218 
 
MS 
95 % 
1.438-1.445 
1.049-1.055 
 
 
09.352 
 
Diethyl nonanedioate 
O O
OO
 
 
10549 
624-17-9 
Liquid 
C13H24O4 
244.33 
Practically insoluble 
or insoluble 
Freely soluble 
290 
 
NMR 
95 % 
1.432-1.438 
0.970-0.976 
 
 
09.353 
 
Diethyl oxalate 
O
O
O
O  
 
 
95-92-1 
Liquid 
C6H10O4 
146.14 
Practically insoluble 
or insoluble 
Freely soluble 
185 
 
MS 
95 % 
1.407-1.413 
1.076-1.082 
 
 
09.354 
 
Diethyl pentanedioate 
O O
O O
 
 
 
818-38-2 
Liquid 
C9H16O4 
188.22 
Practically insoluble 
or insoluble 
Freely soluble 
233 
 
MS 
95 % 
1.421-1.427 
1.019-1.025 
 
 
09.360 
 
Ethyl 2-acetoxypropionate 
O
O
O
O
 
 
 
2985-28-6 
Liquid 
C7H12O4 
160.17 
Practically insoluble 
or insoluble 
Freely soluble 
76 (13 hPa) 
 
MS 
95 % 
1.405-1.411 
1.041-1.047 
 
Racemate. 
09.502 
 
Ethyl butyryl lactate 
O
O
O
O
 
 
2242 
71662-27-6 
Liquid 
C9H16O4 
188.22 
Sparingly soluble 
Freely soluble 
208 
 
MS 
95 % 
1.408-1.414 
1.021-1.027 
 
Racemate. 
09.558 
 
Dimethyl malonate O O
O O  
 
11754 
108-59-8 
Liquid 
C5H8O4 
132.12 
Practically insoluble 
or insoluble 
Freely soluble 
181 
 
MS 
1.411-1.417 
1.150-1.156 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
95 % 
09.565 
1846 
Hex-3-enyl 2-oxopropionate 
O
O
O
 
3934 
10684 
68133-76-6 
Liquid 
C9H14O3 
170.21 
Practically insoluble 
or insoluble 
Freely soluble 
76 (0.7 hPa) 
 
IR NMR 
98 % 
1.437-1.445 
0.982-0.990 
 
Register name to be changed 
to Hex-(3Z)-enyl 2-
oxopropionate (EFFA, 
2010a). 
09.580 
 
Hexyl lactate 
O
OH
O
 
 
 
20279-51-0 
Liquid 
C9H18O3 
174.24 
Slightly soluble 
Freely soluble 
221 
 
MS 
95 % 
1.426-1.432 
0.951-0.957 
 
Racemate. 
09.590 
 
Isobutyl lactate 
O
O
OH  
 
10709 
585-24-0 
Liquid 
C7H14O3 
146.19 
Slightly soluble 
Freely soluble 
182 
 
MS 
95 % 
1.415-1.421 
0.968-0.974 
 
Racemate. 
09.601 
 
Isopentyl lactate 
O
O
OH  
 
10720 
19329-89-6 
Liquid 
C8H16O3 
160.21 
Slightly soluble 
Freely soluble 
202 
 
MS 
97 % 
1.421-1.427 
0.958-0.974 
 
Racemate. 
09.626 
 
Methyl 2-oxopropionate 
O
O
O  
 
10848 
600-22-6 
Liquid 
C4H6O3 
120.09 
Sparingly soluble 
Freely soluble 
137 
 
MS 
95 % 
1.401-1.407 
1.145-1.151 
 
 
09.629 
 
Methyl 3-acetoxyhexanoate 
O
OO
O
 
 
10755 
77118-93-5 
Liquid 
C9H16O4 
188.22 
Practically insoluble 
or insoluble 
Freely soluble 
55 (0.7 hPa) 
 
MS 
95 % 
1.420-1.426 
1.013-1.019 
 
Racemate. CASrn in 
Register to be changed to 
21188-60-3. 
CASrn in Register refers to 
the (R) enantiomer. 
09.633 
 
Methyl 5-hydroxydecanoate 
O
OH O
 
 
 
101853-47-8 
Solid 
C11H22O3 
202.29 
Practically insoluble 
or insoluble 
Freely soluble 
278 
28 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
09.634 
 
Methyl acetoacetate 
O
O O
 
 
 
105-45-3 
Liquid 
C5H8O3 
116.12 
Sparingly soluble 
Freely soluble 
169 
28 
MS 
95 % 
1.415-1.421 
1.073-1.079 
 
 
09.644 
 
Methyl lactate 
O
OH
O
 
 
 
27871-49-4 
Liquid 
C4H8O3 
104.10 
Sparingly soluble 
Freely soluble 
244 
 
MS 
95 % 
1.408-1.414 
1.060-1.066 
 
Register name to be changed 
to (S)-Methyl lactate. 
09.683 
 
Pentyl lactate 
O
O
OH  
 
 
6382-06-5 
Liquid 
C8H16O3 
160.21 
Slightly soluble 
Freely soluble 
206 
 
MS 
95 % 
1.423-1.429 
0.965-0.971 
 
Racemate. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.815 
 
Propyl lactate 
O
O
OH  
 
 
616-09-1 
Liquid 
C6H12O3 
132.16 
Sparingly soluble 
Freely soluble 
170 
 
MS 
95 % 
1.414-1.420 
1.000-1.006 
 
Racemate. 
09.824 
 
Ethyl 2-acetylbutyrate 
O
O O  
 
607-97-6 
Liquid 
C8H14O3 
158.20 
Practically insoluble 
or insoluble 
Freely soluble 
198 
 
MS 
95 % 
1.417-1.423 
0.982-0.988 
 
Racemate. 
09.832 
 
Ethyl 3-acetohexanoate 
O
O
O
 
 
10566 
21188-61-4 
Liquid 
C10H18O3 
186.24 
Practically insoluble 
or insoluble 
Freely soluble 
110 (12 hPa) 
 
MS 
95 % 
1.419-1.425 
1.009-1.015 
 
Racemate. 
09.833 
 
iso-Propyl 4-oxopentanoate 
O
O
O  
 
 
21884-26-4 
Liquid 
C8H14O3 
158.20 
Sparingly soluble 
Freely soluble 
209 
 
MS 
95 % 
1.418-1.424 
0.981-0.987 
 
 
09.862 
 
Ethyl 3-acetoxy octanoate 
O
O
O
O  
 
85554-66-1 
Solid 
C12H22O4 
230.30 
Practically insoluble 
or insoluble 
Freely soluble 
276 
21 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
09.874 
 
Di(2-methylbutyl) malate 
O
O
OH O
O  
 
 
 
Solid 
C14H26O5 
274.35 
Sparingly soluble 
Freely soluble 
335 
74 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate. CASrn in 
Register to be introduced 
253596-99-5. 
09.916 
 
Ethyl 3-hydroxyoctanoate 
O
OOH
 
 
10603 
7367-90-0 
Liquid 
C10H20O3 
188.27 
Practically insoluble 
or insoluble 
Freely soluble 
118 (12 hPa) 
 
MS 
95 % 
1.421-1.427 
0.973-0.979 
 
Racemate (EFFA, 2010a). 
09.951 
1968 
Dioctyl adipate 
O
O
O
O  
4476 
 
123-79-5 
Liquid 
C22H42O4 
370.6 
Insoluble 
Soluble 
175 (3hPa) 
-70 
MS 
99 % 
1.443-1.447 
0.925 
 
 
10.038 
 
Dec-7-eno-1,4-lactone O O
 
 
 
67114-38-9 
Liquid 
C10H16O2 
168.24 
Practically insoluble 
or insoluble 
Freely soluble 
165 (0.3 hPa) 
 
MS 
95 % 
1.462-1.468 
0.974-0.980 
 
Racemate, mixture of (Z)- 
and (E)-isomers (EFFA, 
2010a). 
Composition of mixture to 
be specified. 
10.039 
 
cis-Dec-7-eno-1,4-lactone O O
 
 
 
63095-33-0 
Liquid 
C10H16O2 
168.24 
Practically insoluble 
or insoluble 
Freely soluble 
165 (0.3 hPa) 
 
MS 
95 % 
1.462-1.468 
0.974-0.980 
 
Racemate. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
10.040 
 
Dec-8-eno-1,5-lactone OO
 
 
 
32764-98-0 
Liquid 
C10H16O2 
168.24 
Practically insoluble 
or insoluble 
Freely soluble 
157 (15 hPa) 
 
MS 
95 % 
1.462-1.468 
0.972-0.978 
 
Racemate, mixture of (Z)- 
and (E)-isomers (EFFA, 
2010a). 
Composition of mixture to 
be specified. 
10.045 
 
Heptano-1,5-lactone O O
 
 
10660 
3301-90-4 
Liquid 
C7H12O2 
128.17 
Practically insoluble 
or insoluble 
Freely soluble 
104 (12 hPa) 
 
MS 
95 % 
1.451-1.457 
1.031-1.037 
 
Racemate. 
10.047 
 
Hexadecano-1,16-lactone 
C
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
O
O
 
 
109-29-5 
Solid 
C16H30O2 
254.41 
Practically insoluble 
or insoluble 
Freely soluble 
128 (1 hPa) 
34 
MS 
95 % 
n.a. 
n.a. 
 
 
10.048 
 
Hexadecano-1,4-lactone O O
 
 
10673 
730-46-1 
Solid 
C16H30O2 
254.41 
Practically insoluble 
or insoluble 
Freely soluble 
185 (5 hPa) 
38 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
10.049 
 
Hexadecano-1,5-lactone OO
 
 
10674 
7370-44-7 
Solid 
C16H30O2 
254.41 
Practically insoluble 
or insoluble 
Freely soluble 
130 (1 hPa) 
38 
MS 
95 % 
n.a. 
n.a. 
 
Racemate. 
10.052 
 
3-Methylnonano-1,4-lactone O O
 
 
 
33673-62-0 
Liquid 
C10H18O2 
170.25 
Practically insoluble 
or insoluble 
Freely soluble 
115 (3 hPa) 
 
MS 
95 % 
1.444-1.450 
0.945-0.951 
 
Racemate. 
10.055 
 
Pentano-1,5-lactone O O
 
 
10907 
542-28-9 
Liquid 
C5H8O2 
100.12 
Sparingly soluble 
Freely soluble 
219 
 
MS 
95 % 
1.451-1.457 
1.101-1.107 
 
 
10.058 
 
Tridecano-1,5-lactone OO
 
 
10902 
7370-92-5 
Liquid 
C13H24O2 
212.33 
Practically insoluble 
or insoluble 
Freely soluble 
188 (15 hPa) 
 
MS 
95 % 
1.455-1.463 
0.939-0.953 
 
Racemate. 
Flavouring Group Evaluation 10, Revision 3
 
 
34 EFSA Journal 2012; 10(3):2563 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 10, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
10.059 
 
Hexadec-7-en-1,16-lactone   6) 
O
C O
CH2
CH2
CH2C
H2
C
H2
HC
HC
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
 
 
123-69-3 
Liquid 
C16H28O2 
252.40 
Practically insoluble 
or insoluble 
Soluble 
188 (20 hPa) 
 
MS 
95 % 
1.482-1.488 
0.955-0.961 
 
CASrn in Register refers to 
the Z-isomer. 
Stereoisomeric composition 
to be specified. 
10.063 
 
Hexadec-9-en-1,16 lactone   6) 
O
C O
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
HC
HC
H2C
H2C
H2
C
H2
C
CH2
CH2
 
 
28645-51-4 
Liquid 
C16H28O2 
252.40 
Practically insoluble 
or insoluble 
Soluble 
131 (0.9 hPa) 
 
 
95 % 
1.476-1.482 
0.953-0.959 
ID 7). 
CASrn in Register does not 
specify isomeric 
composition. Stereoisomeric 
composition to be specified. 
10.068 
 
Pentadecano-1,14-lactone 
C
CH2
CH2
C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH
CH3
O
O
 
 
32539-85-8 
Liquid 
C15H28O2 
240.38 
Practically insoluble 
or insoluble 
Freely soluble 
108 (0.1 hPa) 
 
MS 
95 % 
1.466-1.472 
0.942-0.948 
 
Racemate. 
10.168 
 
5,6-Dimethyl-tetrahydro-pyran-2-
one 
OO  
4141 
 
10413-18-0 
Liquid 
C7H12O2 
128.17 
Slightly soluble 
Freely soluble 
60 
 
NMR MS 
98 % 
1.452-1.458 
1.019-1.025 
 
Mixture of ((R/R), (R/S), 
(S/R) & (S/S) in equal 
ratios) (EFFA, 2010a). 
10.170 
 
5-Pentyl-3H-furan-2-one   6) O O O O
66% of the 3H-isomer 33% of the 5H-isomer
Commercial compound:
 
4323 
 
51352-68-2 
Liquid 
C9H14O2 
154.2 
Sparingly soluble 
Soluble 
73 at 1.2 Torr 
 
IR NMR MS 
95 
1.447-1.459 
0.970-0.980 
 
Mixture of 3H and 5H 
isomer (2:1) (Flavour 
Industry, 2010g). 
Stereoisomeric composition 
to be specified. 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
7) ID: Missing identification test. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.132 
 
Butane-1,3-diol OH
OH
0.0061 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.198 
 
Octane-1,3-diol 
OH
OH 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
05.149 
 
Glutaraldehyde O O  0.055 
 
Class I 
A3: Intake below threshold 
4) 6)  
07.169 
 
1-Hydroxypropan-2-one O
OH  
0.22 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.053 
 
Malonic acid 
HO OH
O O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.082 
 
Glutaric acid O
HO
O
OH
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.090 
 
2-Hydroxy-4-methylvaleric acid 
OH
OH
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.103 
 
Nonanedioic acid HO OH
O O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
08.113 
 
Succinic acid, disodium salt 
Na+
-O
O
O
O-
Na+
1500 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.333 
 
sec-Butyl lactate 
O
OH
O
3.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.345 
 
Di-isopentyl succinate 
O
O
O
O
0.037 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.346 
 
Dibutyl malate 
OH
O
O
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.347 
 
Dibutyl succinate O
O
O
O
0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.348 
 
Diethyl adipate 
O
O
O
O
0.027 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.349 
 
Diethyl citrate 
O O
O
OH
OHO
O 0.12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.350 
 
Diethyl fumarate 
O
O
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.351 
 
Diethyl maleate 
O O
O O 12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.352 
 
Diethyl nonanedioate 
O O
OO 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.353 
 
Diethyl oxalate 
O
O
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.354 
 
Diethyl pentanedioate 
O O
O O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.360 
 
Ethyl 2-acetoxypropionate 
O
O
O
O 4.9 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.502 
 
Ethyl butyryl lactate 
O
O
O
O 0.5 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.558 
 
Dimethyl malonate O O
O O
0.097 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.565 
1846 
Hex-3-enyl 2-oxopropionate 
O
O
O 0.74 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.580 
 
Hexyl lactate 
O
OH
O 0.49 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.590 
 
Isobutyl lactate 
O
O
OH
3.7 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.601 
 
Isopentyl lactate 
O
O
OH
7.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.626 
 
Methyl 2-oxopropionate 
O
O
O
0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.629 
 
Methyl 3-acetoxyhexanoate 
O
OO
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.633 
 
Methyl 5-hydroxydecanoate 
O
OH O 0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.634 
 
Methyl acetoacetate 
O
O O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.644 
 
Methyl lactate 
O
OH
O 0.34 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.683 
 
Pentyl lactate 
O
O
OH
0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.815 
 
Propyl lactate 
O
O
OH
0.62 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.832 
 
Ethyl 3-acetohexanoate 
O
O
O 0.33 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.833 
 
iso-Propyl 4-oxopentanoate 
O
O
O
0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.862 
 
Ethyl 3-acetoxy octanoate 
O
O
O
O 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.874 
 
Di(2-methylbutyl) malate 
O
O
OH O
O
0.015 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.916 
 
Ethyl 3-hydroxyoctanoate 
O
OOH 0.011 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.951 
1968 
Dioctyl adipate 
O
O
O
O
6.1 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.038 
 
Dec-7-eno-1,4-lactone O O 0.37 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.039 
 
cis-Dec-7-eno-1,4-lactone O O 1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.040 
 
Dec-8-eno-1,5-lactone OO 0.011 
 
Class I 
A3: Intake below threshold 
4) 7)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
10.045 
 
Heptano-1,5-lactone O O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.047 
 
Hexadecano-1,16-lactone 
C
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
O
O
0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.048 
 
Hexadecano-1,4-lactone O O 0.0061 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.049 
 
Hexadecano-1,5-lactone OO 0.024 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.052 
 
3-Methylnonano-1,4-lactone O O 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.055 
 
Pentano-1,5-lactone O O
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.058 
 
Tridecano-1,5-lactone OO 0.61 
 
Class I 
A3: Intake below threshold 
4) 6)  
10.059 
 
Hexadec-7-en-1,16-lactone 
O
C O
CH2
CH2
CH2C
H2
C
H2
HC
HC
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
1.9 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.063 
 
Hexadec-9-en-1,16 lactone 
O
C O
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
HC
HC
H2C
H2C
H2
C
H2
C
CH2
CH2
48 
 
Class I 
A3: Intake below threshold 
4) 7)  
10.068 
 
Pentadecano-1,14-lactone 
C
CH2
CH2
C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH
CH3
O
O
0.9 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day
) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
10.168 
 
5,6-Dimethyl-tetrahydro-pyran-
2-one 
OO
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.824 
 
Ethyl 2-acetylbutyrate 
O
O O 0.0012 
 
Class I 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
06.088 
 
2-Ethyl-4-methyl-1,3-dioxolane 
OO
 
0.0061 
 
Class II 
A3: Intake below threshold 
4) 6)  
06.090 
 
4-Hydroxymethyl-2-methyl-1,3-
dioxolane 
O
O
HO
0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
06.095 
 
4-Methyl-2-propyl-1,3-dioxolane 
O
O 0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
06.135 
1732 
2-Isobutyl-4-methyl-1,3-
dioxolane 
O
O
 
1.2 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.242 
 
2-Butoxyethan-1-ol O
OH
 0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
06.097 
 
1,1,3-Triethoxypropane 
O O
O 0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
06.102 
 
2-Hexyl-5-hydroxy-1,3-dioxane 
O
O
HO 0.011 
 
Class III 
A3: Intake below threshold 
4) 6)  
10.170 
 
5-Pentyl-3H-furan-2-one O O O O
66% of the 3H-isomer 33% of the 5H-isomer
Commercial compound:
1.2 
 
Class III 
No evaluation 
  a) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
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7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) 1/3 of the named compound correspond to FL-no: 10.054 which is included in FGE.217: additional genotoxicity data required. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Methanol 
 OH  
Not evaluated as flavouring substance  Not in EU-Register 
 Glycerol 
909 
OH
OH
HO
No evaluation 
Pending definition of “flavouring agent” 
 
 Not in EU-Register 
 Propylene glycol 
925 
OH
OH No evaluation 
Pending definition of “flavouring agent” 
 
 Not in EU-Register 
 3-Ethoxypropan-1-al 
O O  
Not evaluated as flavouring substance  Not in EU-Register 
 3-Hydroxyoctanoic acid 
OH
OOH Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxydecanoic acid O
OH
OH Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxy-8-decenoic 
acid 
OH
OH O Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxy-4-
methylhexanoic acid 
OH
OH O Not evaluated as flavouring substance  Not in EU-Register 
 Citric acid 
HO OH
O
OH
OHO
O
Not evaluated as flavouring substance  Not in EU-Register 
 Oxalic acid 
HO
OH
O
O Not evaluated as flavouring substance  Not in EU-Register 
 Acetoacetic acid O O
OH
Not evaluated as flavouring substance  Not in EU-Register 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 2-Acetylbutyric acid 
HO
O O Not evaluated as flavouring substance  Not in EU-Register 
 Maleic acid 
HO OH
O O Not evaluated as flavouring substance  Not in EU-Register 
 3-Acetohexanoic acid 
O
OH
O Not evaluated as flavouring substance  Not in EU-Register 
 2-Acetoxypropionic acid O
OH
O
O
Not evaluated as flavouring substance  Not in EU-Register 
 3-Acetoxyhexanoic acid 
O
OH
O
O Not evaluated as flavouring substance  Not in EU-Register 
 3-Acetoxyoctanoic acid 
O
OH
O
O Not evaluated as flavouring substance  Not in EU-Register 
 3-Hydroxyhexanoic acid 
OH
OOH Not evaluated as flavouring substance  Not in EU-Register 
 4-Hydroxy-2-nonenoic 
acid 
OH
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
 4-Hydroxy-3-nonenoic 
acid 
OH
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 (E)-4-Hydroxydec-7-
enoic acid 
OH
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
 (Z)-4-Hydroxydec-7-
enoic acid 
OH
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxyheptanoic acid 
OH
OOH Not evaluated as flavouring substance  Not in EU-Register 
 16-Hydroxyhexadecanoic 
acid 
OH
O
HO
Not evaluated as flavouring substance  Not in EU-Register 
 4-Hydroxyhexadecanoic 
acid 
OH
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxyhexadecanoic 
acid 
OH
OOH Not evaluated as flavouring substance  
 
Not in EU-Register 
 4-Hydroxy-3-
methylnonanoic acid 
OH
OH
O Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxypentanoic acid 
HO OH
O Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxytridecanoic 
acid 
OH
OOH Not evaluated as flavouring substance  Not in EU-Register 
 16-Hydroxyhexadec-7-
enoic acid 
OH
O
HO
Not evaluated as flavouring substance  Not in EU-Register 
 16-Hydroxyhexadec-9-
enoic acid 
OH
O
HO
Not evaluated as flavouring substance  Not in EU-Register 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 14-
Hydroxypentadecanoic 
acid 
HO
OH
O Not evaluated as flavouring substance  Not in EU-Register 
 5-Hydroxy-4-
methylhexanoic acid 
OHHO
O Not evaluated as flavouring substance  Not in EU-Register 
02.001 2-Methylpropan-1-ol 
251 OH  
Category 1 a) 
 
Category A b) 
Class I 
A3: Intake above threshold 
 
02.002 Propan-1-ol 
82 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.003 Isopentanol 
52 OH  
Category 1 a) 
No safety concern d) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
02.004 Butan-1-ol 
85 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.005 Hexan-1-ol 
91 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.006 Octan-1-ol 
97 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
02.040 Pentan-1-ol 
88 
OH  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
02.076 2-Methylbutan-1-ol 
1199 
OH
 
Category 1 a) 
No safety concern e) 
Category B c) 
 
Class I 
A3: Intake below threshold 
 
02.078 Ethanol 
41 
OH  Category 1 a) 
No safety concern d) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 
1997a), the Committee concluded that 
ethanol posed no safety concern at its 
current level of intake when ethyl esters are 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
used as flavouring agents. 
02.079 Isopropanol 
277 
OH
 
Category 1 a) 
No safety concern f) 
 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.121 Butan-2-ol 
 
OH
 
Category 1 a) 
 
 
 
 
No evaluation 
 
02.159 Hex-3-en-1-ol 
315 
OH   
 
Category A c) 
 
 
No evaluation 
 
05.001 Acetaldehyde 
80 
O  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
05.002 Propanal 
83 
O
 Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
05.003 Butanal 
86 
O  Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
05.006 3-Methylbutanal 
258 O  
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
05.031 Heptanal 
95 
O
 Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.002 Acetic acid 
81 
O
OH  
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.004 Lactic acid 
930 
OH
OH
O  
 
No safety concern g) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
08.017 l-Malic acid 
619 
OH
O
HO
O
OH
 
 
No safety concern h) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.019 Pyruvic acid 
936 
O
O
OH
 
 
No safety concern g) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.023 4-Oxovaleric acid 
606 
O
OH
O
 
 
No safety concern h) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.024 Succinic acid 
 
O
OH
O
HO
 
 
 
Category A c) 
 
 
No evaluation 
 
08.025 Fumaric acid 
618 
O
OH
O
HO
 
 
No safety concern h) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.026 Adipic acid 
623 
O
HO
OH
O  
 
No safety concern h) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: Not 
endogenous, A5: Adequate NOAEL exists 
 
08.053 Malonic acid 
 
HO OH
O O
 
 
 
Category A c) 
FGE.10 
Class I 
A3: Intake below threshold 
 
08.082 Glutaric acid 
 
O
HO
O
OH  
 
 
 
FGE.10 
Class I 
A3: Intake below threshold 
 
08.103 Nonanedioic acid 
 
HO OH
O O  
 
 
 
FGE.10 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (SCF, 1995). 
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b) (JECFA, 1999b). 
c) (CoE, 1992). 
d) (JECFA, 1997a). 
e) (JECFA, 2004a). 
f) (JECFA, 2000a). 
g) (JECFA, 2002b). 
h) (JECFA, 2000b). 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
 3-(Hydroxymethyl)-2-
heptanone 
O
OH
2804 
592 
 
604 
Tentative JECFA spec. 
(JECFA, 2003b) 
4.6  
No safety concern d) 
Category B 
Not in EU-Register. 
02.047 3,7-Dimethyloctane-1,7-diol 
OHHO  
2586 
559 
107-74-4 
610 
JECFA specification (JECFA, 
2000d) 
9.7  
No safety concern a) 
Category A b) 
JECFA evaluated 
hydroxycitronellol 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by CASrn 
in Register. 
05.012 3,7-Dimethyl-7-
hydroxyoctanal HO O  
2583 
100 
107-75-5 
611 
JECFA specification (JECFA, 
1999c) 
24  
No safety concern a) 
Category A b) 
JECFA evaluated 
hydroxycitronellal 
(CASrn as in Register). 
CASrn in Register refers 
to the racemate. 
05.079 Citronellyl oxyacetaldehyde 
O
O
 
2310 
2012 
7492-67-3 
592 
JECFA specification (JECFA, 
2003b) 
24  
No safety concern a) 
Category B b) 
JECFA evaluated 
citronelloxyacetaldehyd
e (CASrn as in 
Register). (R)- or (S)- 
enantiomer not specified 
by CASrn in Register. 
06.010 1,1-Diethoxy-3,7-
dimethyloctan-7-ol 
OHO
O
 
2584 
44 
7779-94-4 
613 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern a) 
Category B b) 
JECFA evaluated 
hydroxycitronellal 
diethyl acetal (CASrn as 
in Register). (R)- or (S)- 
enantiomer not specified 
by CASrn in Register. 
06.011 1,1-Dimethoxy-3,7-
dimethyloctan-7-ol 
HO O
O
 
2585 
45 
141-92-4 
612 
JECFA specification (JECFA, 
1999c) 
0.037  
No safety concern a) 
Category A b) 
JECFA evaluated 
hydroxycitronellal 
dimethyl acetal (CASrn 
as in Register). (R)- or 
(S)- enantiomer not 
specified by CASrn in 
Register. 
06.038 4,4-Dimethoxybutan-2-one 
O
OO
 
3381 
10029 
5436-21-5 
593 
JECFA specification (JECFA, 
1999c) 
0.012  
No safety concern a) 
 
 
08.017 l-Malic acid 
OH
O
HO
O
OH
 
2655 
17 
6915-15-7 
619 
JECFA specification (JECFA, 
2000d) 
13000  
No safety concern a) 
Category A b) 
JECFA evaluated l-
malic acid (CASrn 97-
67-6). (R)- or (S)-
enantiomer not specified 
by CASrn in Register. 
GrADI: not specified 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
(JECFA, 1970a). 
08.018 Tartaric acid OH
OHO
HO
O
OH
 
3044 
18 
133-37-9 
621 
JECFA specification (JECFA, 
1999c) 
3800  
No safety concern a) 
Category A b) 
JECFA evaluated 
tartaric acid ((+)-, (-)-, 
(+/-)-, meso-) (CASrn 
87-69-4). CASrn in 
Register refers to 
(2R,3R)-isomer.  
No ADI (JECFA, 
1978a). 
08.023 4-Oxovaleric acid 
O
OH
O 2627 
23 
123-76-2 
606 
JECFA specification (JECFA, 
2002d) 
190  
No safety concern a) 
Category A b) 
 
08.025 Fumaric acid 
O
OH
O
HO
2488 
25 
110-17-8 
618 
JECFA specification (JECFA, 
2000d) 
780  
No safety concern a) 
Category A b) 
GrADI not specified 
(JECFA, 1990a). 
08.026 Adipic acid O
HO
OH
O
2011 
26 
124-04-9 
623 
JECFA specification (JECFA, 
1999c) 
11  
No safety concern a) 
Category A b) 
ADI: 0-5 (JECFA, 
1978a). 
08.033 Prop-1-ene-1,2,3-tricarboxylic 
acid 
O
HO
OHO
O
OH  
2010 
33 
499-12-7 
627 
JECFA specification (JECFA, 
2002d) 
0.012  
No safety concern a) 
Category A b) 
JECFA evaluated 
aconitic acid (CASrn as 
in Register). (Z)- or (E)- 
isomer not specified by 
CASrn in Register. 
08.037 2-Oxoglutaric acid O
OH
O
HO
O
3891 
653 
328-50-7 
634 
JECFA specification (JECFA, 
1999c) 
ND  
No safety concern a) 
Category A b) 
 
08.051 3-Methyl-2-oxobutyric acid 
OH
O
O  
3869 
2262 
759-05-7 
631 
JECFA specification (JECFA, 
1999c) 
0.012  
No safety concern a) 
Category B b) 
JECFA evaluated 3-
methyl-2-oxobutanoic 
acid (the acid and 
sodium salt) (CASrn as 
in Register). CASrn in 
Register refers to the 
acid. 
08.052 4-Methyl-2-oxovaleric acid O
OH
O  
3871 
2263 
816-66-0 
633 
JECFA specification (JECFA, 
1999c) 
ND  
No safety concern a) 
Category B b) 
JECFA evaluated 4-
Methyl-2-oxopentanoic 
acid and its sodium salt 
(CASrn 816-66-0 and 
4502-00-5). 
08.066 2-Oxobutyric acid 
OH
O
O
3723 
 
600-18-0 
589 
JECFA specification (JECFA, 
2000d) 
0.024  
No safety concern a) 
 
 
Flavouring Group Evaluation 10, Revision 3
 
 
50 EFSA Journal 2012; 10(3):2563 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
08.086 3-Hydroxy-2-oxopropionic 
acid 
O
OH
O
HO
3843 
 
1113-60-6 
635 
JECFA specification (JECFA, 
1999c) 
ND  
No safety concern a) 
 
 
08.093 3-Methyl-2-oxovaleric acid 
OH
O
O  
3870 
10146 
39748-49-7 
632 
JECFA specification (JECFA, 
1999c) 
ND  
No safety concern a) 
 
JECFA evaluated 3-
methyl-2-oxopentanoic 
acid (the acid and 
sodium salt) (CASrn 
1460-34-0). CASrn 
39748-49-7 replaced by 
CASrn 1460-34-0 in the 
CASrn system 
(SciFinder). (R)- or (S)-
enantiomer not specified 
by CASrn in Register. 
09.225 1,3-Nonanediol acetate OH
O
O
 
2783 
2075 
1322-17-4 
605 
JECFA specification (JECFA, 
2005b) 
1.8  
No safety concern a) 
Deleted b) 
Reg. CASrn refers to 
incompletely defined 
substance (mixed 
esters).  
Deleted: Subst. for 
which CoE had no 
information as to their 
real use in foodstuffs 
and/or for which 
insufficient technical 
and/or toxicological 
information was 
available (CoE, 1992). 
09.280 Nonane-1,4-diyl diacetate 
O
O
O
O
 
3579 
11927 
67715-81-5 
609 
JECFA specification (JECFA, 
2002d) 
0.037  
No safety concern a) 
 
JECFA evaluated 1,4-
nonanediol diacetate 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by CASrn 
in Register. 
09.401 Isopentyl acetoacetate O O
O  
3551 
227 
2308-18-1 
598 
JECFA specification (JECFA, 
2000d) 
ND  
No safety concern a) 
Category B b) 
 
09.402 Ethyl acetoacetate O O
O  
2415 
240 
141-97-9 
595 
JECFA specification (JECFA, 
1999c) 
1200  
No safety concern a) 
Category B b) 
 
09.403 Butyl acetoacetate 
O
O O
 
2176 
241 
591-60-6 
596 
JECFA specification (JECFA, 
2000d) 
63  
No safety concern a) 
Category B b) 
 
09.404 Isobutyl acetoacetate O O
O
2177 
242 
7779-75-1 
597 
JECFA specification (JECFA, 
2000d) 
ND  
No safety concern a) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.405 Geranyl acetoacetate 
O
O O
 
2510 
243 
10032-00-5 
599 
JECFA specification (JECFA, 
2001c) 
ND  
No safety concern a) 
Category B b) 
 
09.435 Ethyl 4-oxovalerate O
O
O
2442 
373 
539-88-8 
607 
JECFA specification (JECFA, 
1999c) 
470  
No safety concern a) 
Category B b) 
 
09.436 Butyl 4-oxovalerate 
O
O
O
2207 
374 
2052-15-5 
608 
JECFA specification (JECFA, 
2002d) 
ND  
No safety concern a) 
Category B b) 
 
09.439 Diethyl malate 
OH
O
O
O
O
 
2374 
382 
7554-12-3 
620 
JECFA specification (JECFA, 
2000d) 
3.7  
No safety concern a) 
Deleted b) 
JECFA evaluated 
diethyl malate. CASrn in 
Register refers to the 
racemate. Deleted: 
Subst. for which CoE 
had no information as to 
their real use in 
foodstuffs and/or for 
which insufficient 
technical and/or 
toxicological 
information was 
available(CoE, 1992). 
09.441 Butyl ethyl malonate 
O
O
O
O
 
2195 
384 
17373-84-1 
615 
Tentative JECFA specification 
(JECFA, 2003b) 
ND  
No safety concern a) 
Category A b) 
 
09.444 Diethyl succinate O
O
O
O
2377 
438 
123-25-1 
617 
JECFA specification (JECFA, 
2002d) 
120  
No safety concern a) 
Category B b) 
 
09.445 Dimethyl succinate O
O
O
O
2396 
439 
106-65-0 
616 
JECFA specification (JECFA, 
2002d) 
73  
No safety concern a) 
Category B b) 
 
09.446 Diethyl tartrate 
O
O
O OH
O  
2378 
440 
87-91-2 
622 
JECFA specification (JECFA, 
2002d) 
15  
No safety concern a) 
Category A b) 
JECFA evaluated 
diethyl tartrate (CASrn 
as in Register). Register 
CASrn refers to the 
(2R,3R)-enantiomer. 
ADI acceptable 
(JECFA, 2000b). 
09.474 Dibutyl sebacate O
O
O
O
2373 
622 
109-43-3 
625 
JECFA specification (JECFA, 
2003b) 
ND  
No safety concern a) 
Category A b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.475 Diethyl sebacate O
O
O
O
2376 
623 
110-40-7 
624 
JECFA specification (JECFA, 
2002d) 
120  
No safety concern a) 
Category A b) 
 
09.490 Diethyl malonate 
O O
OO
 
2375 
2106 
105-53-3 
614 
JECFA specification (JECFA, 
2002d) 
650  
No safety concern a) 
Category A b) 
 
09.510 Ethyl aconitate 
HO O
O
O OH
O
 
2417 
11845 
1321-30-8 
628 
JECFA specification (JECFA, 
2005b) 
ND  
No safety concern a) 
 
JECFA evaluated ethyl 
aconitate (mixed esters) 
(CASrn as in Register). 
Register CASrn refers to 
incompletely defined 
substance. 
09.511 Tributyl acetylcitrate 
O O
O
O
OO
O
O
3080 
 
77-90-7 
630 
JECFA specification (JECFA, 
2000d) 
ND  
No safety concern a) 
 
 
09.512 Triethyl citrate 
O O
O
OH
OO
O
3083 
11762 
77-93-0 
629 
JECFA specification (JECFA, 
2000d) 
2900  
No safety concern a) 
 
ADI: 0-20 (JECFA, 
1984a). 
09.514 Ethyl 2,4-dioxohexanoate 
O
O
O O 3278 
11903 
13246-52-1 
603 
JECFA specification (JECFA, 
2003b) 
ND  
No safety concern a) 
 
 
09.522 Ethyl 3-hydroxybutyrate O
OHO  
3428 
10596 
5405-41-4 
594 
JECFA specification (JECFA, 
2000d) 
7.9  
No safety concern a) 
 
JECFA evaluated ethyl 
3-hydroxybutyrate 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
09.532 Methyl 3-hydroxyhexanoate O
O
OH
 
3508 
10812 
21188-58-9 
600 
JECFA specification (JECFA, 
2000d) 
0.85  
No safety concern a) 
 
JECFA evaluated 
methyl 3-
hydroxyhexanoate 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by 
Register CASrn. 
09.533 Ethyl brassylate 
O
O 3543 
10571 
105-95-3 
626 
JECFA specification (JECFA, 
2002d) 
3.0  
No safety concern a) 
 
 
09.535 Ethyl 3-hydroxyhexanoate 
O
OOH 3545 
11764 
601 
JECFA specification (JECFA, 
60  
No safety concern a) 
JECFA evaluated ethyl 
3-hydroxyhexanoate 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
2305-25-1 2002d)  (CASrn as in Register). 
Register CASrn refers to 
the racemate. 
09.542 Ethyl 3-oxohexanoate 
O
OO
 
3683 
 
3249-68-1 
602 
JECFA specification (JECFA, 
2002d) 
0.024  
No safety concern a) 
 
 
09.548 Methyl 2-hydroxy-4-
methylvalerate 
O
O
OH  
3706 
 
40348-72-9 
590 
JECFA specification (JECFA, 
2003b) 
0.49  
No safety concern a) 
 
JECFA evaluated 
methyl 2-hydroxy-4-
methylpentanoate 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by 
Register CASrn. 
09.550 Methyl 2-oxo-3-methylvalerate 
O
O
O  
3713 
 
3682-42-6 
591 
JECFA specification (JECFA, 
2001c) 
ND  
No safety concern a) 
 
JECFA evaluated 
methyl 2-oxo-3-
methylpentanoate 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by 
Register CASrn. 
10.001 Nonano-1,4-lactone O O
 
2781 
178 
104-61-0 
229 
JECFA specification (JECFA, 
2000d) 
1000  
No safety concern c) 
Category A b) 
JECFA evaluated 
gamma-nonalactone 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by 
Register CASrn 
ADI: 0-1.25 (JECFA, 
1968). 
10.002 Undecano-1,4-lactone O O
 
3091 
179 
104-67-6 
233 
JECFA specification (JECFA, 
1998b) 
1200  
No safety concern c) 
Category A b) 
JECFA evaluated 
gamma-undecalactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
ADI: 0-1.25 (JECFA, 
1968). 
10.003 Hexadec-6-eno-1,16-lactone 
C
CH2
CH2
CH2C
H2
C
H
HC
H2C
H2C
H2C
H2C
H2C
H2
C
H2
C
CH2
CH2
O
O
Z-isomer shown
2555 
180 
7779-50-2 
240 
JECFA specification (JECFA, 
2001c) 
5.1  
No safety concern c) 
Category B b) 
JECFA evaluated 
omega-6-
hexadecenlactone 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
not specified by 
Register CASrn. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
10.004 Pentadecano-1,15-lactone 
C
CH2
CH2
CH2C
H2
C
H2
H2C
H2C
H2C
H2C
H2C
H2C
H2
C H2C
CH2
O
O
2840 
181 
106-02-5 
239 
JECFA specification (JECFA, 
2000d) 
73  
No safety concern c) 
Category B b) 
 
10.006 Butyro-1,4-lactone O O
 
3291 
615 
96-48-0 
219 
JECFA specification (JECFA, 
1998b) 
110  
No safety concern c) 
Category A b) 
 
10.007 Decano-1,5-lactone OO
 
2361 
621 
705-86-2 
232 
JECFA specification (JECFA, 
2000d) 
7200  
No safety concern c) 
Category B b) 
JECFA evaluated delta-
decalactone (CASrn as 
in Register). Register 
CASrn refers to the 
racemate. 
10.008 Dodecano-1,5-lactone OO
 
2401 
624 
713-95-1 
236 
JECFA specification (JECFA, 
2000d) 
5800  
No safety concern c) 
Category B b) 
JECFA evaluated delta-
dodecalactone (CASrn 
as in Register). Register 
CASrn refers to the 
racemate. 
10.009 Dodec-6-eno-1,4-lactone O O
 
3780 
625 
18679-18-0 
249 
JECFA specification (JECFA, 
2001c) 
0.012  
No safety concern c) 
Category A b) 
JECFA evaluated 1,4-
dodec-6-enolactone 
(CASrn as in Register). 
Register CASrn refers to 
the (Z)-isomer. 
10.010 Hexano-1,5-lactone OO
 
3167 
641 
823-22-3 
224 
JECFA specification (JECFA, 
1998b) 
320  
No safety concern c) 
Category B b) 
JECFA evaluated delta-
hexalactone (CASrn as 
in Register). Register 
CASrn refers to the 
racemate. 
10.011 Undecano-1,5-lactone OO
 
3294 
688 
710-04-3 
234 
JECFA specification (JECFA, 
1998b) 
300  
No safety concern c) 
Category B b) 
JECFA evaluated 5-
hydroxyundecanoic acid 
delta-lactone (CASrn as 
in Register). Register 
CASrn refers to the 
racemate. 
10.012 5-Methylfuran-2(3H)-one O O
 
3293 
731 
591-12-8 
221 
JECFA specification (JECFA, 
1998b) 
300  
No safety concern c) 
Category B b) 
 
10.013 Pentano-1,4-lactone O O
 
3103 
757 
108-29-2 
220 
JECFA specification (JECFA, 
1998b) 
120  
No safety concern c) 
Category A b) 
JECFA evaluted 
gamma-valerolactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
10.014 Nonano-1,5-lactone OO
 
3356 
2194 
3301-94-8 
230 
JECFA specification (JECFA, 
1998b) 
130  
No safety concern c) 
Category B b) 
JECFA evaluated 
hydroxynonanoic acid 
delta-lactone (CASrn as 
in Register). Register 
CASrn refers to the 
racemate. 
10.015 Octano-1,5-lactone OO
 
3214 
2195 
698-76-0 
228 
JECFA specification (JECFA, 
2000d) 
230  
No safety concern c) 
Category B b) 
JECFA evaluated delta-
octalactone (CASrn as 
in Register). Register 
CASrn refers to the 
racemate. 
10.016 Tetradecano-1,5-lactone OO
 
3590 
2196 
2721-22-4 
238 
JECFA specification (JECFA, 
1998b) 
110  
No safety concern c) 
Category B b) 
JECFA evaluated delta-
tetradecalactone (CASrn 
as in Register). (R)- or 
(S)- enantiomer not 
specified by Register 
CASrn. 
10.017 Decano-1,4-lactone O O
 
2360 
2230 
706-14-9 
231 
JECFA specification (JECFA, 
1998b) 
1600  
No safety concern c) 
Category A b) 
JECFA evaluated 
gamma-decalactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
10.018 4-Butyloctano-1,4-lactone O O
 
2372 
2231 
7774-47-2 
227 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern c) 
Deleted b) 
Deleted CoE: the CoE 
Committee of Experts 
had no information as to 
the real use in foodstuffs 
and/or for which 
insufficient 
technological and/or 
toxicological 
information was 
available (CoE, 1992). 
10.019 Dodecano-1,4-lactone O O
 
2400 
2240 
2305-05-7 
235 
JECFA specification (JECFA, 
1998b) 
190  
No safety concern c) 
Category A b) 
JECFA evaluted 
gamma-dodecalactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
10.020 Heptano-1,4-lactone O O
 
2539 
2253 
105-21-5 
225 
JECFA specification (JECFA, 
2000d) 
170  
No safety concern c) 
Category A b) 
JECFA evaluated 
gamma-heptalactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
10.021 Hexano-1,4-lactone O O
 
2556 
2254 
695-06-7 
223 
JECFA specification (JECFA, 
1998b) 
160  
No safety concern c) 
Category A b) 
JECFA evaluted 
gamma-hexalactone 
(CASrn as in Register). 
Register CASrn refers to 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
the racemate. 
10.022 Octano-1,4-lactone O O
 
2796 
2274 
104-50-7 
226 
JECFA specification (JECFA, 
2000d) 
430  
No safety concern c) 
Category A b) 
JECFA evaluated 
gamma-octalactone 
(CASrn as in Register). 
Register CASrn refers to 
the racemate. 
10.026 3-Heptyldihydro-5-methyl-
2(3H)-furanone 
O
O
 
3350 
10953 
40923-64-6 
244 
JECFA specification (JECFA, 
2003b) 
0.037  
No safety concern c) 
 
JECFA evaluated 3-
heptyldihydro-5-methyl-
2(3H)-furanone (CASrn 
as in Register). (R)- or 
(S)-enantiomer not 
specified by Register 
CASrn. 
10.027 3,7-Dimethyloctano-1,6-
lactone OO
 
3355 
11833 
499-54-7 
237 
JECFA specification (JECFA, 
2003b) 
0.012  
No safety concern c) 
 
JECFA evaluated 6-
hydroxy-3,7-
dimethyloctanoic acid 
lactone (CASrn as in 
Register). (R)- or (S)-
enantiomer not specified 
by Register CASrn. 
10.028 Dodecano-1,6-lactone 
OO
 
3610 
 
16429-21-3 
242 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern c) 
 
JECFA evaluated 
epsilon-dodecalactone 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by 
Register CASrn. 
10.029 Decano-1,6-lactone OO
 
3613 
 
5579-78-2 
241 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern c) 
 
JECFA evaluated 
epsilon-decalactone 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by 
Register CASrn. 
10.033 Dec-7-eno-1,5-lactone OO
 
3745 
 
34686-71-0 
247 
JECFA specification (JECFA, 
2000d) 
0.22  
No safety concern c) 
 
JECFA evaluated 5-
Hydroxy-7-decenoic 
acid delta-lactone 
(CASrn 25524-95-2 
which refers to the (Z)-
isomer). Neither (Z)- or 
(E)-isomer nor (R)- or 
(S)-enantiomer specified 
by Register CASrn. 
10.035 Undec-8-eno-1,5-lactone OO
 
3758 
 
68959-28-4 
248 
JECFA specification (JECFA, 
2000d) 
0.012  
No safety concern c) 
 
JECFA evaluated 5-
hydroxy-8-undecenoic 
acid delta-lactone 
(CASrn as in Register). 
(R)- or (S)-enantiomer 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
not specified by 
Register CASrn. 
10.051 5-Hexyl-5-
methyldihydrofuran-2(3H)-one 
O
O
 
3786 
 
7011-83-8 
250 
JECFA specification (JECFA, 
1998b) 
ND  
No safety concern c) 
 
JECFA evaluated 
gamma-
methyldecalactone 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by 
Register CASrn. 
10.053 3-Methyloctano-1,4-lactone O O
 
3803 
10535 
39212-23-2 
437 
JECFA specification (JECFA, 
1998b) 
ND  
No safety concern c) 
 
JECFA evaluated 4-
hydroxy-3-
methyloctanoic acid 
gamma-lactone (CASrn 
as in Register). (R)- or 
(S)-enantiomer not 
specified by Register 
CASrn. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2000b). 
b) (CoE, 1992). 
c) (JECFA, 1999b). 
d) (JECFA, 2000c). 
ND No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 1 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 2 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 3 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 4 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 5 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 6 
1996a; JECFA, 1997a; JECFA, 1999b). 7 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-8 
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 9 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 10 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 11 
safety concern. 12 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 13 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 14 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 15 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 16 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 17 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 18 
(JECFA, 1996a). 19 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 20 
address the following questions: 21 
• can the flavourings be predicted to be metabolised to innocuous products11 (Step 2)?  22 
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 23 
• are the flavourings or their metabolites endogenous12 (Step A4)?  24 
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 25 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 26 
toxicological background information available for compounds structurally related to the candidate 27 
substances is considered (supporting substances), in order to assure that these data are consistent with the 28 
results obtained after application of the Procedure.  29 
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 30 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 31 
 32 
                                                     
 
11 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the estimated intakes of 
the flavouring agent” (JECFA, 1997a). 
 
12 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; 
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 1 
II.1 Normal and Maximum Use Levels 2 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 3 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 4 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 5 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 6 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 7 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
The “normal and maximum use levels” are provided by Industry for 61 of the candidate substances in the 8 
present Flavouring Group Evaluation (Table II.1.2) (EFFA, 2001a; EFFA, 2003c; EFFA, 2003s; EFFA, 9 
2004ag; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2010g; Flavour Industry, 2010n). 10 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.10Rev3 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.132 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.198 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.242 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
05.149 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
06.088 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
06.090 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
06.095 7 5 10 7 - 10 5 10 2 2 - - - - 5 10 20 5 
Flavouring Group Evaluation 10, Revision 3
 
 
86 EFSA Journal 2012; 10(3):2563 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.10Rev3 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
35 25 50 35 - 50 25 50 10 10 - - - - 25 50 100 25 
06.097 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
06.102 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
52 
5 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
07.169 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
08.053 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.082 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.090 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
- 
- 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
15 
75 
5 
25 
08.103 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
09.333 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.345 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.346 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.347 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.348 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.349 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.350 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.351 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.352 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.353 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.354 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.360 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.502 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.558 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.565 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.580 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
200 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.590 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.601 10 
50 
5 
75 
10 
50 
7 
35 
- 
- 
20 
100 
15 
75 
15 
75 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
50 
20 
100 
20 
100 
5 
25 
09.626 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.629 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.633 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.634 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.644 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
- 
- 
- 
- 
5 
25 
10 
50 
10 
50 
5 
25 
09.683 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.815 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.824 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.10Rev3 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
09.832 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.833 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.862 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.874 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.916 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.951 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
6 
10 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
6 
10 
10.038 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.039 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.040 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.045 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.047 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.048 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.049 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.052 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.055 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.058 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.059 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
30 
5 
25 
10 
50 
20 
100 
5 
25 
10.063 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.068 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.168 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
10.170 5 
20 
2 
10 
1 
5 
1 
5 
1 
5 
4 
20 
2,2 
10 
3 
15 
- 
- 
- 
- 
- 
- 
- 
- 
101 
1005 
- 
- 
3 
10 
2 
10 
2 
10 
2 
10 
II.2 mTAMDI Calculations 1 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 2 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 3 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 4 
multiplied by the reported use levels in the different food categories and summed up.  5 
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 1 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 2 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 3 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 4 
following way (see Table II.2.2): 5 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 6 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 7 
(EC, 2000a) 8 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 9 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 10 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 11 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 12 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 13 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 1 
The mTAMDI values (see Table II.2.3) are presented for each of the 61 flavouring substances in the present 2 
flavouring group, for which Industry has provided use and use levels (EFFA, 2001a; EFFA, 2003c; EFFA, 3 
2003s; EFFA, 2004ag; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2010g; Flavour Industry, 4 
2010n). The mTAMDI values are only given for the highest reported normal use levels. 5 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.132 Butane-1,3-diol 3900 Class I 1800 
02.198 Octane-1,3-diol 3900 Class I 1800 
05.149 Glutaraldehyde 1600 Class I 1800 
07.169 1-Hydroxypropan-2-one 1600 Class I 1800 
08.053 Malonic acid 3200 Class I 1800 
08.082 Glutaric acid 3200 Class I 1800 
08.090 2-Hydroxy-4-methylvaleric acid 3800 Class I 1800 
08.103 Nonanedioic acid 3200 Class I 1800 
08.113 Succinic acid, disodium salt  Class I 1800 
09.333 sec-Butyl lactate 3900 Class I 1800 
09.345 Di-isopentyl succinate 3900 Class I 1800 
09.346 Dibutyl malate 3900 Class I 1800 
09.347 Dibutyl succinate 3900 Class I 1800 
09.348 Diethyl adipate 3900 Class I 1800 
09.349 Diethyl citrate 3900 Class I 1800 
09.350 Diethyl fumarate 3900 Class I 1800 
09.351 Diethyl maleate 3900 Class I 1800 
09.352 Diethyl nonanedioate 3900 Class I 1800 
09.353 Diethyl oxalate 3900 Class I 1800 
09.354 Diethyl pentanedioate 3900 Class I 1800 
09.360 Ethyl 2-acetoxypropionate 3900 Class I 1800 
09.502 Ethyl butyryl lactate 3900 Class I 1800 
09.558 Dimethyl malonate 3900 Class I 1800 
09.565 Hex-3-enyl 2-oxopropionate 3900 Class I 1800 
09.580 Hexyl lactate 3900 Class I 1800 
09.590 Isobutyl lactate 3900 Class I 1800 
09.601 Isopentyl lactate 5100 Class I 1800 
09.626 Methyl 2-oxopropionate 3900 Class I 1800 
09.629 Methyl 3-acetoxyhexanoate 3900 Class I 1800 
09.633 Methyl 5-hydroxydecanoate 3900 Class I 1800 
09.634 Methyl acetoacetate 3900 Class I 1800 
09.644 Methyl lactate 3600 Class I 1800 
09.683 Pentyl lactate 3900 Class I 1800 
09.815 Propyl lactate 3900 Class I 1800 
09.832 Ethyl 3-acetohexanoate 3900 Class I 1800 
09.833 iso-Propyl 4-oxopentanoate 3900 Class I 1800 
09.862 Ethyl 3-acetoxy octanoate 3900 Class I 1800 
09.874 Di(2-methylbutyl) malate 3900 Class I 1800 
09.916 Ethyl 3-hydroxyoctanoate 3900 Class I 1800 
09.951 Dioctyl adipate 800 Class I 1800 
10.038 Dec-7-eno-1,4-lactone 3900 Class I 1800 
10.039 cis-Dec-7-eno-1,4-lactone 3900 Class I 1800 
10.040 Dec-8-eno-1,5-lactone 3900 Class I 1800 
10.045 Heptano-1,5-lactone 3900 Class I 1800 
10.047 Hexadecano-1,16-lactone 3900 Class I 1800 
10.048 Hexadecano-1,4-lactone 3900 Class I 1800 
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TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
10.049 Hexadecano-1,5-lactone 3900 Class I 1800 
10.052 3-Methylnonano-1,4-lactone 3900 Class I 1800 
10.055 Pentano-1,5-lactone 3900 Class I 1800 
10.058 Tridecano-1,5-lactone 3900 Class I 1800 
10.059 Hexadec-7-en-1,16-lactone 3900 Class I 1800 
10.063 Hexadec-9-en-1,16 lactone 3900 Class I 1800 
10.068 Pentadecano-1,14-lactone 3900 Class I 1800 
10.168 5,6-Dimethyl-tetrahydro-pyran-2-one 3900 Class I 1800 
09.824 Ethyl 2-acetylbutyrate 3900 Class I 1800 
06.088 2-Ethyl-4-methyl-1,3-dioxolane 3900 Class II 540 
06.090 4-Hydroxymethyl-2-methyl-1,3-dioxolane 3900 Class II 540 
06.095 4-Methyl-2-propyl-1,3-dioxolane 3800 Class II 540 
06.135 2-Isobutyl-4-methyl-1,3-dioxolane  Class II 540 
02.242 2-Butoxyethan-1-ol 3900 Class II 540 
06.097 1,1,3-Triethoxypropane 3900 Class II 540 
06.102 2-Hexyl-5-hydroxy-1,3-dioxane 4100 Class III 90 
10.170 5-Pentyl-3H-furan-2-one 3800 Class III 90 
 1 
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ANNEX III: METABOLISM 1 
III.1. Introduction 2 
III.1.1. Equilibrium Between Aliphatic Lactones and Ring-opened Hydroxycarboxylic Acids: Effect of 3 
pH 4 
In general, lactones are formed by acid-catalysed intramolecular cyclisation of hydroxycarboxylic acids. In 5 
an aqueous environment, a pH-dependent equilibrium is established between the open-chain 6 
hydroxycarboxylate anion and the lactone ring. In basic media, such as blood, the open-chain 7 
hydroxycarboxylate anion is favoured while in acidic media, such as gastric juice and urine, the lactone ring 8 
is favoured (see Figure III.1). Enzymes, such as lactonase, may catalyse the hydrolysis reaction, but for 9 
simple saturated lactones, the ring-opening reaction and reverse cyclisation are in equilibrium, mainly 10 
controlled by pH conditions. Both the aliphatic lactones and the ring-opened hydroxycarboxylic acids can be 11 
absorbed from the gastrointestinal tract. However, the simple lactones, with low molecular weight, being 12 
uncharged, may cross the cell membrane more easily than the acidic form, which penetrates the cells as a 13 
weak electrolyte (Guidotti and Ballotti, 1970). 14 
 15 
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Figure III.1. Equilibrium of gamma- and delta-lactone and hydroxycarboxylate anion 17 
 18 
III.1.2. Hydrolysis of Aliphatic Lactones 19 
Fifteen candidate substances [FL-no: 10.038, 10.039, 10.040, 10.045, 10.047, 10.048, 10.049, 10.052, 20 
10.055, 10.058, 10.059, 10.063, 10.068, 10.168 and 10.170] are simple aliphatic lactones that are expected to 21 
readily undergo hydrolysis in vivo. 22 
Information on the disposition of these substances is mainly derived from studies on a single supporting 23 
substance, butyro-1,4-lactone [FL-no: 10.006], which has been extensively studied due to the production of 24 
CNS depression, attributed to its hydrolysis product, gamma-hydroxybutyrate. No data on the candidate 25 
substances are available. 26 
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When 4-hydroxybutanoic acid gamma-lactone (butyro-1,4-lactone) is administered intravenously (Roth and 1 
Giarman, 1966), intraperitoneally (i.p.) or orally (Guidotti and Ballotti, 1970) to rats, the open-chain 4-2 
hydroxybutanoate anion is detected in the blood and tissues and the sedative effect produced by 4-3 
hydroxybutanoate was evidenced (Roth and Giarman, 1966; Guidotti and Ballotti, 1970). The half-life for 4 
the conversion of the lactone ring to the open-chain anion in the blood is less than one minute. The reaction 5 
is catalysed by gamma-lactonase, which shows greater activity in the plasma than in the liver or brain 6 
(Fishbein and Bessman, 1966). 7 
Hydrolysis of various aliphatic lactones (1 mM), including those formed from tertiary alcohols, has been 8 
described after in vitro incubation in basic simulated intestinal fluid and rat liver homogenate, (Morgareidge, 9 
1962a; Morgareidge, 1963a). 10 
Table III.1.  Hydrolysis of various aliphatic lactones 11 
Substance Test System % Hydrolysis Time (hr) Reference 
Gamma-Valerolactone Simulated intestinal fluid 32 4 (Morgareidge, 1962a) 
Rat liver homogenate 93 1 (Morgareidge, 1963a) 
Gamma-Nonalactone Rat liver homogenate 
(pH= 7.5) 
62-94 1 (Morgareidge, 1963a) 
Rat liver homogenate 
(pH =8) 
81-88 1 (Morgareidge, 1963a) 
Gamma-Undecalactone Simulated intestinal fluid 58 1 (Morgareidge, 1962a) 
Rat liver homogenate 
(pH= 7.5) 
26-40 4 (Morgareidge, 1963a) 
Rat liver homogenate 
(pH= 8) 
45-70 1 (Morgareidge, 1963a) 
Omega-6-Hexadecenlactone Simulated intestinal fluid 92 0.25 (Morgareidge, 1962a) 
Simulated intestinal fluid 96 1 (Morgareidge, 1963a) 
4,4-Dibutyl-gamma-
butyrolactone 
Simulated intestinal fluid 92 1 (Morgareidge, 1962a) 
As shown in Table III.1, the rate and the extent of hydrolysis differ, depending on the lactone tested. The 12 
observation that gamma-lactones, sterically hindered gamma-lactones and omega-lactones are hydrolysed to 13 
the ring-opened form under these conditions supports the conclusion that the ring-opened hydroxycarboxylic 14 
acid anion exists in body fluids at basic pH. In acidic media, such as the gastric juice and the urine, the 15 
lactone form predominates. 16 
Gamma-valerolactone and gamma-hexalactone have been detected in the urine of normal human adults 17 
(Zlatkis and Liebich, 1971). 18 
III.1.3. Absorption of Aliphatic Lactones 19 
Aliphatic lactones or the ring-opened hydroxycarboxylic acids are expected to be absorbed from the 20 
gastrointestinal tract. In rats, single oral doses >100 mg/kg bw/day of the supporting substance gamma-21 
butyrolactone [FL-no: 10.006] were absorbed rapidly and completely from the intestinal tract (Arena and 22 
Fung, 1980; Guidotti and Ballotti, 1970; Lettieri and Fung, 1978). However, the lactone being an uncharged 23 
low molecular weight molecule may cross the cell membrane more easily than the ring-opened form, which 24 
penetrates the cells as a weak electrolyte (Guidotti and Ballotti, 1970). 25 
In humans, paraoxonase (PON1), a serum enzyme belonging to the class of A-carboxyesterases (Aldridge, 26 
1953), is known to rapidly hydrolyse a broad range of aliphatic lactone substrates including beta-, gamma-, 27 
delta- and omega-lactones, lactones fused to alicyclic rings such as 2-(2-hydroxycyclopent-4-enyl)ethanoic 28 
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acid gamma-lactone (Billecke et al., 2000). Activities of paraoxonase isoenzymes (Q & R) in human blood 1 
exhibit a bimodal distribution that is accounted for by a Q/R (glutamine or arginine) polymorphism with Q-2 
type homozygotes showing a lower activity than QR heterozygotes or R homozygotes (Humbert et al., 3 
1993). 4 
Incubation of 1 mM of human R-type PON1 with aliphatic lactones gamma-butyrolactone, gamma-5 
valerolactone, gamma-decanolactone and undecano-gamma-lactone resulted in hydrolysis rates of 9.1, 7.0, 6 
19.0 and 13.0 μmol/min/ml substrate, respectively (Billecke et al., 2000). Hydrolysis is slower for the 7 
alicyclic fused-ring lactone, 2-(2-hydroxycyclopent-4-enyl)ethanoic acid gamma-lactone, with a hydrolysis 8 
rate of less than 3 μmol/min/ml substrate in the Q and R isoenzymes of PON1 (Billecke et al., 2000). 9 
Based on these data, it is concluded that a wide variety of lactones readily hydrolyse in human blood serum 10 
support either prior to absorption or upon entering systemic circulation. 11 
III.1.4. Metabolism of Lactones Formed From Linear and Branched-chain Aliphatic Hydroxy-12 
carboxylic Acids 13 
No literature data on the candidate substances are available; however, due to the simple structure of the 14 
substances, information on their metabolic fate may be derived from text books. 15 
Linear aliphatic hydroxycarboxylic acids are hydrolysed and rapidly oxidised via the fatty acid pathway. 16 
Linear saturated 5-hydroxycarboxylic acids formed from delta-lactones are converted, via acetyl coenzyme 17 
A (CoA), to hydroxythioesters, which then undergo beta-oxidation and cleavage to yield an acetyl CoA 18 
fragment and a new beta-hydroxythioester reduced by two carbons. Even numbered-carbon acids continue to 19 
be oxidised and cleaved to yield acetyl CoA while odd numbered-carbon acids yield acetyl CoA and 20 
propionyl CoA. Acetyl CoA enters the citric acid cycle directly while propionyl CoA is transformed into 21 
succinyl CoA, which then enters the citric acid cycle (Voet and Voet, 1990). 22 
Linear saturated 4- or 6-hydroxycarboxylic acids formed from gamma- or epsilon-lactones participate in the 23 
same pathway as linear saturated 5-hydroxycarboxylic acids; however, loss of an acetyl CoA fragment 24 
produces an alpha-hydroxythioester, which undergoes oxidation and alpha-decarboxylation to yield a linear 25 
carboxylic acid and eventually carbon dioxide (Voet and Voet, 1990). In rats and dogs, the supporting 26 
substances, 14CO1-gamma-decalactone and 14CO1-gamma-dodecalactone, are metabolised in a manner similar 27 
to 14CO1-lauric acid, with approximately 75 % of the labeled 14CO being eliminated as carbon dioxide within 28 
48 hours (Fassett, 1961). 29 
The metabolic fate of the supporting substance butyro-1,4-lactone [FL-no: 10.006] has been extensively 30 
studied in animals and humans. The majority of 14C-labeled 4-hydroxybutanoate administered by intravenous 31 
injection to rats was recovered as 14CO2 within 2.5 hours (Roth and Giarman, 1965). Oxidation of gamma-32 
butyrolactone to succinate by alcohol dehydrogenase and succinic semialdehyde dehydrogenase occurs 33 
primarily in the liver (Jakoby and Scott, 1959); succinate then participates in the citric acid cycle (Doherty 34 
and Roth, 1978; Lee, 1977; Möhler et al., 1976; Walkenstein et al., 1964). However, this pathway accounts 35 
for only a limited proportion of the metabolised compound. The main biotransformation route through which 36 
gamma-butyrolactone is metabolised is beta-oxidation as indicated by the presence of (S)-3,4-37 
dihydroxybutyric acid, glycolic acid and 3-oxobutyric acid in the urine of human volunteers given orally 1.0 38 
g gamma-butyrolactone [FL-no: 10.006] (Lee, 1977); other intermediates derived from beta-oxidation have 39 
previously been detected in samples of human urine (Walkenstein et al., 1964). 40 
If the lactone is formed from a linear hydroxycarboxylic acid containing unsaturation, cleavage of acetyl 41 
CoA units will continue along the carbon chain until the position of unsaturation is reached. If the 42 
unsaturation begins at an odd-numbered carbon, acetyl CoA fragmentation will eventually yield a 3-enoyl 43 
CoA, which is converted to the trans-Δ2-enoyl CoA before entering the fatty acid pathway. If unsaturation 44 
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begins at an even-numbered carbon, acetyl CoA fragmentation yields a Δ2-enoyl CoA product, which is a 1 
substrate for further fatty acid oxidation. If the stereochemistry of the double bond is cis, hydration yields 2 
(R)-3-hydroxyacyl CoA, which is isomerised to (S)-3-hydroxyacyl CoA by 3-hydroxyacyl CoA epimerase 3 
prior to entering into normal fatty acid metabolism (Voet and Voet, 1990). 4 
The principal metabolic pathways utilized for detoxication of branched-chain hydroxycarboxylic acids are 5 
influenced by the chain length and the position and size of alkyl substituents. Short-chain (< C6) branched 6 
aliphatic hydroxycarboxylic acids may be excreted conjugated mainly with glucuronic acid, or undergo 7 
alpha- or beta-oxidation followed by cleavage and complete metabolism to CO2 (Voet and Voet, 1990; 8 
Williams, 1959a) via the fatty acid pathway and the tricarboxylic acid cycle. Alternatively, as chain length, 9 
substitution and lipophilicity increase, the hydroxycarboxylic acid may undergo a combination of omega-, 10 
omega-1 and beta-oxidation to yield polar hydroxyacid, ketoacid and hydroxydiacid metabolites that may be 11 
excreted as the glucuronic acid or sulphate conjugates in the urine and, to a lesser extent, in the faeces. 12 
Methyl substituted carboxylic acids are, to some extent, omega-oxidised in animals to form diacids, which 13 
can be detected in the urine (Williams, 1959a). 14 
Carboxylic acids with a methyl substituent located at an even-numbered carbon (e.g. 2-methylpentanoic acid 15 
or 4-methyldecanoic acid) are metabolised extensively in the fatty acid pathway to CO2 via beta-oxidation 16 
and cleavage of the longer branched-chain. If the methyl group is located at an odd-numbered carbon such as 17 
the 3-position, beta-oxidation is inhibited and omega-oxidation predominates, primarily leading to polar, 18 
acidic metabolites capable of being excreted in the urine as such or as conjugates (Williams, 1959a). Larger 19 
alkyl substituents (> C2) located at the alpha- or beta-position inhibit metabolism to CO2 (Albro, 1975;  20 
Deisinger et al., 1994; Deuel, 1957) in which case there is either direct conjugation of the acid with 21 
glucuronic acid or omega-oxidation leading to diacid metabolites, which may be conjugated and excreted. 22 
III.2. Absorption, Metabolism and Elimination of: Esters, Acetals, Aliphatic Primary 23 
Alcohols, Aldehydes, and Carboxylic Acids Containing Additional Oxygenated Functional 24 
Groups 25 
III.2.1. Mono- and Di-esters 26 
Thirty-two candidate substances are esters or diesters [FL-no: 09.333, 09.345 - 09.354, 09.360, 09.502, 27 
09.558, 09.565, 09.580, 09.590, 09.601, 09.626, 09.629, 09.633, 09.634, 09.644, 09.683, 09.815, 09.824, 28 
09.832, 09.833, 09.862, 09.874 09.916 and 09.951]. They are expected to undergo hydrolysis in humans to 29 
yield their corresponding alcohol (linear or branched-chain aliphatic alcohols) and acid components (i.e. 30 
alpha-, beta- or gamma-keto or hydroxy acids; or simple aliphatic acids, diacids or triacids), which would be 31 
further metabolised. The presence of a second oxygenated functional group has little if any effect on 32 
hydrolysis of these esters; therefore the discussion and conclusions presented in previous evaluations 33 
(FGE.01 and FGE.02) apply equally well to the candidate esters in the present evaluation. 34 
Hydrolysis is catalysed by classes of enzymes recognised as carboxylesterases or esterases (Heymann, 1980), 35 
the most important of which are the B-esterases (Anders, 1989; Heymann, 1980). Acetyl esters are the 36 
preferred substrates of C-esterases (Heymann, 1980). In mammals, these enzymes occur in most tissues 37 
throughout the body (Anders, 1989; Heymann, 1980) but predominate in the hepatocytes (Heymann, 1980). 38 
The majority of degradation products yielded from the candicate ester hydrolysis are endogenous in 39 
mammals and are known to be completely metabolised, through different reactions, depending on their chain 40 
length and degree of branching and functional groups. It is likely that multiple metabolic reactions will occur 41 
for some hydrolysis products. The most probable metabolic reactions are the following: 42 
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• Oxidation of alcohols to aldehydes and acids. 1 
• Conjugation of alcohols and acids to glucuronides and sulphates. 2 
• Beta-oxidation of carboxylic acids. 3 
• Omega-oxidations of carboxylic acids. 4 
However, the hydrolysis product of the candidate substance ethyl 2-acetylbutyrate [FL-no: 09.824], 2-acetyl 5 
butyric acid, has some structural similarities to valproic acid, which together with a number of its derivatives 6 
has been recognised to be teratogenic in rodents and in humans (Nau and Löscher, 1986; Samren et al., 1997; 7 
Kaneko et al., 1999). Although it can be predicted that 2-acetyl butyric acid is further metabolised through 8 
the above mentioned pathways of detoxication for carboxylic acids, the structural similarity with valproic 9 
acid does no allow to anticipate that ethyl 2-acetylbutyrate [FL-no: 09.824] is metabolised to innocuous 10 
products. 11 
While no hydrolysis data have been provided for the esters of the present group of flavourings, information 12 
on some structurally related esters could be found. 13 
In vitro incubation of the supporting substance methyl 2-oxo-3-methylvalerate [FL-no: 09.550], with a 2 % 14 
pancreatin solution (pH = 7.5), resulted in virtually complete hydrolysis (> 98 %) within 80 minutes 15 
(Leegwater and VanStraten, 1979). The supporting substance dibutyl sebacate [FL-no: 09.474] in 10 % 16 
acacia solution, was hydrolysed in vitro in a 10 % crude pancreatic lipase solution (Smith, 1953b). 17 
The supporting substance 14C-tributyl acetylcitrate [FL-no: 09.511], administered to male Sprague-Dawley 18 
rats by gavage at a dose level of 70 mg/kg bw, was rapidly absorbed (t½  = 1 hour) and partially hydrolysed. 19 
More than 87 % of the administered radioactivity was eliminated within 24 hours after dosing. At least nine 20 
urinary metabolites (59 - 70 %) were detected. Five metabolites were positively identified as the partially 21 
hydrolysed mono-, di- and tri-alkylesters of citric acid. Three metabolites (25 - 26 %) were identified in the 22 
faeces; approximately 2 % of the administered dose was eliminated as 14CO2 (Hiser et al., 1992). 23 
III.2.2. Acetals 24 
Six candidate substances [FL-no: 06.088, 06.090, 06.095, 06.097, 06.102 and 06.135] are acetals, which may 25 
undergo acid catalysed hydrolysis in the gastric environment to yield their component aldehydes and 26 
alcohols prior to absorption. 27 
In vitro experiments using simulated gastric fluid revealed the rates of hydrolysis of acetals to be dependent 28 
on the structures of the aldehyde and alcohol moieties. Acetals derived from short (< C8) chain saturated 29 
aldehydes were hydrolysed almost instantly (Engel, 2003). 30 
Hydroxycitronellal dimethyl acetal similar to the supporting substance hydroxycitronellal diethyl acetal   was 31 
> 99 % hydrolysed in vitro to the terpenoid hydroxycitronellal and methanol in simulated gastric juice (pH 32 
about 2.1) after 1 hour and > 6 % hydrolysed in intestinal fluid (pH = 7.5) after 2 hours (Morgareidge, 33 
1962b). 34 
Once hydrolysed, the component alcohol, aldehydes and acids are expected to be completely metabolised, 35 
through the above mentioned common routes of biotransformations and excreted. 36 
III.2.3. Alpha-hydroxy- and Alpha-keto-acids and Their Esters 37 
One candidate substance [FL-no: 08.090] is an alpha-hydroxyacid. In addition alpha-keto- and alpha-38 
hydroxyacids are formed by hydrolysis of candidate esters [FL- No: 09.333, 09.346, 09.353, 09.565, 09.580, 39 
Flavouring Group Evaluation 10, Revision 3
 
 
96 EFSA Journal 2012; 10(3):2563 
09.590, 09.601, 09.626, 09.644, 09.683, 09.815 and 09.874]. They would be expected to be metabolised like 1 
endogenous alpha-ketoacids formed from oxidative deamination of amino acids such as isoleucine, 2 
methionine and valine in vivo. 3 
The supporting substance, 2-oxobutyric acid [FL-no: 08.066] (i.e. alpha-ketobutyric acid), is endogenous in 4 
humans as a product of methionine degradation and undergoes alpha-decarboxylation to yield propionyl 5 
CoA. Propionyl CoA ultimately enters the tricarboxylic acid cycle as succinyl CoA (Voet and Voet, 1990). 6 
III.2.4. Beta-keto- and Beta-hydroxyacids and Their Esters 7 
One candidate substance [FL-no: 08.053] is a beta-ketoacid. In addition eight candidate substances [FL-no: 8 
09.346, 09.558, 09.629, 09.634, 09.824, 09.862, 09.874 and 09.916] are precursor of acetoacetic acid or its 9 
beta-hydroxy or aldehyde precursor. [FL-no: 09.346, 09.629, 09.862, 09.874 and 09.916] can be oxidised in 10 
vivo to acetoacetic acid. Acetoacetic acid is endogenous in humans and is formed from the condensation of 11 
two acetyl CoA units in the fatty acid pathway. It is released from the liver into the bloodstream and 12 
transported to peripheral tissues where it is converted to acetyl CoA and is completely metabolised. At 13 
elevated endogenous levels, beta-ketoacids may undergo non-enzymatic decarboxylation, which, for 14 
acetoacetic acid, yields acetone and CO2 (Voet and Voet, 1990). 15 
III.2.5. Gamma-keto- and Gamma-hydroxyacids and Their Esters 16 
Gamma-hydroxy and gamma-keto acids are produced by hydrolysis of two candidate substances [FL-no: 17 
09.832 and 09.833]. They are expected to be completely metabolised to CO2 at low levels of exposure from 18 
use as flavouring substances. At elevated levels of exposure, the ketone function may be reduced to the 19 
corresponding secondary alcohol (Bosron and Li, 1980) and excreted as the glucuronic acid conjugate 20 
(Williams, 1959a). 21 
Products of partial beta-oxidation or glucuronic acid conjugation have also been identified in the urine. 22 
When 1.0 g of the structurally related substance gamma-hydroxybutyrate [FL-no: 10.006] was administered 23 
to humans, it was excreted in the urine as S-3,4-dihydroxybutyrate, 3-oxobutyric acid and glycolate (Lee, 24 
1977). 25 
III.2.6. Aliphatic Di- and Tricarboxylic Acids and Their Esters 26 
Among candidate substances the aliphatic di- and tri-carboxylic acids and their precursors [FL-no: 05.149, 27 
08.053, 08.082, 08.103, 08.113, 09.345, 09.346, 09.347, 09.348, 09.349, 09.350, 09.351, 09.352, 09.353, 28 
09.354, 09.558, 09.874 and 09.951] either occur endogenously in humans or are structurally related to 29 
endogenous substances. Succinic acid (from [FL-no: 09.345 and 09.347]), fumaric acid (from [FL-no: 30 
09.350]), l-malic acid (from [FL-no: 09.346 and 09.874]), maleic acid (from [FL-no 09.351]) and citric acid 31 
(from [FL-no: 09.349]), are components of the tricarboxylic acid cycle (Voet and Voet, 1990). Fumaric acid 32 
is present in the blood, brain, liver, muscle and kidney of normal rats (Marshall et al., 1949). Moreover, the 33 
following acids are present in the urine of normal adults, citric, tartaric, malic, aconitic, fumaric and adipic 34 
(Hanson, 1943; Osteux and Laturaze, 1954). Alpha-ketoglutaric acid is an intermediate metabolite of citric 35 
acid, fumaric acid and succinic acid, and is formed via alpha-oxidation (Krebs et al., 1938; Simola and 36 
Krusius, 1938). 37 
Simple aliphatic di- and tricarboxylic acid candidate substances and component acids of the candidate esters 38 
are metabolised in the fatty acid beta-oxidation pathway or tricarboxylic acid cycle. When the supporting 39 
substance 14C-l-malic acid [FL-no: 08.017] was administered to male albino Wistar rats by gavage at a dose 40 
level of 2.5 mg/kg bw, 93 % of the radioactivity was recovered in expired air, urine and faeces (Dargel, 41 
1966). 42 
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After the administration of the radioactive supporting substance adipic acid [FL-no: 08.026] to rats by 1 
stomach tube at a dose level of 200 - 300 mg/kg bw, the compound was extensively metabolised. Labelled 2 
products identified in the urine included glutamic acid, lactic acid, beta-ketoadipic acid and citric acid. The 3 
presence of the beta-oxidation metabolite, beta-ketoadipic acid, indicates that adipic acid participates in beta-4 
oxidation in the fatty acid pathway (Rusoff et al., 1960). 5 
The linear and branched-chain aliphatic primary alcohol components of candidate substances that are simple 6 
aliphatic di- and tricarboxylic acid esters would be oxidised in the presence of alcohol dehydrogenase to their 7 
corresponding aldehydes which, in turn, would be oxidised to their corresponding carboxylic acids (Bosron 8 
and Li, 1980; Feldman and Weiner, 1972; Levi and Hodgson, 1989). The resulting carboxylic acids would 9 
be metabolised in the fatty acid pathway and tricarboxylic acid cycle (Voet and Voet, 1990) or conjugated to 10 
glucuronides and sulphates and excreted. Branched-chain diols or keto alcohols may undergo oxidation to 11 
their corresponding aldehydes and carboxylic acid, which would be further metabolised or excreted, through 12 
the common routes of biotransformation of carboxylic acids. 13 
III.2.7. Aliphatic Alkoxy- alcohol and Diols 14 
Among candidate substances, one is an alkoxy-alcohol [FL-no: 02.242] and two are diols [FL-no: 02.132 and 15 
02.198]. 16 
The metabolism and disposition of 2-butoxyethanol [FL-no: 02.242] were extensively studied, and details are 17 
reported below. However, it can be anticipated that the major metabolite is butoxyacetic acid, which is 18 
primarily responsible for the hemolysis of red blood cells and other toxic effects induced by 2-19 
butoxyethanol. 20 
1-Hydroxypropan-2-one [FL-no: 07.169] (acetol) is an endogenous metabolite of acetone which is also an 21 
endogenous substance formed from the degradation of body fat/fatty acids. 22 
The metabolism in mammals of acetone, which at low concentrations, primarily occurs in the liver, is shown 23 
in Figure III.2. At low acetone concentrations in blood, i.e. in healthy humans not exposed to external 24 
sources, in amounts of approximately 4 - 12 mg per person corresponding to 0.7 to 2 mg/l blood (Ashley et 25 
al., 1994; Dick el al., 1988; Wang et al, 1994c), the major pathway is via the methylglyoxal route. At higher 26 
acetone concentrations in the blood, e.g. after acetone exposure, after fasting or in relation to certain 27 
deceases the propan-1,2-diol route is the dominating pathway. In the fist step acetone is oxidized to 1-28 
hydroxypropan-2-one via acetone monooxygenase (p-450 IIE1). 1-Hydroxypropan-2-one is oxidised to 2-29 
oxopropanal via acetol monooxygenase (p-450 IIE1), or at higher acetone concentrations to propan-1,2-diol. 30 
2-Oxopropanal is then oxidised to pyruvate leading to glucose formation (Morgott, 1993; WHO, 1998a; 31 
NAS/COT, 2005). 32 
The diols are anticipated to be metabolised by the common route of alcohol biotransformation, i.e. direct 33 
conjugation or oxidation by alcohol-dehydrogenase to their corresponding aldehydes and carboxylic acid, 34 
which would be further metabolised or excreted. 35 
 36 
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Figure III.2.  Acetone metabolism (methylglyoxal pathway) 2 
III.3. Studies on Candidate Substances 3 
2-Butoxyethan-1-ol [FL-no: 02.242] 4 
Several experiments by the oral route of administration have been conducted, indicating that 2-butoxyethan-5 
1-ol is rapidly absorbed, metabolised and eliminated. Butoxyacetic acid is its major metabolite, metabolism 6 
being mainly catalysed by hepatic alcohol dehydrogenase; most excretion is in the urine (Corley et al., 1994; 7 
Ghanayem et al., 1987a; Ghanayem et al., 1987b; Ghanayem et al., 1987c; Medinsky et al., 1990). 8 
The distribution and excretion of 14C-butoxyethanol and its metabolites was evaluated using male F344 rats 9 
(9 - 13 weeks old). A single 125 or 500 mg/kg dose of 14C-butoxyethanol was administered to each animal 10 
via gavage. Animals were killed 48 hours post-administration and tissues excised. At 48 hours, 11 
approximately 18 % and 10 % of the administered dose was exhaled as 14CO2  for the 125 and 500 mg/kg 12 
doses, respectively; whereas only between 2 and 3 % was excreted in the faeces. The percentage of the 125 13 
mg/kg dose excreted in the urine (70 %) was significantly greater than the percentage excreted after the 500 14 
mg/kg dose (40 %). Butoxyacetic acid was the only urinary metabolite detected for the 125 mg/kg dose; the 15 
glucuronide conjugates of butoxyethanol and butoxyacetic acid (23 %) were also detected in the urine of 16 
animals dosed with the higher dose. A small portion (8 %) of the 500 mg/kg dose was excreted in the bile 8 17 
hours after dosing. Compared to the 125 mg/kg dose group, tissue concentrations of 14C-butoxyethanol 48 18 
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hours after administration were significantly greater in specific organs of rats that received the 500 mg/kg 1 
dose. In both dose groups the highest concentration of radioactivity was detected in the forestomach, 2 
followed by the liver, kidneys, spleen and the glandular stomach (Ghanayem et al., 1987c). 3 
The metabolism and excretion of 2-butoxyethan-1-ol [FL-no: 02.242] were evaluated using both young (4 to 4 
5 weeks old) and adult (9 to 13 weeks old) male F344 rats with the same experimental design described in 5 
Ghanayem et al. (1987c), except that 14C-butoxyethanol was administered at a single oral dose (500 mg/kg). 6 
There was a significantly higher proportion of the administered dose eliminated as CO2 in young rats as 7 
compared to older rats. Similarly, a significantly higher proportion of the administered dose was excreted in 8 
the urine of the young rats. The butoxyacetic acid/butoxyethanol-glucuronide + butoxyethanol-sulphate ratio 9 
was significantly greater in older rats (Ghanayem et al., 1987a), which are consistently more susceptible to 10 
the toxic action of 2-butoxyethan-1-ol . There was a strong correlation between the amount of butoxyacetic 11 
acid in the urine and 2-butoxyethanol-induced haematotoxicity. Moreover, metabolic activation via alcohol 12 
and aldehyde dehydrogenases is a prerequisite for the induction of toxic effects, since pre-treatment of rats 13 
with pyrazole (alcohol dehydrogenase inhibitor) or cyanamide (aldehyde dehydrogenase inhibitor) protected 14 
rats against 2-butoxyethanol-induced haematotoxicity and increased the urinary amount of butoxyethanol- 15 
conjugates (glucuronide and sulphate) (Ghanayem et al., 1987b). 16 
2-Butoxyethan-1-ol [FL-no: 02.242] was administered to male F344/N rats (11 to 12 weeks old) at 17 
concentrations in drinking water of 290, 860 and 2590 ppm over a 24 hours period. Butoxyethanol was 18 
administered as 2-butoxy[U-14C]ethanol, and exhaled air, urine and faeces were collected over a 72 hours 19 
period. Most 14C was excreted either in the urine or exhaled as CO2: 50 - 60 % of the administered dose was 20 
eliminated in the urine as butoxyacetic acid and 8 to 10 % as CO2. Analysis of urine samples collected 21 
during the 12 - 24 hours after dosing indicated that the majority of the radioactivity was associated with 22 
butoxyacetic acid while 10 % of the administered dose was identified as glycol ether. Minor levels of 23 
glucuronide conjugate of butoxyethanol and unmetabolised butoxyethanol were also reported (Medinsky et 24 
al., 1990). 25 
Non-oxidative metabolism of 2-butoxyethan-1-ol [FL-no: 02.242] via fatty acid conjugation was also 26 
investigated in the liver of F344 male rats following a single oral administration of 500 mg/kg [ethyl-1,2-14C] 27 
2-butoxyethanol. Animals were killed two hours after treatment and samples prepared for analysis. It was 28 
demonstrated that 2-butoxyethan-1-ol is metabolised non-oxidatively via conjugation with long-chain fatty 29 
acids, and the formation of these esters appears to be catalysed by the enzymes involved in fatty acid 30 
conjugation of xenobiotic alcohols. However, the biological significance of 2-butoxyethan-1-ol conjugation 31 
with fatty acids remains unclear, although several such lipid conjugates were found to be toxic in laboratory 32 
animals and cell lines (Kaphalia et al., 1996). 33 
The elimination kinetics of 2-butoxyethan-1-ol were studied in a once-through isolated perfused rat liver 34 
system in the presence and absence of ethanol. Dose-dependent Michaelis-Menten kinetics were observed in 35 
the elimination of 2-butoxyethan-1-ol. The apparent Km ranged from 0.32 to 0.70 mM and the maximum 36 
elimination rate ranged from 0.63 to 1.4 micromol/min/g liver in six experiments. The results support the 37 
hypothesis that 2-butoxyethan-1-ol is metabolised mainly via oxidation by alcohol dehydrogenase in the rat 38 
liver at concentration which can be considered representative of human exposure (Johanson et al., 1986). 39 
Butane-1,3-diol [FL-no: 02.132] 40 
Two groups of 14 rats were administered a control diet (70 % carbohydrate and 30 % fat) or a treatment diet 41 
(45 % carbohydrate, 30 % fat and 25 % butane-1,3-diol). Blood acetoacetate and beta-hydroxybutyrate 42 
concentrations were increased significantly and blood pyruvate concentration was decreased significantly in 43 
rats administered the treatment diet. Addition of butane-1,3-diol to in vitro liver tissue slices, as they were 44 
metabolising glucose to lactate and pyruvate, greatly decreased pyruvate levels and significantly increased 45 
lactate/pyruvate ratios. When butane-1,3-diol and glucose were used as substrates, there was a large increase 46 
in acetoacetate and beta-hydroxybutyrate formation in liver tissue slices with butane-1,3-diol. Therefore, 47 
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butane-1,3-diol is metabolised in the cytosol and converted by the liver in vivo and in vitro to ketones prior 1 
to its oxidation in the tricarboxylic acid cycle (Mehlman et al., 1971). 2 
Tate et al. (1971) found that the conversion of butane-1,3-diol to beta-hydroxybutyrate in rat liver was 3 
strongly dependent in NAD+ and it was inhibited by pyrazole. Since pyrazole is a specific inhibitor of 4 
alcohol dehydrogenase (ADH), this inhibition indicated ADH as the catalyst in the catabolism in the cytosol 5 
of butane-1,3-diol to an intermediate, aldol. Aldol is then further oxidised to beta-hydroxybutyrate (Tate et 6 
al., 1971). 7 
Diethyl maleate [FL-no: 09.351] 8 
Traditionally diethyl maleate [FL-no: 09.351] has been utilised to acutely deplete reduced glutathione (GSH) 9 
in the tissues, since it forms GHS-conjugates very rapidly, causing a significant decrease in GSH content 10 
(Boyland & Chasseaud, 1970). The liver is the most sensitive organ to diethyl maleate-induced GSH 11 
depletion, generally occurring 30 - 90 minutes after intraperitoneal injection of the compound. In the rat, the 12 
formed GSH-conjugates are excreted in bile or as mercapturates in urine (Barnhart and Combes, 1978). 13 
The excretion of mercapturic acid was determined in chimpanzees and rats after the administration of diethyl 14 
maleate [FL-no: 09.351]. The excretion rate of endogenous thioethers in the urine of untreated chimpanzees 15 
and rats was 18.0 and 94.4 micromol/kg bw/24 hours, respectively. The value in man was nearly the same as 16 
found in chimpanzees. The administration of diethyl maleate at 30, 75 and 200 mg/kg bw led to a dose-17 
dependent increase in the excretion of urinary mercaptic acids in both species, but the increase in rats was 18 
about twice that of chimpanzees. Additional experiments indicate that the observed species differences are 19 
due to differences in the glutathione conjugation (Summer et al., 1979a).  20 
Glutaric acid [FL-no: 08.082] 21 
Rat liver mitochondria metabolise glutarate [FL-no: 08.082] at a slow rate as compared with glutaryl CoA. 22 
The stimulatory effect of citric acid cycle intermediates, NAD and CoA on glutarate metabolism was 23 
interpreted as a manifestation of their involvement in the activation of glutarate by a thiol transferase with 24 
succinyl CoA as the coenzyme A donor (Besrat et al., 1969). 25 
Glutaraldehyde [FL-no: 05.149] 26 
Material mass balance and pharmacokinetics studies were conducted with glutaraldehyde [FL-no: 05.149] in 27 
groups of F344 rats (four/sex) and New Zealand white rabbits (two/sex) using the intravenous route of 28 
exposure at dose volumes of 0.2 ml and 2.5 ml, respectively. Rats and rabbits received intravenous doses of 29 
0.075 and 0.75 % glutaraldehyde in the tail vein or ear vein, respectively. Glutaraldehyde was distributed 30 
rapidly and eliminated when administered intravenously to rats and rabbits. When a single infusion of 0.075 31 
% glutaraldehyde was administered, 75 to 80 % of the dose in the rat and 66 to 71 % in the rabbit were 32 
recovered as 14CO2 during the first 24 hours following administration, with 80 % of the 14CO2 being 33 
recovered during the first four hours. When a single infusion of 0.75 % glutaraldehyde was administered, the 34 
proportion of the dose recovered as 14CO2 decreased and the amount of radioactivity recovered in urine, 35 
tissues and carcass increased as compared to the 0.075 % glutaraldehyde infusion. Also the average plasma 36 
concentration of radioactivity increased 10-fold in rats and rabbits with a 10-fold increase in dose, but the 37 
tissue concentration increased by an even greater amount. The results suggest that the mechanisms involved 38 
in the disposition of glutaraldehyde were saturated when the higher dose was administered and resulted in a 39 
shift in the elimination pathway (McKelvey et al., 1992). Although the metabolism of glutaraldehyde has not 40 
been studied in detail, it has been suggested that it is oxidised first to a mono- or dicarboxylic acid by 41 
aldehyde dehydrogenase (Weiner, 1980; Hjelle and Peterson, 1983) and then further oxidised through an 42 
acidic intermediate to CO2 (McKelvey et al., 1992). 43 
Nonanedioic acid [FL-no: 08.103] 44 
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Following intravenous administration in human volunteers, nonanedioic acid [FL-no: 08.103] and its major 1 
catabolite, pimelic acid, are found in serum and urine indicating transformation by mitochondrial beta-2 
oxidative enzymes. Serum levels of nonanedioic acid are short-lived following a single 5 or 10 g intravenous 3 
(i.v.) infusion over 1-hour. In the first hour after the cessation of i.v. administration, serum levels of 4 
nonanedioic acid decreased to about 25 % of their peak values. Administration of multiple intravenous doses 5 
at the same concentrations as the one-hour doses produces sustained higher levels of nonanedioic acid in the 6 
serum during the period of administration (Passi et al., 1989). 7 
III.4. Conclusions 8 
In general, lactones are formed by acid-catalysed intramolecular cyclisation of hydroxycarboxylic acids. In 9 
an aqueous environment, a pH-dependent equilibrium is established between the open-chain 10 
hydroxycarboxylate anion and the lactone ring. In basic media, such as blood, the open-chain 11 
hydroxycarboxylate anion is favoured, while in acidic media, such as gastric juice and urine, the lactone ring 12 
is favoured. 13 
Lactones formed from linear saturated and branched-chain aliphatic hydroxycarboxylic acids are hydrolysed 14 
to the corresponding hydroxycarboxylic acid that then enters the fatty acid pathway and undergoes alpha- or 15 
beta-oxidation and cleavage to form acetyl CoA and a chain-shortened carboxylic acid. The carboxylic acid 16 
is then reduced by two-carbon fragments until either acetyl CoA or propionyl CoA is produced. These 17 
fragments are then completely metabolised in the citric acid cycle. 18 
Mono- and di-esters included in the present FGE are expected to undergo hydrolysis in humans to yield their 19 
corresponding alcohol (linear or branched-chain aliphatic alcohols) and acid components (i.e. alpha-, beta- or 20 
gamma-keto- or hydroxy-acids; or simple aliphatic acids, diacids or triacids), which would be further 21 
metabolised and excreted through the common pathways of detoxication of aliphatic alcohols and carboxylic 22 
acids). The hydrolysis product of the candidate substance ethyl 2-acetylbutyrate [FL-no: 09.824], 2-acetyl 23 
butyric acid, which shows some structural similarities to valproic acid, which together with a number of its 24 
derivatives, has been recognised to be teratogenic in rodents and in humans (Nau and Löscher, 1986; Samren 25 
et al., 1997; Kaneko et al., 1999). Therefore, it cannot be anticipated that ethyl 2-acetylbutyrate [FL-no: 26 
09.824] is metabolised to innocuous products. 27 
The presence of a second oxygenated functional group has little, if any, effect on hydrolysis of these esters. 28 
The most probable metabolic reactions of the hydrolysis products are: oxidation of alcohols to aldehydes and 29 
acids; conjugation of alcohols and acids to glucuronides and sulphates; beta-oxidation of carboxylic acids; 30 
omega-oxidations of carboxylic acids. 31 
Beta-keto acids and derivatives like acetoacetic acid undergo decarboxylation. Along with alpha-keto and 32 
alpha-hydroxyacids, they yield breakdown products, which are incorporated into normal biochemical 33 
pathways. The gamma-keto-acids and related substances may undergo complete or partial beta-oxidation to 34 
yield metabolites that are eliminated in the urine. Omega-substituted derivatives are readily oxidised and/or 35 
excreted in the urine. Simple aliphatic di- and tricarboxylic acids participate in the tricarboxylic acid cycle. 36 
Six candidate substances [FL-no: 06.088, 06.090, 06.095, 06.097, 06.102 and 06.135] are acetals, which may 37 
be expected to undergo acid catalysed hydrolysis in the gastric environment to yield their component 38 
aldehydes and alcohols prior to absorption. Once hydrolysed, the component alcohols and aldehydes are 39 
expected to be metabolised primarily through the above mentioned common routes of biotransformations and 40 
excreted. 41 
The linear and branched-chain aliphatic primary alcohol components of candidate substances that are simple 42 
aliphatic di- and tricarboxylic acid esters would be oxidised in the presence of alcohol dehydrogenase to their 43 
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corresponding aldehydes which, in turn, would be oxidised to their corresponding carboxylic acids. The two 1 
diols [FL-no: 02.132 and 02.198] may be anticipated to participate in the same routes of biotransformation. 2 
Among candidate substances, an alkoxy-alcohol 2-butoxyethanol [FL-no: 02.242] is mainly metabolised to 3 
butoxyacetic acid, which has been identified as the major responsible for the hemolysis of red blood cells 4 
and other toxic effects induced by 2-butoxyethanol. 5 
In summary, it can be anticipated that primary and secondary aliphatic saturated or unsaturated alcohols, 6 
aldehydes, carboxylic acids, acetals and esters with an additional oxygenated functional group and aliphatic 7 
lactones included in the present FGE are generally hydrolysed and completely metabolised to innocuous 8 
products many of which are endogenous in humans, at the estimated level of intake as flavouring substances. 9 
The consideration on the actual levels of intake becomes particularly relevant for one candidate substance, 10 
diethyl maleate [FL-no: 09.351]; as when administered at high doses, it is able to induce severe GSH 11 
depletion, due to its prompt metabolism to GSH-conjugates. This may also be the case for the structurally 12 
related diethyl fumarate [FL-no: 09.350]. 13 
For three of the candidate substances it cannot be concluded that they are metabolised to innocuous products. 14 
These are 2-butoxyethanol [FL-no: 02.242], the major metabolite of which butoxyacetic acid has been 15 
recognised as responsible for haematotoxic effects induced by 2-butoxyethanol [FL-no: 02.242], 1,1,3-16 
triethoxypropane [FL-no: 06.097], which may be metabolised to the structurally related ethoxypropanoic 17 
acid and finally, ethyl 2-acetylbutyrate [FL-no: 09.824], whose hydrolysis gives rise to 2-acetylbutyric acid, 18 
with some structural similarities to valproic acid, a known teratogenic compound. 19 
 20 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for 16 candidate substances of the present Flavouring Group Evaluation from chemical groups 9, 13 and 30, for 43 
supporting substances evaluated by the JECFA at the 49th and 53rd meetings (JECFA, 1998a; JECFA, 2000c). The supporting substances are listed in brackets. 
Table IV.1: ACUTE TOXICITY 
Chemical Name  [FL-no:] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  
(Methyl 2-hydroxy-4-methylpentanoate [09.548]) Mouse  NR  Oral  40001  (Pellmont, 1978)  
(Methyl 2-oxo-3-methylvalerate  [09.550]) Rat  M  Gavage  > 5000  (Moreno, 1979b)  
(Butyro-1,4-lactone [10.006]) Mouse  NR  Gavage  1245  (Schafer and Bowles, 1985) 
(Pentano-1,4-lactone  [10.013]) Rat  NR  Oral  > 5000  (Moreno, 1978e) 
Rat  NR  Gavage  8800  (Deichmann et al., 1945) 
Rabbit  NR  Gavage  2480  (Deichmann et al., 1945) 
(Hexano-1,4-lactone  [10.021]) Rat  NR  Oral  > 5000  (Moreno, 1977f)  
(Hexano-1,5-lactone  [10.010]) Rat  M  Gavage  13,030  (Smyth et al., 1962) 
(Heptano-1,4-lactone  [10.020]) Rat  NR  Oral  > 5000  (Moreno, 1977g) 
(Octano-1,4-lactone  [10.022]) Rat  NR  Oral  > 5000  (Moreno, 1974c) 
(Octano-1,5-lactone  [10.015]) Rat  NR  Oral  > 5000  (Moreno, 1977h)  
(Nonano-1,4-lactone  [10.001]) Rat  M, F  Gavage  9780  (Jenner et al., 1964) 
Rat  M  Oral  6600  (Moreno, 1972b) 
Guinea pig M, F  Gavage  3440  (Jenner et al., 1964) 
(Decano-1,4-lactone  [10.017]) Rat  NR  Oral  > 5000 (Moreno, 1975h) 
(Decano-1,5-lactone  [10.007]) Rat  NR  Oral  > 5000  (Levenstein, 1975c) 
(Decano-1,6-lactone  [10.029]) Mouse  M, F  Gavage  5252  (Moran et al., 1980) 
(Undecano-1,4-lactone  [10.002]) Rat  M, F  Gavage  18500  (Jenner et al., 1964) 
(Undecano-1,5-lactone  [10.011]) Rat  NR  Oral  > 5000  (Moreno, 1975i) 
(Dodecano-1,4-lactone  [10.019]) Rat  NR  Oral  > 5000  (Moreno, 1974d) 
(Dodecano-1,5-lactone  [10.008]) Rat  NR  Oral  > 5000  (Moreno, 1977e) 
(Dodecano-1,6-lactone  [10.028]) Mouse  M, F  Gavage  7898  (Moran et al., 1980) 
(Pentadecano-1,15-lactone  [10.004]) Rat  NR  Oral  > 5000  (Levenstein, 1974c) 
(5-Methylfuran-2(3H)-one  [10.012]) Mouse  M, F  Gavage  2800  (Moran et al., 1980) 
(Dodec-6-eno-1,4-lactone  [10.009]) Rat  M, F  Oral  > 5000  (Watanabe and Morimoto, 1990) 
(3,7-Dimethyloctano-1,6-lactone  [10.027]) Rat  M, F  Gavage  > 5000  (Lewis and Palanker, 1979a) 
(5-Hexyl-5-methyldihydrofuran-2(3H)-one  [10.051]) Rat  NR  Oral  > 5000  (Moreno, 1976j)  
(Citronellyl oxyacetaldehyde [05.079]) Rat  NR  Oral  > 5000  (Moreno, 1973d)  
1-Hydroxypropan-2-one [07.169] Rat  NR  Oral  22002  (Smyth and Carpenter, 1948) 
(4,4-Dimethoxybutan-2-one [06.038]) Rat  M  Gavage  6200  (EPA, 1971) 
(Ethyl acetoacetate [09.402]) Rat  NR  Oral  39803  (Smyth et al., 1949) 
Methyl acetoacetate [09.634] Rat  NR  Oral  3000  (Smyth and Carpenter, 1948) 
Rat  NR  Oral  2800  (BASF, 1978) 
(Butyl acetoacetate [09.403]) Rat  F  Gavage  11260  (Smyth et al., 1954) 
(Geranyl acetoacetate [09.405]) Rat  NR  Oral  > 5000  (Moreno, 1976k) 
(Ethyl 3-oxohexanoate [09.542]) Mouse  NR  Oral  4000 – 8000 (Pellmont, 1973a)  
2-Butoxyethan-1-ol [02.242] Rat  M  Gavage  1480  (Smyth et al., 1941) 
Rat  NR  Oral  1174  (BASF, 1956) 
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Table IV.1: ACUTE TOXICITY 
Chemical Name  [FL-no:] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  
Rat  NR  Oral  620  (Rowe and Wolf, 1982) 
Rat  M, F  Oral  2800  (Carpenter et al., 1956) 
Rat  M  Gavage  2680  (Myers and Homan, 1980) 
Rat  NR  Oral  470  (Wolf, 1959) 
Rat  M  Gavage  1190 – 2800 (Weil and Wright, 1967) 
Rat  M  Gavage  1590  (Moreno, 1976l) 
Rat  M  Gavage  7500  (Moreno, 1976l)  
Rat  NR  Oral  1746  (Eastman Kodak Co., 1989) 
Rat  M  Gavage  7292  (Eastman Kodak Co., 1984) 
Mouse  NR  Oral  1230  (Carpenter et al., 1956) 
Mouse  NR  Oral  1170 – 1700 (Dow Chemical Company, 1982a) 
Mouse  NR  Oral  1519  (Eastman Kodak Co., 1989)  
Mouse  M  Gavage  2406  (Eastman Kodak Co., 1984) 
Rabbit  M  Oral  320 – 370 (Carpenter et al., 1956) 
Guinea pig M, F  Oral  1200  (Carpenter et al., 1956) 
Guinea pig M, F  Gavage  1200  (Smyth et al., 1941) 
Butane-1,3-diol [02.132] Rat  F  Gavage  > 5000  (CTFA, 1978) 
Rat  M  Gavage  18610  (Smyth et al., 1941) 
Rat  M  Gavage  22800  (Smyth et al., 1951a) 
Rat  NR5  Oral  29590  (Bornmann, 1954) 
Mouse  NR5  Oral  23440  (Bornmann, 1954) 
Mouse  NR  Oral  23310  (Kopf et al., 1950; Loeser, 1949) 
Mouse  NR  Oral  12980  (Wenzel and Koff, 1956) 
Guinea pig M, F  Gavage  11460  (Smyth et al., 1941) 
(4-Oxovaleric acid [08.023]) Rat  NR  Oral  1850  (Moreno, 1977j) 
(Ethyl 4-oxovalerate  [09.435]) Rat  NR  Oral  > 5000  (Moreno, 1978f) 
Octane-1,3-diol [02.198] Rat  NR  Oral  > 20000  (Frankenfeld et al., 1975) 
(3,7-Dimethyloctane-1,7-diol [02.047]) Rat  M, F  Gavage  > 5000  (Levenstein, 1973b) 
(1,1-Dimethoxy-3,7-dimethyloctan-7-ol [06.011]) Rat  NR  Oral  > 5000  (Shelanski and Moldovan, 1973b) 
1,1,3-Triethoxypropane [06.097] Rat  M  Gavage  1600  (Smyth et al., 1951a) 
Diethyl oxalate [09.353] Rat  NR  Oral  400 – 1600 (Patty, 1963) 
Malonic acid [08.053] Rat  NR  Oral  1310  (Bio-Fax, 1971) 
Dimethyl malonate [09.558]  Rat  NR  Oral  4620  (Levenstein, 1976b) 
Rat  NR  Oral  5331  (Merck Index, 1992) 
(Diethyl malonate [09.490]) Rat  NR  Oral  14900  (Smyth et al., 1969a) 
Mouse  NR  Gavage  5400  (Wolven and Levenstein, 1969) 
(Diethyl succinate [09.444]) Rat  NR  Oral  85303  (Smyth et al., 1951a) 
(Fumaric acid [08.025]) Rat  M, F  Oral  M:  10700; F: 9300 (Vernot et al., 1977) 
Diethyl fumarate [09.350]  Rat  NR  Oral  1500  (Hood, 1951) 
(l-Malic acid [08.017]) Rat  NR  Oral  3500  (Morgareidge, 1973a) 
Mouse  NR  Oral  2660  (Morgareidge, 1973b) 
Rabbit  NR  Oral  3000  (Morgareidge, 1973c) 
Diethyl maleate [09.351] Rat  M  Gavage  3200  (Smyth et al., 1949) 
(Tartaric acid (d-, l-, dl-, meso-) [08.018]) Rat  NR  Oral  75006  (Foulger, 1947) 
Glutaric acid [08.082] Mouse  NR  Oral  6000  (Boyland, 1940) 
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Table IV.1: ACUTE TOXICITY 
Chemical Name  [FL-no:] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  
Glutaraldehyde [05.149] Rat  NR  Gavage  252  (Stonehill et al., 1963) 
Rat  M  Gavage  7337  (Ballantyne and Myers, 2001) 
Rat  M  Gavage  23808  (Smyth et al., 1962) 
Rat  M  Gavage  5409  (Striegel and Carpenter, 1964) 
Rat  M, F  Oral  M:  134; F:  165 (Ikeda, 1980) 
Rat  M  Gavage  13007  (Myers et al., 1977b) 
Rat  M  Gavage  18708  (Myers et al., 1977c) 
Mouse  NR  Gavage  352  (Stonehill et al., 1963) 
Mouse  M, F  Oral  M:  100; F: 110   (Ikeda, 1980) 
Mouse  M, F  Gavage  M:  1527 ; F: 1137 (Ballantyne and Myers, 2001) 
Mouse  M, F  Gavage  M:  1518 ; F: 1158  (Union Carbide Corp., 1992) 
(Adipic acid [08.026]) Mouse  M  Oral  190010  (Horn et al., 1957) 
Diethyl adipate [09.348] Rat  NR  Oral  > 1600  (Patty, 1963) 
Nonanedioic acid [08.103] Rat  M, F  Gavage  > 4000  (Mingrone et al., 1983) 
Rabbit  M, F  Gavage  > 4000  (Mingrone et al., 1983) 
(Diethyl sebacate [09.475]) Rat  M, F  Gavage  14470  (Jenner et al., 1964) 
Rat  M  Oral  3200011  (Smith, 1953b) 
Mouse  NR  Gavage  > 32000  (Lawrence et al., 1974) 
(Triethyl citrate [09.512]) Rat  NR  Gavage  70004  (Finkelstein and Gold, 1959) 
(Tributyl acetylcitrate [09.511])  Rat  NR  Gavage  > 3000012  (Finkelstein and Gold, 1959) 
(3-Hydroxy-2-oxopropionic acid [08.086]) Rat  NR  Oral  2000  (Hoechst, 1995) 
Succinic acid, disodium salt [08.113] Rat NR Oral >1200 MHLW Japan 2002 in: (OECD, 2003) 
M = Male; F = Female  
NR: Not reported. 
1 Dosed in 5 % gum arabic.  
2 Data derived from a range-finding study.  
3 Actual LD50 not reported.Study conducted as a dose range-finder (DRF).  
4 Actual LD50 not reported.Value reported as approximate LD50. 
5 Data point not verified.  
6 Actual LD50 not reported.Value reported as MFD (assumed to be Median Fatal Dose).  
7 Glutaraldehyde dosed as a 50 % (w/w) solution.The LD50 is expressed as mg of actual active ingredients.  
8 Test substance administered as a 25 % solution. The LD50 is expressed as mg of actual active ingredients.  
9 Test substance administered as a 45 % aqueous solution.The LD50 is expressed as mg of actual active ingredients.  
10 Dosed as a 6 % suspension in 0.5 % methyl cellulose.  
11 Actual LD50 not reported.Value represents lowest dose level tested causing mortality. Animals dosed at 16,000 mg/kg had 100 % survival rate, while animals dosed at 32,000 mg/kg had 100 %  fatality. Acute lethal dose for dibutyl sebacate is 
between 16,000 and 32,000 mg/kg.  
12 Value represents the maximum dose level tested. Animals dosed at 30,000 mg/kg had 100 % survival rate.  
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Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for five candidate substances of the present Flavouring Group Evaluation from 
chemical groups 9, 13 and 30 and for 20 supporting substances evaluated by the JECFA at the 49th and 53rd meetings (JECFA, 1998a; JECFA, 2000c). 
Furthermore, data are available for two structurally related substances. The supporting and structurally related substances are listed in brackets. 
Table IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
 Chemical Name  [FL-no:] Species; Sex 
No./Group1 
Route  Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
 
(Butyro-1,4-lactone [10.006]) 
 
Mouse; M, F 
5/20 
Gavage  90  525  (NTP, 1992e) a) 
Rat; M, F 
5/20 
Gavage  90  450  (NTP, 1992e) a) 
Mouse; M, F 
2/100 
Gavage  2 years  262  (NTP, 1992e) a) 
Rat; M, F 
2/100 
Gavage  2 years  112  (NTP, 1992e) a) 
Rat; M, F 
1/7 
Diet  4 – 6 months  1002  (Fassett, 1961)  
Pentano-1,4-lactone  [10.013]) Rat; M, F 
1/30 
Diet  90  M: 492 ; F: 51.12 (Oser et al., 1965) a) 
Rat; M, F 
1/10 
Diet  90  5002  (Hagan et al., 1967) a) 
(Octano-1,5-lactone  [10.015]) Rat; M, F  
1/7 
Diet  4 - 6 months  322  (Fassett, 1961)  
(Nonano-1,4-lactone   [10.001])  Rat; M, F 
1/30 
Diet  90  M: 62.82 ; F: 72.52 (Oser et al., 1965) a) 
Rat; M, F 
1/7 
Diet  4-6 months  322  (Fassett, 1961)  
Rat; M, F 
1/20 
Diet  2 years  2502  (Bär and Griepentrog, 1967) a) 
(Decano-1,4-lactone  [10.017]) Rat; M, F 
1/7 
Diet  4-6 months  322  (Fassett, 1961)  
(Decano-1,5-lactone  [10.007]) Rat; M, F 
1/NR 
Diet  49 weeks  1502  (Fassett, 1961)  
Dog; M, F 
1/NR 
Diet  38 weeks  2502  (Fassett, 1961)   
(Undecano-1,4-lactone  [10.002]) 
 
Rat; M, F  
1/30 
Diet  90  M: 14.62 ; F: 16.52 (Oser et al., 1965) a) 
Rat; M, F 
1/7 
Diet  4-6 months  322  (Fassett, 1961)  
Rat; M, F 
1/20 
Diet  2 years  2502  (Bär and Griepentrog, 1967) a) 
Rat; M, F  
NR4 
Diet  90  14.12, 3 (Shillinger, 1950)  
(Dodecano-1,4-lactone  [10.019]) Rat;  M, F 
1/7 
Diet  4-6 months  322  (Fassett, 1961)  
(Dodecano-1,5-lactone  [10.008]) Rat; M, F  
1/NR 
Diet  49 weeks  3002  (Fassett, 1961)  
Dog; M, F Diet  38 weeks  1502  (Fassett, 1961)  
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Table IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
 Chemical Name  [FL-no:] Species; Sex 
No./Group1 
Route  Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
 
1/NR 
(5-Methylfuran-2(3H)-one  [10.012]) Rat; M, F  
1/NR 
Diet  90  M: 17.42 ; F: 17.72 (Shellenberger, 1971c) a) 
(Ethyl acetoacetate [09.402]) Rat; M, F 
3/32 
Diet  28 - 29  300  (Cook et al., 1992) a) 
2-Butoxyethan-1-ol [02.242] 
 
Rat; M, F 
4/20 
Diet  91 – 93   40  (Union Carbide Corp., 1963) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
4/10 
Diet  90  No NOAEL derived 13  (Union Carbide Corp., 1952)   FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
4/10 
Diet  90  76   (Carpenter et al., 1956) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
5/20 
Drinking water 13 weeks  1500 ppm (150 mg/kg/day) (NTP, 1993a) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M  
3/10 
Gavage  6 weeks  222  (Krasavage, 1983) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
5/10 
Drinking water 14  400  (NTP, 1993a) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M, F 
5/20 
Drinking water 13 weeks  6000 ppm (1200 mg/kg/day) (NTP, 1993a) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
4/64 
Drinking water 21  M: < 2000 ppm (200 mg/kg/day);  
F: < 1600 ppm (160 mg/kg/day) 
(Exon et al., 1991) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M, F 
5/10 
Drinking water 14  < 1505  (NTP, 1993a) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M  
NR 
Oral  5 week  1000  (Bernstein, 1984) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M 
3/5 
Gavage  5 weeks6  < 500  (Nagano et al., 1977) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M 
3/NR 
Gavage  5 weeks  10007  (Nagano et al., 1979) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse;  
M3/NR 
Gavage  5 weeks  < 5008  (Nagano et al., 1984) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; M, F 
4/50 
Inhalation 2 years  (NTP, 2000b)  
Mouse; M, F 
4/50 
Inhalation 2 years   (NTP, 2000b)  
Butane-1,3-diol [02.132] Rat; M  
15/10 
Diet  30 weeks  200000 ppm (10000 mg/kg/day) (Miller and Dymsza, 1967) Study aimed at elucidating the usability of 
butane-1,3-diol as synthetic energy source. 
It is of limited value for toxicological 
evaluation. 
Rat; M, F 
3/60 
Diet  2 years  100000 ppm (5000 mg/kg/day) (Scala and Paynter, 1967) Some details of results not reported (e.g. 
consumption, histopathological 
evaluation), limited value. 
Dog; M, F  
3/8 
Diet  2 years  30000 ppm (750 mg/kg/day) (Scala and Paynter, 1967)  
Dog; M, F 
4/8 
Diet  13 weeks  6000  (Reuzel et al., 1978) Methods, results, discussion 
comprehensible. Valid study. 
(4-Oxovaleric acid [08.023]) Rat: NR Diet  16  10002  (Tischer et al., 1942) a) 
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Table IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
 Chemical Name  [FL-no:] Species; Sex 
No./Group1 
Route  Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
 
2/3 
(3,7-Dimethyl-7-hydroxyoctanal [05.012])  Rat; M, F  
1/20  
1/60 
Diet  2 years  2502  (Bär and Griepentrog, 1967) a) 
Malonic acid [08.053] Rat; M, F  
3/140 
Diet  2 years  109  (Hogan and Rinehart, 1979)  
(Diethyl malonate [09.490])  Rat; M, F  
2/20 
Diet  13 weeks  < 500  (Posternak, 1964a) a) 
Rat; M, F 
1/20-32 
Diet  90  402  (Posternak et al., 1969) a) 
(Fumaric acid [08.025]) Rat 
2/14 
1/20 
Diet10  2 years  13802  (Levey et al., 1946) a) 
Guinea pig; M, F 
1/NR 
Diet  1 year  4002  (Levey et al., 1946) a) 
Rat; M, F  
Rat; M 
4/12 
3/12 
Diet  2 years  1200  (Fitzhugh and Nelson, 1947) a) 
Rabbit; NR 
3/15 
Diet10  150  20702  (Packman et al., 1963) a) 
(Tartaric acid (d-, l-, dl-, meso-) [08.018]) Dog; NR 
1/4 
Oral  90-114  < 990  (Krop et al., 1945) a) 
Rat; M, F  
4/12 
Diet  2 years  12002  (Fitzhugh and Nelson, 1947) a) 
Rabbit: NR 
3/15 
Diet2  150  23102  (Packman et al., 1963) a) 
Glutaraldehyde [05.149] 
 
 
 
 
 
 
 
 
Rat; M, F  
4/10 
Diet  7  1.0  (Union Carbide Corp., 1986)  
Rat; M, F  
3/NR 
Drinking water 14  100 ppm (10 mg/kg/day) (Union Carbide Corp., 1993)  
Rat; NR  
3/3 
Drinking water 11 weeks  5000 ppm (500 mg/kg/day) (Spencer et al., 1978)  
Mouse; M, F 
3/40 
Drinking water 90  100 ppm (20 mg/kg/day) (Bushy Run Research Center, 
1989) 
 
Rat; M, F  
3/NR 
Drinking water 13 weeks  50 ppm (5 – 7 mg/kg/day) (Union Carbide Corp., 1986)  
Dog;, M, F 
3/8 
Drinking water 13 weeks  50 ppm (3.2 mg/kg/day) (Bushy Run Research Center, 
1990)   
 
Rat; M, F 
3/200 
Drinking water 2 years  50 ppm (4 mg/kg/day) (Van Miller et al., 2002) Large Granular Lymphocytic Leukemia in 
treated as well as control rats; no clear  
dose-resposne relationship. Otherwise no 
significant increase in neoplasia. 
(Adipic acid [08.026]) Rat; M, F 
4/20-39 
Diet 2 years  ~ 150011 (Horn et al., 1957) a) 
Nonanedioic acid [08.103] Rat; M, F  
2/30 
Diet  90 and 180  280  (Mingrone et al., 1983) Details of methods not reported, study not 
performed according to appropiate 
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Table IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
 Chemical Name  [FL-no:] Species; Sex 
No./Group1 
Route  Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
 
guidelines. Study of limited value. 
Rabbit; M, F 
2/20 
Diet  90 and 180  400  (Mingrone et al., 1983)  
Rat; F  
1/10 
Diet  3 month12  140  (Mingrone et al., 1983)  
Rabbit; F  
1/10 
Diet  3 months12  200  (Mingrone et al., 1983)  
(Diethyl sebacate [09.475]) Rat; M, F  
2/10 
Diet  17-18 wks or 27-28 wks 10002  (Hagan et al., 1967) a) 
Rat; M  
4/10 
Diet  1 year  12502  (Smith, 1953b) a) 
Rat; M  
5/16 
Diet  2 years  62502  (Smith, 1953b) a) 
(Triethyl citrate [09.512]) Rat; M, F  
3/7 
Diet  2 months  40002  (Finkelstein and Gold, 1959) a) 
Cat; NR 
1/6 
Gavage  2 months  < 285  (Finkelstein and Gold, 1959) a) 
(Tributyl acetylcitrate [09.511])  Rat; M, F  
2/4 
Diet  2 months  50002  (Finkelstein and Gold, 1959) a) 
Cat; NR 
2/4 
Gavage  2 months  < 5700  (Finkelstein and Gold, 1959) a) 
(Succinate, monosodium)  
 
Rat; M,F 
10/10 
Drinking water 13 weeks  1250 (Maekawa et al., 1990) in 
(OECD, 2003) 
 
Rat; M,F 
50/50 
Drinking water 2 years 2000  (Maekawa et al., 1990) in 
(OECD, 2003) 
Monosodium succinate was given ad 
libitum in drinking water at levels of 0, 1, 
or 2 % to F344 rats (50 males, 50 females). 
No toxic lesion specifically caused by 
long-term administration of monosodium 
succinate was detected. 
(Succinate, disodium hexahydrate) Rat; M,F 
12 /12 
Gavage 
0, 100,300, 1000 
mg/kg) 
 
Males: 52 days, starting at 
14 days before mating. 
Females: Day 14 before 
mating until  day 4 of 
lactation 
Males: 100  
Females: 300 
MHLW, Japan 2002 in 
(OECD, 2003) 
Combined repeated dose toxicity study 
with the reproduction/developmental 
toxicity screening test, guideline [OECD 
TG 422].  
Euqivalent NOAEL for sodium succinate: 
males 60 mg/kg; females, 180 mg/kg. 
NR: Not reported. 
M = Male; F = Female.    
a) Study summarised by JECFA  at the 49th or 53rd meetings (JECFA, 1998a; JECFA, 2000c). 
1 Number of groups represents the number of treatment groups investigated.Control groups are not reported. 
2 This study was performed at either a single dose level or multiple dose levels that produced no adverse effects.  
3 Article published in Russian. Data point not verified.  
4 Six animals per treatment group. The treatment groups for males were not the same as the females. Males were administered 2000 or 6000 ppm of the test substance, while the corresponding dose levels for the females were 1600 and 4800 ppm, 
respectively.  
5 Compared to the control group absolute and relative thymus weights were significantly lower in males. These findings were not seen in females receiving up to 650 mg/kg/day.  
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6 Animals dosed 5 days a week for five weeks.  
7 Changes in absolute or relative testis weights were not observed. 
8 A decrease in red cell count was noted in the 500 mg/kg dose group and higher dose groups.  
9 No treatment related effects were noted upon mortality, ophthalmology or body weights in the males. Microscopic evaluation noted that the transitional cell carcinomas were found in the urinary bladder. The findings were indicated to be dose 
related.  
10 Administered as the sodium salt. 
11 Rats fed a maximum dose of ca. 2500 mg/kg/day over a two-year period showed no gross or microscopic changes to their organs. There was no change in the incidence of tumours and mortality was unaffected.  There was a slight reduction in 
body weight in animals dosed at ca. 1500 mg/kg/day and above. 
12Animals were dosed for 19 gestational days prior to the three month exposure period that is reported.  
13 The value of the study is limited by high mortality in all treatment and control groups. 
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Developmental and reproductive toxicity data are available for five candidate substances of the present Flavouring Group Evaluation from groups 9, 13 and 30 
of the present Flavouring Group Evaluation and for two supporting substance evaluated by JECFA at the 49th and 53rd meetings (JECFA, 1998a; JECFA, 
2000c). Furthermore, data are available for one structurally related substance. The supporting and structurally related substances are listed in brackets. 
Table IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  [FL-no:] Species;  
Sex  
Route  No. groups/ 
No. per group1  
Duration  
(days)  
NOAEL  
(mg/kg/day) 
Reference  Comments 
(Butyro-1,4-lactone [10.006]) Rat; F Gavage  5/10  Developmental toxicity: Gestation 
days 6-15 
500  (Kronevi et al., 1988)  
2-Butoxyethan-1-ol [02.242] Mouse; M, F Drinking water 5/16 FACB: (Task 1) 2 weeks  0.5 %2 (1000 mg/kg/day) (Gulati et al., 1985b; 
Heindel et al., 1990) 
FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M, F Drinking water 3/40  FACB:  (Task 2) 14 weeks3 Reproductive: 0.5 %4  
(1000 mg/kg/day)  
(Gulati et al., 1985b; 
Heindel et al., 1990) 
FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M, F Drinking water 1/40  FACB: (Task 3) 14 weeks3  M:  1.0 % F:  < 1.0 %5 
(2000 mg/kg/day) 
(Gulati et al., 1985b; 
Heindel et al., 1990) 
FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; M, F Lactation/ Drinking 
water 
1/40  FACB: (Task 4) 32 weeks  0.5 %6 (1000 mg/kg/day) (Gulati et al., 1985b; 
Heindel et al., 1990) 
FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Rat; F  Gavage  3/45-47 
3/52-59 
Developmental toxicity: Gestation 
days 9 – 11 and 11 - 13 
Maternal: 30 Fetal: 100 (Sleet et al., 1989) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; F Gavage  5/6  Developmental toxicity: Gestation 
days 8 - 14 
Maternal: 1000 Fetal: 
650 
(Wier et al., 1987) FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
Mouse; F Gavage  1/50  Developmental toxicity: Gestation 
days 6 – 13  
Maternal: < 11807 Fetal: 
11807 
(Hardin et al., 1987; 
Schuler et al., 1984; 
Smith, 1983) 
FGE.10 refers to (EPA, 1999; EU-RAR, 
2004a). 
 Mouse; M, F Drinking water 4/20 During 7 days premating and 98 
days cohabitation 
Maternal: 720 
Fetal: none 
(EU_RAR, 2004a)  
Butane-1,3-diol [02.132] Rat; M, F  Diet  3/50  Five generations ~ 2 years Reproduction: 5 %8 
(5000 mg/kg/day) 
Teratogenicity: 5 % 
(5000 mg/kg/day) 
(Hess et al., 1981)  
Rat; M, F  Gavage  3/10  Developmental toxicity: Gestation 
days 6 – 15  
Maternal: 706; 
Fetal: 706 
(Mankes et al., 1986)  
Glutaric acid [08.082] Rat; F  Gavage  3/NR  Developmental toxicity: NR Maternal: 1300 Fetal: 
1300 
(Bradford et al., 1984)  
Rabbit; F Gavage  3/NR  Developmental toxicity: NR Maternal: 500 Fetal: 500 (Bradford et al., 1984)  
Glutaraldehyde [05.149] Rat; M, F  Drinking water 3/56  Reproductive toxicity: 39 weeks9 Adult:  50 ppm (5.6 
mg/kg/day) Fetal: 250 
ppm (24.3 mg/kg/day) 
Reproductive: > 1000 
ppm (84.5mg/kg/day) 
(Neeper-Bradley and 
Ballantyne, 2000) 
 
Rat; F Drinking water 3/25  Developmental toxicity: Gestation 
days 6 – 16 
Maternal: 50 ppm (5 
mg/kg/day); Fetal: 750 
ppm(68 mg/kg/day)10 
(Hellwig, 1991a)  
Rat; F  Gavage  3/21 – 26 Developmental toxicity: Gestation 
days 6 – 15 
Maternal: 50; Fetal: 100 (Ema et al., 1992)  
Mouse; F  Oral  3/NR  Developmental toxicity: Gestation 
days 7 – 12 
Embryotoxicity: 30; 
Fetal: 30, Teratogenicity: 
30 
(Union Carbide Corp., 
1986) 
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Table IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name  [FL-no:] Species;  
Sex  
Route  No. groups/ 
No. per group1  
Duration  
(days)  
NOAEL  
(mg/kg/day) 
Reference  Comments 
Rabbit; F Gavage  3/15  Developmental toxicity: Gestation 
days 7 – 19  
Maternal: 15; Fetal: 15 (Hellwig, 1991b)  
(Adipic acid  [08.026]) Rat; F  Gavage  4/24-28 Developmental toxicity: Gestation 
days 6 – 15 
288  (Morgareidge, 1973d)  
Mouse; F Gavage  4/20 – 21 Developmental toxicity: Gestation 
days 6 – 15 
263  (Morgareidge, 1973d)  
Rabbit; F Gavage  4/10 – 14 Developmental toxicity: Gestation 
days 6 – 18  
250  (Morgareidge, 1974a)  
Nonanedioic acid [08.103] Rat; F  Diet  1/20  Developmental toxicity: Gestation 
days 0 - 19 
140  (Mingrone et al., 1983)  
Rabbit; F  Diet  1/30  Developmental toxicity: Gestation 
days 0 - 19 
200  (Mingrone et al., 1983)  
(Succinate, disodium hexahydrate) Rat; M,F Gavage 
(0, 100,300, 1000 
mg/kg) 
4 per sex/ 12 Males: 52 days, starting at 14 days 
before mating. 
Females: Day 14 before mating until  
day 4 of lactation 
M, F: 1000 MHLW, Japan 2002 in 
(OECD, 2003) 
Combined repeated dose toxicity study with 
the reproduction/developmental toxicity 
screening test, guideline [OECD TG 422].  
Euqivalent NOAEL for sodium succinate: m, 
600 mg/kg. 
M = Male; F = Female.  
NR = Not Reported.  
FACB = Fertility Assessment by Continuous Breeding.  
1 Number of groups represents the number of treatment groups investigated. Control groups are not reported.   
2 Dose range-finding phase: Based on the results of this dose range-finding study the highest concentration investigated further was 2 % in the drinking water.  
3 Mice were exposed to the test article for a seven day premating period, followed by a 14 week cohabitation/breeding period.  
4 Continuous breeding phase: All breeding pairs in the 0.5 % treatment group were fertile (delivered at least one litter). The fertility of the 1.0 and 2.0 % treatment groups was significantly affected.  
5 Crossover mating trial: Reproductive capacity of female mice is relatively more susceptible than males under the same exposure conditions.  
6 Offspring reproductive performance phase: Reproductive performance was not affected, but the mean liver and kidney weights for females was significantly different from that of the control group when organ weight was adjusted for body weight.  
7 1180 mg/kg/day was the only dose level tested. Compared to the control group the 1180 mg/kg/day decreased the number of viable litters; therefore increasing the number of failed pregnancies. There were no significant observations noted in the 
liveborn pups.  
8 Dose related reproductive effects were noted after five successive matings of the F1A generation.  
9 F0 and F1 animals dosed for a 10 week pre-breeding period and through mating, and gestation and lactation of offspring.  
10 Glutaraldehyde was evidentially unpalatable, as water consumption was reduced in the mid- and high-dose groups; however, no signs of toxicity were observed at these dose groups.  
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In vitro mutagenicity/genotoxicity data are available for nine candidate substances of the present Flavouring Group Evaluation from chemical groups 9, 13 
and 30 of the present Flavouring Group Evaluation and for 22 supporting substance evaluated by JECFA at the 49th and 53rd meetings (JECFA, 1998a; 
JECFA, 2000c). Furthermore, data are available for one structurally related substance. Supporting and structurally related substances are listed in brackets. 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] E ndpoint Test Object  Concentration / Dose Result  Reference  Comments 
(Butyro-1,4-lactone [10.006]) Ames test  S. typhimurium TA98, TA100, TA1535 0.1 - 50 µmoles/plate (8.6 - 4305 
µg/plate) 
Negative1 
 
(Loquet et al., 1981) No control values are given for inactive 
compounds. Conclusion not 
comprehensible.  
Ames test  S. typhimurium TA98, TA100, TA102 0.013 - 1.3 mmol (11.2 - 1120 
µg/ml) 
Negative1  (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
100 - 10000 µg/plate Negative1  (NTP, 1992e)  
Ames test  S. typhimurium TA98, TA100, TA1537, 5,000 or 2000 µg/plate  Negative1  (MacDonald, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
0 - 10000 µg/plate Negative1  (Haworth et al., 1983)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
NR  Negative1  (Garner et al., 1981)  
Ames test  S. typhimurium TA98,TA100, TA1535, 
TA1537, TA1538 
4 - 2500 µg/plate Negative1  (Trueman, 1981)  
Ames test  S. typhimurium TA92, TA98, TA100, 
TA1535, TA1537, TA1538 
0.2 - 2000 µg/plate Negative1  (Brooks and Dean, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
10000 µg/ml  Negative1  (Baker and Bonin, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
500 µg/plate  Negative1  (Rowland and Severn, 1981)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
500 µg/plate  Negative1  (Simmon and Shephard, 1981)  
Ames test  S. typhimurium TA98, TA100,  TA1537 NR  Negative1  (Nagao and Takahashi, 1981)  
Ames test  S. typhimurium TA98, TA100,  1000 mg  Negative1  (Ichinotsubo et al., 1981b)  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
10 - 10000 µg/plate  Negative3  (Richold and Jones, 1981)  
Reverse bacterial mutation 
assay 
E. coli WP2 (p) up to 500 µg/plate (high dose 
studies) 
up to 100 µg/plate (low dose 
studies) 
Negative3  (Venitt and Crofton-Sleigh, 
1981) 
 
Reverse bacterial mutation 
assay 
E. coli  SA500  NR  Lethal4  (Dambly et al., 1981) Authors state “toxic, preventing adequate 
testing“. 
Reverse mutation assay E. coli WP2 uvrA  
pKM102 
NR  Negative1  (Matsushima et al., 1981)  
Forward mutation assay S. typhimurium TM677 1000 µg/ml  Negative3  (Skopeck et al., 1981)  
Microtiter fluctuation test S. typhimurium TA98, TA1535, TA1537 10 - 1000 µg/ml  Negative3  (Gatehouse, 1981)  
Microtiter fluctuation test S. typhimurium TA98, TA100 NR  Negative3  (Hubbard et al., 1981)  
(Butyro-1,4-lactone [10.006]) 
continued 
Microtiter fluctuation test E. coli WP2 uvrA  10 - 1000 µg/ml  Negative3  (Gatehouse, 1981)  
Rec-assay  Bacillus subtilis H17, M45 20 µl (20000 µg) Positive1 (Kada, 1981) Reliable study, conclusion comprehensible. 
Differential killing test E. coli WP2 pol A, WP2 uvrA, WP67 
uvrA, WP67 pol A, CM871 uvrA recA, 
LexA 
NR  Negative1  (Green, 1981)  
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Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] E ndpoint Test Object  Concentration / Dose Result  Reference  Comments 
Differential killing test E. coli WP2 pol A, WP2 uvrA, WP67 
uvrA, WP67 pol A, CM871 uvrA recA, 
LexA 
1000 µg/ml  Negative2  (Tweats, 1981)  
Mitotic crossing-over S. cerevisiae  1000 µg/ml  Negative1  (Kassinova et al., 1981)  
Mitotic gene conversion S. cerevisiae (JDI) 750 µg/ml  Negative2  (Sharp and Parry, 1981)  
Cell growth inhibition S. cerevisiae (JDI) 750 µg/ml  Negative2  (Sharp and Parry, 1981)  
DNA polymerase I inhibition 
test 
E. coli  W3110 & P3478 10 µl (10000 µg) Positive2 
Negative3 
(Rosenkranz et al., 1981) Reliable study, conclusion comprehensible. 
Forward mutation assay S. Pombe  20 µg/ml1  Negative3  (Loprieno, 1981)  
Unscheduled DNA synthesis Human HeLa S3 cells 0.1 - 100 µg/ml  Negative1  (Martin and McDermid, 1981)  
ADP-ribosyl transferase 
activity 
Human FL cells  10-3 to 10-7 mol/L 
(0.0086  – 86 µg/ml)3   
Negative  (Yingnian et al., 1990)  
Clastogenic activity Rat liver cell line RL1 250 µg/ml  Negative  (Dean, 1981)  
Mammalian cell 
transformation 
BHK-21 hamster kidney cells 250 µg/ml Positive1 (Styles, 1981) No specific genotoxicity endpoint. 
Degranulation assay Rat  25 mg/ml (25000 µg/ml) Positive  (Fey et al., 1981) No genetic endpoint (displacement of 
polysomes from ER). 
Sister chromatid exchange Chinese hamster ovary cells 494 - 4940 µg/ml 
494 - 1480 µg/ml 
3010 - 4940 µg/ml 
Negative2  
Negative3 
Positive3 
(NTP, 1992e) Study in complinace with NTP laboratory 
health and safety requirements, conclusion 
comprehensible. 
Chromosomal aberration   Chinese hamster ovary cells 400 - 2580 µg/ml 
400 - 1500 µg/ml 
> 2580 µg/ml 
Negative2
Negative3 
Positive3 
(NTP, 1992e) Study in complinace with NTP laboratory 
health and safety requirements, conclusion 
comprehensible. Cells were selected for 
scoring on the basis of good morphology 
and completeness of karyotype. 
Pentano-1,5-lactone [10.055]  Microbial assay  E. coli  B/rWP2(trp-), WP2(trp-), 
WP2(uvrA-) 
1 - 3 mg/plate (1000-3000 
µg/plate) 
Negative5 (Kuroda et al., 1986) Review, data cannot be validated. 
(Hexano-1,5-lactone  [10.010])  Ames test  S. typhimurium  TA98, TA100 NR  Negative2  (Kawachi et al., 1980b) Summary of results on 186 compounds. No 
details on methods, concentrations and data 
given, results cannot be validated. 
Rec-assay  B. subtilis  NR  Negative2  (Kawachi et al., 1980b) Summary of results on 186 compounds. No 
details on methods, concentrations and data 
given, results cannot be validated. 
Sister chromatid exchange Hamster lung fibroblast cells NR  Negative3  (Kawachi et al., 1980b) Summary of results on 186 compounds. No 
details on methods, concentrations and data 
given, results cannot be validated. 
Chromosomal aberration Hamster lung fibroblast cells NR  Positive2  (Kawachi et al., 1980b) Summary of results on 186 compounds. No 
details on methods, concentrations and data 
given, results cannot be validated. 
Chromosomal aberration  Human embryo fibroblast cells NR  Negative3  (Kawachi et al., 1980b) Summary of results on 186 compounds. No 
details on methods, concentrations and data 
given, results cannot be validated. 
(Heptano-1,4-lactone  [10.020]) Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
100,000 µg/plate Negative1 (Heck et al., 1989) Abstract only, study cannot be validated. 
Unscheduled DNA synthesis Rat hepatocytes  3000 µg  Negative1  (Heck et al., 1989) Abstract only, study cannot be validated. 
(Nonano-1,4-lactone  [10.001]) Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
37500 µg/plate Negative1  (Heck et al., 1989) Abstract only, study cannot be validated. 
Mammalian  Mouse lymphoma L5178y TK+/- 1000 µg/ml  Negative2 (Heck et al., 1989) Abstract only, study cannot be validated. 
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600 µg/ml Positive3 
Unscheduled DNA synthesis Rat hepatocytes  500 µg  Negative1  (Heck et al., 1989) Abstract only, study cannot be validated. 
Mutation assay       E.coli WP2 uvrA 0.2 - 1.6 mg/plate (200-1600 
µg/plate) 
Negative4 (Yoo, 1986) Methods in Japanese, tables only in 
English. Study cannot be validated 
Rec-assay  B. subtilis M45 & H17 20 µl/disk (20000 µg/disk) Positive4  (Yoo, 1986) Methods in Japanese, tables only in 
English. Study cannot be validated 
(Undecano-1,4-lactone  [10.002]) Ames test  S. typhimurium TA92, TA94, TA98, 
TA100, TA1535, TA1537, TA2637 
5 mg/plate (5000 µg/plate) Negative1  (Ishidate et al., 1984)  
Ames test  S. typhimurium TA97, TA98, TA100, 
TA102 
0.1 mg/disk (100 µg/disk) Negative1  (Fujita and Sasaki, 1987)  
Rec-assay  B. subtilis H17 & M45 19 µg  Negative1  (Oda et al., 1979)  
Rec-assay  B. subtilis H17 & M45 10 µl/plate (10000 µg/plate) Positive6 (Yoo, 1986) Methods in Japanese, tables only in 
English. Study cannot be validated. 
Rec-assay  B. subtilis H17 & M45 10 µl/plate  (10000 µg/plate) Positive3 
Negative2 
(Kuroda et al., 1984a) Abstract only translated, study cannot be 
validated. 
Chromosomal aberration  Chinese hamster fibroblast 0.5 mg/ml (500 µg/ml) Negative1  (Ishidate et al., 1984)  
(Undecano-1,5-lactone   [10.011])  Rec-assay B. subtilis H17 & M45 19 µg Negative1 (Oda et al., 1979)  
Rec-assay  B. subtilis  10 µl/plate (10000 µg/plate) Positive1  (Kuroda et al., 1984a) Abstract only translated, study cannot be 
validated. 
(Pentadecano-1,15-lactone  [10.004]) Ames test  S. typhimurium TA98, TA100, TA102 50 µmol (12 µg/ml)  Negative1  (Aeschbacher et al., 1989)  
(5-Methylfuran-2(3H)-one  [10.012]) Ames test  S. typhimurium TA98, TA100 5 - 50 µg/plate  Negative1  (Turek et al., 1997)  
(Dodec-6-eno-1,4-lactone  [10.009]) 
  
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
500 µg/plate  Negative1  (Watanabe and Morimoto, 
1990) 
 
Rec-assay  E. coli WP2 uvrA  500 µg/plate  Negative1  (Watanabe and Morimoto, 
1990) 
 
1-Hydroxypropan-2-one [07.169] Ames test  S. typhimurium TA100 20 - 400 µg/plate  Positive1  (Yamaguchi, 1982) Effect dose-dependent, conclusion 
comprehensible. 
Ames test  S. typhimurium TA104 68 µmoles (5 µg/ml) Positive2  (Marnett et al., 1985a) Authors state that each compound was 
tested to its toxic limits, data for maximum 
non-toxic dose given only. 
Ames test  S. typhimurium TA100 500 µg/plate  Positive1  (Yamaguchi and Nakagawa, 
1983) 
Numerical value given was obtained from 
dose-response curves of five concentration 
levels. 
Ames test  S. typhimurium TA100 NR  Positive2  (Garst et al., 1983) Appropriate controls (idomethan for 
volatile compounds, sterility of compounds 
and solvent). Test compound judged 
positive when dose-related doubling of 
revertants were found. 
(Ethyl 3-hydroxybutyrate [09.522]) Ames test  S. typhimurium  TA97, TA98, TA100, 
TA1535 
NR  Negative4  (Zeiger and Margolin, 2000)  
(Ethyl acetoacetate [09.402])   Ames test; preincubation 
protocol 
S. typhimurium TA92, TA100, TA1535, 
TA1537, TA94 and TA98 
25 mg/plate (25000 µg/plate) Negative1  (Ishidate et al., 1984)  
Ames test; preincubation 
protocol 
S. typhimurium TA97, TA102 0.1 - 10 mg/plate  (10 - 10000 
µg/plate)  
Negative1 (Fujita and Sasaki, 1987)  
Rec-assay  B. subtilis; H17, M45 20 µg/disk  Negative1  (Oda et al., 1979)  
Rec-assay  B. subtilis; H17, M45 20 µl/disk (20000 µg/disk) Positive  (Yoo, 1986) Methods in Japanese, tables only in 
English. Study cannot be validated. 
Rec-assay  E. coli; WP2 uvrA  200 - 1600 µg/plate   Positive8  (Yoo, 1986) Methods in Japanese, tables only in 
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English. Study cannot be validated. 
Rec-assay  B. subtilis; H17, M45 10 - 20 µl/ml (10 - 20 µg/ml) Negative1  (Kuroda et al., 1984a) Abstract only translated. Study cannot be 
validated. 
Rec-assay  B. subtilis; H17, M45  10 - 20 µl/ml (10 - 20 µg/ml) Positive1  (Kuroda et al., 1984a) Abstract only translated. Study cannot be 
validated. 
Chromosomal aberration Chinese hamster fibroblast cells 1 mg/ml (2000 µg/ml) Negative1  (Ishidate et al., 1984)  
Methyl acetoacetate [09.634] Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
E. coli WP2 uvrA 
1 - 5000 µg/plate Negative1  (Shimizu et al., 1985) Modified Ames, reincubation. Reliable 
study, conclusion comprehensible. 
2-Butoxyethan-1-ol [02.242] Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
10 - 5000 µg/plate Negative1 (Okamoto and Riccio, 1985) Study performed in compliance with US-
FDA GLP standards. Reliable study, 
conclusion comprehensible. 
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
E. coli WP2 uvrA 
9.8 - 156.3 µg/plate Negative1  (Henrich and McMahon, 1988) Test material: mixture of 2-butoxyethanol 
(2 % w/v) with tricholorbenzene and 
anionic emulsifiers. Test compound 
produced no revertants vs solvent control. 
Ames test  S. typhimurium TA97, TA98, TA100, 
TA102, TA104, TA1535, TA1537 
100 - 10000 µg/plate Negative1  (Zeiger et al., 1992) NTP-study within mutagenicity testing 
program. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA97, TA98, TA100, 
TA1535, TA1537, TA1538 
5000 - 20000 µg/plate Negative1  (Sippel, 1977) Negative as defined by less than 2-times of 
the spontaneous reversion rate. Reliable 
study, conclusion comprehensible. 
Ames test  S. typhimurium TA97a, TA100 
E. coli WP2uvrA 
500 - 1000 µg/plate Negative1  (Gollapudi et al., 1996) Re-examination of EGBE to valdazte report 
by Hoflack et al (1995) on mutagenicity of 
the compound in a test with TA97a. reliable 
study, conclusion comprehensible. 
Ames test  S. typhimurium TA97a, TA98, TA100, 
TA102 
14 mg/plate (14000 µg/plate) 
conc. range: 0,8 - 115 
micromol/plate, positive ab 19 
micromol = 2,2mg/plate 
Negative with 
TA98, 
TA100,TA102, 
positive with 
TA97a1  
(Hoflack et al., 1995) Positive with TA97a, but not reproduced in 
study specifically addressing this finding 
(Gollapudi et al., 1996). 
Mutagenicity Assay Bacteriophage T4D E. coli CR63 and 
K12 
19.6 - 111.1 µl/ml Negative9  (Kvelland, 1988) Highly toxic at all concentrations tested, 
bacteriophage yield less than 1 %. 
Forward mutation assay Chinese hamster ovary cells V79 16.92 mM (2000 µg/ml)3 Positive2  (Elias et al., 1996) It is noted that doses applied exceeded the 
maximum recommended doses according to 
currunt OECD guidelines. 
Forward mutation assay Chinese hamster ovary cells V79 1 %  Negative1  (Slesinski and Weil, 1980) Reliable study (5 concentrations each test, 
1 % without S9 (non-toxic), 0,3 % with 
S9), conclusion comprehensible. 
Forward mutation assay Chinese hamster ovary cells AS52 0.38 - 7.6 mM (898 µg/ml) Negative1  (Chiewchanwit and Au, 1995) Non-cytotoxic concentration range. 
Reliable study, conclusion comprehensible. 
Sister chromatid exchange Chinese hamster ovary cells 0.007 -  0.25 % Negative1  (Slesinski and Weil, 1980) Reliable study, conclusion comprehensible. 
Sister chromatid exchange Chinese hamster ovary cells V79 16.92 mM (2000 µg/ml) Positive2, 10  (Elias et al., 1996) It is noted that doses applied exceeded the 
maximum recommended doses according to 
current OECD Guidelines. 
Sister chromatid exchange Human peripheral lymphocytes 3000 ppm  Positive1  (Villalobos-Pietrini et al., 
1989) 
Cited in review on 2-Butoxyethanol. Study 
cannot be evaluated. 
Sister chromatid exchange  Chinese hamster ovary cells 5000 µg/ml  Negative1  (NTP, 2000b) NTP-study within mutagenicity testing 
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program. Reliable study, conclusion 
comprehensible. 
Chromosomal aberrations Chinese hamster ovary cells 5000 µg/ml  Negative1  (NTP, 2000b) NTP-study within mutagenicity testing 
programme. Reliable study, conclusion 
comprehensible. 
Chromosomal aberrations Chinese hamster ovary cells V79 16.92 mM (2000 µg/ml) Negative2 (Elias et al., 1996) Reliable report with details on purity of test 
compounds, methods and results. 50 % 
growth inhibition (at 24 hours) approx. at 
90 mM, but value cannot be precisely 
derived from the graphic presentation. 
Chromosomal aberrations Human peripheral lymphocytes  3000 ppm  Negative2  (Villalobos-Pietrini et al., 
1989) 
Cited in review on 2-Butoxyethanol. Study 
cannot be evaluated. 
2-Butoxyethan-1-ol [02.242] 
continued 
Chromosomal aberrations Human lymphocytes 16.92 mM (2000 µg/ml) Negative2  (Elias et al., 1996) No information on growth inhibition/ 
survival of treated human lymphocytes 
given. 
In vitro micronucleus test V79 cells 16.92 mM (2000 µg/ml) Positive2  (Elias et al., 1996) It is noted that doses applied exceeded the 
maximum recommended doses according to 
current OECD Guidelines. 
Unscheduled DNA synthesis Rat hepatocytes  0.1 - 100 x 10-3 % Positive1, 11  (Slesinski and Weil, 1980) The interpretation of these findings is 
equivocal due to the methodology applied 
(liquid scintillation) and the absence of 
relation with dose. 
Embryo Transformation 
Assay 
Syrian hamster embryo cells NR  Negative2  (Elias et al., 1996) No specific genotoxic endpoint. 
Embryo Transformation 
Assay 
Syrian hamster embryo cells 500 - 1500 µg/ml Positive4  (Brauninger, 1995) No specific genotoxic endpoint. 
(3,7-Dimethyloctane-1,7-diol 
[02.047]) 
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
3.6 mg/plate (3600 µg/plate) Negative1  (Wild et al., 1983)  
(3,7-Dimethyl-7-hydroxyoctanal 
[05.012]) 
Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
3.6 mg/plate (3600 µg/plate) Negative1  (Wild et al., 1983)  
(1,1-Dimethoxy-3,7-dimethyloctan-
7-ol [06.011]) 
Ames test S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538 
3.6 mg/plate (3600 µg/plate) Negative1  (Wild et al., 1983)  
(Diethyl malonate [09.490]) Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537. 
3 µmol/plate (480 µg/plate) Negative1  (Florin et al., 1980)  
(Dimethyl succinate [09.445])  Ames test  S. typhimurium TA98, TA100, TA1535, 
TA1537 
20000 µg/plate Negative1  (Andersen and Jensen, 1984a)  
Ames test  S. typhimurium TA97, TA98, TA100, 
TA102, TA104, TA1535, TA1537, 
TA1538 
10 mg/plate (10000 µg/plate) Negative1  (Zeiger et al., 1992)  
(Fumaric acid [08.025])   Ames test  S. typhimurium  TA100 1000 µg/plate  Negative4  (Rapson et al., 1980)  
Ames test (preincubation) S. typhimurium TA97, TA98, TA100, 
TA1535, TA1537 
2000 µg/plate  Negative1  (Zeiger et al., 1988)  
Ames test  S. typhimurium TA92, TA94, TA98, 
TA100, TA1535, TA1537 
10 mg/plate (10000 µg/plate) Negative  (Ishidate et al., 1984)  
Chromosomal aberrations  Chinese Hamster fibroblast cells 0.5 mg/ml (500 µg/ml) Negative  (Ishidate et al., 1984)  
(l-Malic acid [08.017]) Ames test  S. typhimurium TA97, TA98, TA100, 
TA104 
2000 µg/plate  Negative1  (Al-Ani and Al-Lami, 1988)  
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Diethyl maleate [09.351]  Forward mutation assay Mouse lymphocytes  L5178Y TK+/-  2.250 - 9.750 x 10-4 mol/l (387 - 
1679 µg/ml) 
Positive1 (Wangenheim and Bolcsfoldi, 
1988) 
No S9 at 2.25 - 9.75 x 10-4 mol/L, doubling 
of the mutation rate at 6 x 10-4 mol/L and 
above, but growth reduction of 70 % or 
more. Study of insufficient value. 
Aneuploidy test      Chinese hamster lung cells V79 5.2 x 10-6 M 
8.7 x 10-6 M 
Negative4
Positive4 
(Önfelt, 1987) Reliable study, conclusion comprehensible. 
Glutaric acid [08.082] REC assay 
Ames  
B subtilis M45 & H17 
S. typhimurium TA98, TA100 
NR  Negative1  (Sakagami et al., 1989) Abstract, data cannot be validated. 
Glutaraldehyde [05.149] Ames test  S. typhimurium TA104 0.5 µmoles (50.06 µg/ml) Positive2  (Marnett et al., 1985a) TA104 tested to reassess mutagenic 
potency of 28 carbonyl compounds. Dose-
dependent increase toxic limits of 
glutaraldehyde. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA1535, TA100, 
TA1537, TA98 
10 mg/plate (10000 µg/plate) Equivocal12
Positive12 
(Haworth et al., 1983) Part of ring study for re-assessment of  250 
chemicals. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA100, TA102, TA104 25 - 300 µg/plate  Positive1  (Dillon et al., 1998) Comparative analysis of TA100, TA102 
and TA104 for sensitivity to 13 aldehydes 
and 4 peroxides. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA102, TA2638, 
E. coli WP2/pKM101, WP2 uvrA 
20 - 1000 µg/plate  Positive3, *  (Watanabe et al., 1998a) *Cytotoxicity noted in doses as low as 250 
µg/plate. 
Ring study (22 laboratories) for 
comparative analysis of TA102, TA2638, 
E. coli WP2/pKM101 and WP2 
uvrA/pKM101. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA102,  
E. coli WP2/pKM101, WP2 uvrA 
5 - 100 µg/plate Positive2  (Wilcox et al., 1990) Comparative analysis of TA102 and E.coli 
WP2 strains. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA102 1000 µg/plate  Positive13 (Müller et al., 1993) Ring study (3 laboratories) to evaluate 
TA102. Reliable, conclusion 
comprehensible. 
Ames test  S. typhimurium TA102, TA2638a 76 µg/plate  Positive3, 14 (Rydén et al., 2000) Comparative analysis on the sensitivity of 
bacterial strains and the possibility of using 
TA2638a. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA102 25 µg/plate  Positive1  (Levin et al., 1982) Test of TA102 for detection of oxidative 
mutagens. Reliable study, conclusion 
comprehensible. 
Ames test  S. typhimurium TA97a, TA98, TA100, 
TA102, TA104 
0.1 - 60 µg/plate  Positive1  (Noblitt et al., 1992) Abstract, data cannot be validated. 
Ames test  S. typhimurium TA1535, TA100, 
TA1537, TA98,  
E. coli WP2 uvrA 
100 - 5000 µg/plate Negative1  (Wagner, 1997) Study in compliance with inter-national 
(US-FDA, US-EPA, UK, Japan) GLP 
Guidelines. Negative result not discussed in 
view of positive results in other studies. 
Reliable study, conclusion comprehensible. 
Ames test  S. typhimurium TA1535, TA100, 15.4 µg/plate2, 15 Negative1  (Slesinski et al., 1983) Lack of mutagenic activity considered to be 
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TA1537, TA1538, TA98 51.6 µg/plate3 due to reaction of glutaraldehyde with 
proteins in cell membrane, cytosol. 
Ames test  S. typhimurium TA97a, TA98, TA100, 
A102, TA104 
0.050 % in 100 µl/plate (100000 
µg/plate) 
Positive14 (Schweikl et al., 1994) Study aimed at elucidating the mutagenic 
potency of 3 different dentin bonding 
agents, pure glutaraldehyde was tested as 
one of the ingredients of these materials. 
Conclusion comprehensible. 
Glutaraldehyde [05.149] continued Ames test  S. typhimurium TA100, TA98 20 µg/plate  Negative1  (Sakagami et al., 1988) Dose-dependent DNA-damage. At 
minimum inhibitory concentration Ames 
test less sensitive than REC-assay (see 
below). 
Ames test  E. coli WP2 uvrA  20 - 10000 µM (2 - 1001 µg/ml) Negative2 (Hemminki et al., 1980) Study aimed at comparison of alkylation 
rate with mutagenicity of directly acting 
chemicals, glutaraldehyde served as 
reference compound. 
Rec-assay  B. subtilis, M-45 (Rec-), H-17 (Rec+) 300 µg/ml  Positive1  (Sakagami et al., 1988) Dose-dependent DNA-damage. At 
minimum inhibitory concentration REC-
assay more sensitive than  Ames test (see 
above). 
L-arabinose resistance 
forward mutation test 
S. typhimurium: BA9, BA13 62 - 250 nmoles/ml (6.2  - 25 
µg/ml) 
Negative15 
Positive15 
(Ruiz-Rubio et al., 1985)  
Forward mutation assay Mouse lymphocytes: L5178Y TK+/- 8 µg/ml  Positive2  (McGregor et al., 1988b) Reliable study, conclusion comprehensible. 
Forward mutation assay Chinese hamster ovary cells 40.8µM (4.08 µg/ml) Negative1  (Slesinski et al., 1983) Lack of mutagenic activity considered to be 
due to reaction of glutaraldehyde with 
proteins in cell membrane, cytosol. 
Sister chromatid exchange Chinese hamster ovary cells 2.5 µM (.25 µg/ml) Negative1  (Slesinski et al., 1983) Lack of mutagenic activity considered to be 
due to reaction of glutaraldehyde with 
proteins in cell membrane, cytosol. 
Sister chromatid exchange Chinese hamster ovary cells 0.5 - 16 µg/ml  Negative/positive2  
Positive3 
(Galloway et al., 1985) Study performed in 2 laboratories aimed to 
develop sensitive test protocol.11-16 
µg/ml, with S9 positive (at least with one 
dose) results in both laboratories. 0,36-16 
µg/ml, without S9 results not consistent. 
Chromosomal aberrations Chinese hamster ovary cells 0.5 - 30 µg/ml  Negative/positive2
Negative3  
(Galloway et al., 1985) Study performed in 2 laboratories aimed to 
develop sensitive test protocol. 1-16 µg/ml, 
with S9 negative results in both 
laboratories: 0,3-30 µg/ml, without S9 
results not consistent. 
Alkaline elution assay Human TK6 lymphoblasts 25 µM (0.25 µg/ml)2 Positive2  (St. Clair et al., 1991) Linear increase in DNA cross linking 
between 1-25 µM. At 20 µM 10 % survival 
only. 
TK6 mutation assay Human TK6 lymphoblasts 20 µM (2 µg/ml) Positive  (St. Clair et al., 1991) Majority of trifluorothymidine resistant 
colonies displayed normal growth, slow-
growing colonies small contribution to 
overall mutant fraction. 
Glutaraldehyde [05.149] continued Unscheduled DNA synthesis Primary rat hepatocytes 51 µM (5.1 µg/ml) Negative1  (Slesinski et al., 1983) Lack of mutagenic activity considered to be 
due to reaction of glutaraldehyde with 
proteins in cell membrane, cytosol. 
Flavouring Group Evaluation 10, Revision 3
 
 
120 EFSA Journal 2012; 10(3):2563 
Table IV.4: GENOTOXICITY (in vitro) 
Chemical Name [FL-no:] E ndpoint Test Object  Concentration / Dose Result  Reference  Comments 
Unscheduled DNA synthesis Rat hepatocytes  100 µM (10 µg/ml) Positive2  (St. Clair et al., 1991) Significant increase over controls at 100 
µM, this concentration tolerated without 
morphological signs of toxicity. 
(Adipic acid [08.026]) Ames test  E. coli WP2 uvrA  5000 µg/plate  Negative1  (Shimizu et al., 1985)  
Ames test  S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98,  
E. coli WP2 uvrA 
10 mg/plate (10000 µg/plate) Negative1  (Prival et al., 1991)  
Ames test (preincubation 
method) 
S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98 
5000 µg/plate  Negative1  (Shimizu et al., 1985)  
(Dibutyl sebacate [09.474]) Ames test  S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98 
3.6 mg/plate (3600 µg/plate) Negative1  (Wild et al., 1983)  
(Ethyl brassylate [09.533]) Ames test  S. typhimurium TA1535, TA100, 
TA1537, TA1538, TA98 
3.6 mg/plate (3600 µg/plate) Negative1  (Wild et al., 1983)  
(Prop-1-ene-1,2,3-tricarboxylic acid  
[08.033]) 
 
Ames test  S. typhimurium TA100, TA1535, 
TA1537, TA98 
20000 µg/plate Negative1  (Andersen and Jensen, 1984a)  
5,6-Dimethyl-tetrahydro-pyran-2-one 
[10.168] 
Ames test S. typhimurium TA98, TA100, TA102, 
TA1535, TA1537 
5000 microgram/plate Negative1 (Uhde, 2004a) Test performed both in the incorporation 
and preincubation assays. 
Succinic acid, disodium salt [08.113] 
 
Ames test S.typhimurium TA97, TA94, TA98, 
TA100, TA1535, and TA1537 
5000 microgram/plate Negative3 (Ishidate et al., 1984) in 
(OECD, 2003) 
GLP-study according to OECD TG 471. 
Ames test S.typhimurium TA97, TA102 10000 microgram /plate Negative1 (Fujita et al., 1994) in (OECD, 
2003) 
GLP-study according to OECD TG 471. 
Chromosomal aberrations 
(polyploidy) 
Chinese hamster lung cells  15000 microgram/ml Equivoval2 (Ishidate et al., 1984) in 
(OECD, 2003) 
GLP-study according to OECD TG 473. 
(Disodium succinate hexahydrate) Ames test S.typhimurium TA97, TA94, TA98, 
TA100, TA1535, and TA1537  
5000 microgram/plate Negative1 MHLW, Japan 2002 in 
(OECD, 2003) 
 
 Chromosomal aberrations 
(polyploidy) 
Chinese hamster lung cells  5000 microgram/ml Negative1 MHLW, Japan 2002 in 
(OECD, 2003) 
 
NR: Not reported. 
1 With and without S-9 metabolic activation.  
2 Without S-9 metabolic activation.  
3 With S-9 metabolic activation.  
4 Presence or absence of metabolic activation not specified.  
5 Anti-mutagenic effects study.  
6 Presence or absence of metabolic activation not specified.  
7 4,5-dimethyl-3-hydroxy-2,5-dihydrofuran-2-one did not form DNA adducts, but 2,5-DMHF does. Study addresses mechanism of chemical reaction of 2,5-dimethyl-4-hydroxy-3(2H)-furanone with DNA.  
8 The concentrations used were 10-fold higher than that of spontaneous revertants.  
9 The test substance had a severe toxic effect on phage yield.  
10 Weak positive results were detected.  
11 The test substance induced statistically significant levels of unscheduled DNA synthesis in two of the six dose levels tested. Therefore, the test substance is considered a weak mutagen.  
12This test compared the results at two different laboratories. Results were equivocal at Case Western Reserve University, while they were positive at Microbiological Associates.  
13Article presents the results from three different laboratories. Results were positive in both water and ethanol; however, it was concluded that TA102 is not sufficiently matured to be employed routinely.  
14Maximum non-toxic dose.  
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15Results were negative in BA9, not BA13.  
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In vivo mutagenicity/genotoxicity data are available for six candidate substances of the present Flavouring Group Evaluation from chemical groups 9, 13 and 
30 of the present Flavouring Group Evaluation and for eight supporting substances evaluated by JECFA at the 49th and 53rd meetings (JECFA, 1998a; JECFA, 
2000c). Supporting substances are listed in brackets. 
Table IV.5: Genotoxicity Studies (In Vivo) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Butyro-1,4-lactone [10.006]) In vivo Bone- marrow 
micronucleus assay 
B6C3F1 mice  Single dose via 
intraperitoneal injection 
80 % of LD50  Negative  (Salamone et al., 1981) Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo Bone- marrow 
micronucleus assay 
CD-1 mice   0.11-0.44 ml/kg 
(110 – 440 mg/kg)   
Negative  (Tsuchimoto and Matter, 
1981) 
Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo micronucleus assay Mice (B6C3F1/BR hybrid)  80 % of LD50 Negative  (Katz et al., 1981) Limited relevance because 
PCE/NCE ratio was not 
reported, thus it is not clear if 
the test substance reached the 
bone marrow. 
In vivo sperm abnormality Mice (CBA X Balb/c)F1  
 
Daily exposure for five 
days via intraperitoneal 
injection 
 0.1-1.0 mg/kg bw/day  Negative  (Topham, 1980) Sperm head abnormality test 
does not make use of a genetic 
endpoint. 
In vivo sex-linked recessive 
test 
D. melanogaster  A: via diet 
B: injection 
A: 20000 or 28000 ppm  
B. 15.000 ppm 
Negative  (Foureman et al., 1994) Study in compliance with OECD 
477. 
(Hexano-1,5-lactone  [10.010]) Chromosomal aberration  
in vivo 
 Rat bone-marrow cell  NR  Negative1 (Kawachi et al., 1980b) Summary of results on 186 
compounds. No details on 
methods, concentrations and 
data given, results cannot be 
validated. 
(Undecano-1,4-lactone  [10.002]) In vivo mouse micronucleus 
test 
 2-6 ddY male mice Via intraperitoneal 
injection 
250-2000 mg/kg  Negative  (Hayashi et al., 1988) Single application, only one 
sampling time. Not in 
compliance with current OECD 
474. 
2-Butoxyethan-1-ol [02.242] In vivo mouse micronucleus 
test 
 Mouse bone marrow Single dose via 
intraperitoneal injection 
1000 mg/kg  Negative  (Elias et al., 1996) Reliable report, decreased 
PCE/NCE ratio demonstrates 
bioavailability of compound at 
target compartment. Conclusion 
comprehensible. 
In vivo mouse micronucleus 
test 
 Mouse bone marrow 3 doses via 
intraperitoneal injection 
450 mg/kg   Negative  (NTP, 2000b)  NTP-study within mutagenicity 
testing program. Reliable study, 
conclusion comprehensible. 
In vivo micronucleus test Rat bone marrow  3 doses via 
intraperitoneal injection 
550 mg/kg  Negative  (NTP, 2000b) NTP-study within mutagenicity 
testing program. Reliable study, 
conclusion comprehensible. 
In vivo DNA adducts Rat brain, kidney, liver, 
spleen and testes 
Single dose via oral 
route 
120 mg/kg  Negative (Keith et al., 1996a) The method (based on 32P-
postlabelling) is aimed at 
detecting hydrophobic DNA 
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Table IV.5: Genotoxicity Studies (In Vivo) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
adducts resulting from CytP450 
induction, not from binding of 
2-butoxyethan-1-ol to DNA . 
In vivo DNA methylation Rat brain, kidney, liver, 
spleen and testes,  
Via oral route NR   Negative (Keith et al., 1996a) Supplementary information not 
directly relevant for genotoxicity 
assessment. 
In vivo DNA adducts Mouse Via oral route NR Negative (Keith et al., 1996a) Detection of hydrophobic DNA 
adducts such as modified 
nucleotides with aliphatic side 
chains. 
In vivo DNA methylation Mouse  Via oral route NR  Negative (Keith et al., 1996a) Supplementary information not 
directly relevant for genotoxicity 
assessment. 
In vivo tumour formation Mouse  Daily dose for two 
weeks via oral route 
120 mg/kg/day  Inconclusive (Keith et al., 1996a) No difference in tumor incident 
observed. However no 
conclusion on the oncogenic 
potential of 2-butoxyethan-1-ol 
can be drawn because of the 
limitations of the experimental 
protocol (treatment, sample size, 
duration of the study, reporting, 
etc.). 
Butane-1,3-diol [02.132]   In vivo cytogenetic assay Rat femur bone marrow Via diet2 5, 10, 24 %  Negative  (Hess et al., 1981) F1A, F2A, F3A generations in a 
multigeneration reproductive 
toxicity study. PCE/NCE ratio 
was not reported, thus it is not 
clear if the test substance 
reached the bone marrow. 
In vivo dominant lethal assay Rat  Animals exposed for 
eight weeks via diet 
5, 10, 24 % Negative  (Hess et al., 1981) F1B generation in a 
multigeneration reproductive 
toxicity study. 
(3,7-Dimethyloctane-1,7-diol 
[02.047]) 
In vivo micronucleus test Mouse   516, 860, 1204 mg/kg  Negative  (Wild et al., 1983) Limited quality since only a 
single sampling time (30 hours 
after treatment) was used and 
PCE/NCE ratio was not 
reported. Therefore it is not 
clear whether the substance had 
reached the bone marrow. 
In vivo Basc test D. melanogaster   10 mM  (1743 µg/ml) Negative  (Wild et al., 1983) A single dose was tested in one 
experiment. Method not 
described in detail. 
(3,7-Dimethyl-7-hydroxyoctanal 
[05.012]) 
In vivo Basc test D. melanogaster   37 mM (6374 µg/ml) Negative  (Wild et al., 1983) A single dose was tested in one 
experiment. Method not 
described in detail. 
In vivo micronucleus test Mouse   345, 603, 861 mg/kg  Negative  (Wild et al., 1983) Limited quality since only a 
single sampling time (30 hours 
after treatment) was used and 
PCE/NCE ratio was not 
reported. Therefore it is not 
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Table IV.5: Genotoxicity Studies (In Vivo) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
clear whether the substance had 
reached the bone marrow. 
(1,1-Dimethoxy-3,7-
dimethyloctan-7-ol [06.011]) 
In vivo Basc test D. melanogaster   25 mM (5459 µg/ml) Negative  (Wild et al., 1983) A single dose was tested in one 
experiment. Method not 
described in detail. 
In vivo micronucleus test Mouse   327, 545, 763 mg/kg  Negative  (Wild et al., 1983) Limited quality since only a 
single sampling time (30 hours 
after treatment) was used and 
PCE/NCE ratio was not 
reported. Therefore it is not 
clear whether the substance had 
reached the bone marrow. 
Malonic acid [08.053]  In vivo mutagenicity assay Rat hepatocytes  400 mg/kg/day exposure 
for 6 weeks via diet 
4000 ppm  Negative  (Ito et al., 1988) GST-P foci assay following 
diethyl nitrosamine exposure. 
Reliable study, conclusion 
comprehensible. 
Glutaric acid [08.082] In vivo bone marrow 
chromosomal aberrations 
Rat bone marrow  Single dose via oral 
gavage 
Males:  2750 mg/kg 
Females:  1375 mg/kg  
Negative  (San Sebastian, 1989a) Reliable study, e.g. cells with 
gaps excluded. Selected copy of 
report without data tables. 
Glutaraldehyde [05.149] In vivo chromosomal 
aberration 
Rat bone marrow  Single dose via oral 
gavage 
Males: 120 mg/kg/bw  
Females:  80 mg/kg/bw 
 
Negative  (Vergnes and Morabit, 
1993a) 
Study in compliance  with 
international  (FDA, TSCA, 
OECD) GLP guidelines. 
Selected copy of report (12 of 
100 pages) available. 
In vivo chromosomal 
aberration 
Rat bone marrow  A single dose or daily 
for five days via oral 
gavage 
Single dose: 0.55 ml/kg (males), 
0,4 ml/kg (females) of a 6, 12 or 
36 % solution. Repeated dose: 
0,55 ml/kg (males) of a 5 % 
solution 
Negative  (Putman, 1987) Time points of investigation: 
single dose: 8, 12 hours. 
Repeated dose: 12hours. Well 
conducted study, conclusion 
comprehensible.  Selected copy 
of  report available. 
In vivo mouse blood 
micronucleus test 
 Mouse  Single dose via oral 
gavage 
250 mg/kg  Negative  (Vergnes and Morabit, 
1993b) 
Selected pages of report 
available (29 of 88 pages). 
In vivo mouse blood 
micronucleus test 
 Mouse  Single dose via 
intraperitoneal injection 
4, 8, 15 mg/kg/bw  Positive  (Noblitt et al., 1993) Abstract, study cannot be 
validated. 
In vivo unscheduled DNA 
synthesis 
Rat  Single dose via oral 
gavage 
30, 150, 600 mg/kg  Negative  (Mirsalis et al., 1989) Reliable part of  In vivo tumour 
formation study, conclusion 
comprehensible. 
In vivo SLRL test D. melanogaster  Three day exposure via 
diet 
3500 ppm  Negative  (Zimmering et al., 1989) Study in compliance with OECD 
477. 
In vivo SLRL test D. melanogaster  Single dose via 
intraperitoneal injection 
three day exposure via 
diet 
Injection:  4000 ppm  
Diet: 10,000 ppm  
Negative  (Yoon et al., 1985) Study in compliance with OECD 
477. 
(Adipic acid [08.026]) In vivo chromosomal 
nondisjunction 
D. melanogaster   4000 ppm  Negative  (Ramel and Magnusson, 
1979) 
 
Diethyl adipate [09.348]  In vivo dominant lethal assay Mouse  (Single1460 mg/kg dose 
via intraperitoneal 
injection) 
1.46 ml/kg  Negative  (Singh et al., 1975) Reliable study, conclusion 
comprehensible. 
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Table IV.5: Genotoxicity Studies (In Vivo) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Dibutyl sebacate [09.474]) In vivo micronucleus test Mouse   943, 1886, 2829 mg/kg  Negative  (Wild et al., 1983) Limited quality since only a 
single sampling time (30 hours 
after treatment) was used and 
PCE/NCE ratio was not 
reported. Therefore it is not 
clear whether the substance had 
reached the bone marrow. 
In vivo Basc test D. melanogaster   19 mM (4642 µg/ml) Negative  (Wild et al., 1983) A single dose was tested in one 
experiment. Method not 
described in detail. 
NR: Not reported. 
1Presence or absence of metabolic activation not specified.  
2 Length of exposure not specified in report. Cytogenetic assay conducted on F1A, F2A and F3A generations of a multiple generation study.  
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ABBREVIATIONS 
ADH  Alcohol dehydrogenase 
ADI  Acceptable Daily Intake 
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CNS  Central Nervous System 
CoA  Coenzyme A 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
DRF  Dose Range Finder 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EPA  Environmental Protection Agency  
ER Endoplasmic Reticulum 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FDA  Food and Drug Administration 
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
GSH  Glutathione 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intraperitoneal 
IR   Infrared spectroscopy 
I.V.  Intravenous 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
LOAEL Lowest Observed Adverse Effect Level 
MFD  Median Fatal Dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
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mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
RfD  Reference dose  
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
